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ABSTRACT 
Urinary tract sensory symptoms provide an additional symptomatic burden 
for women with fibromyalgia. The urogenital symptoms of both fibromyalgia and 
interstitial cystitis have been described as non-infective sensory disorders, suggesting 
the existence of substantial clinical overlap between the two conditions. Research 
suggests that although interstitial cystitis has been treated as a specific bladder 
condition, it may be part of the disorder of central processing of sensory information 
as seen in fibromyalgia. 
The interstitial cystitis symptom index and problem index (ICSI/ICPI) have 
been used to measure lower urinary tract symptoms and to examine the impact of 
these symptoms in patients with interstitial cystitis. This current two phase study was 
designed to test the ICSI/ICPI for use within a population of women diagnosed with 
fibromyalgia known to be experiencing sensory bladder symptoms. 
Phase I involved focus group interviews and discussions with women who 
reported fibromyalgia and bladder irritability (N=lO). This phase was designed to 
identify whether the key indicators and the way in which women experienced 
bladder irritability were indexed by the ICSI/ICPI instrument. The second phase of 
the study tested the ICSI/ICPI within the fibromyalgia population for reliability and 
validity. 
Phase II data was derived via a self-administered questionnaire issued to 
women (N=90) who had been diagnosed with fibromyalgia by a rheumatologist and 
who were experiencing lower urinary tract sensory symptoms. Data analysis revealed 
two separate components in urinary symptom/problem combinations within the 
fibromyalgia population. These components were distinct from those described in the 
ICSI/ICPI. Subsequently, two separate subscales were developed to form the 
Fibromyalgia Bladder Index (FBI). The development and testing of the FBI within 
the fibromyalgia population has provided an accurate measure for assessing the 
symptoms and symptom impact of urinary symptoms for women with this condition. 
The FBI has been developed as an adjunct to clinical assessment and as an outcome 
measure for intervention therapies for patients with fibromyalgia and bladder 
irritability. 
Outcomes of this study form the basis to the following recommendations: 
further refinement of the FBI; utilisation of the index in fibromyalgia assessments; 
development of fibromyalgia educational, support and self help programs; pelvic 
fitness awareness and intervention studies. 
- 3 -
DECLARATION 
I certify that this thesis does not, to be best of my knowledge and belief' 
(i) incorporate without acknowledgement any material previously submitted 
for a degree or diploma in any institution of higher education; 
(ii) contain any material previously published or written by another person 
except where due reference is made in the text; or 
(iii) contain any defamatory material. 
- 4 -
ACKNOWLEDGEMENTS 
The development and completion of this thesis has been a wonderful learning 
curve for me over the past four years. From the initial concepts, preliminary research 
questions and background to the study, I have woven my way through literature 
reviews, theoretical frameworks and measurement models, considered different 
methodologies and recruited wonderful women as study participants from both the 
east and west coasts of Australia. This research trek has continued through software 
packages, data collection and analysis, biostatistics, formatting, findings, discussions 
and recommendations. Throughout this time I have been assisted, supported, 
educated and nurtured by my family, colleagues and friends. They have all played a 
part in my transition into a researcher. My gratitude and thanks especially to 
• My beautiful family, my husband Maurice and children, Sascha, Simone, 
Gabrielle and Stefan for their love, support and encouragement. 
• Professor Linda Kristjanson, Associate Dean of Research and Higher 
Degrees, Faculty of Computing Health and Science, Edith Cowan 
University, Perth for her enthusiasm, capacity, tenacity, and friendship. 
• Associate Professor Geoffrey Littlejohn, Directory of Rheumatology, 
Monash Medical Centre, Melbourne for his advice and expertise in the 
area of fibromyalgia. 
• Mr Stan Wisniewski, Urological Surgeon, Hollywood Private Hospital, 
Nedlands, Perth for his generous hours of urological screening of study 
participants and urological expertise. 
• Dr Thomas Hassard, Biostatisician, University of Manitoba, Canada for 
his statistical brillance 
• Dr Anna Rosamilia, Urogynaecologist (Melbourne) for her enthusiasm 
for this research and her contribution in undertaking the urological 
screenings in Melbourne. 
• The women participants in this study for their capacity, their 'wellness in 
the foreground perspective' in dealing with the chronicity of fibromyalgia 
symptoms and for their contribution to this research. 
• My colleagues at Edith Cowan University "Thank you all" 
- 5 -
TABLE OF CONTENTS 
FIB ROMY ALGIA AND BLADDER IRRITABILITY .................................................................... 2 
ABSTRACT .......................................................................................................................................... 3 
DECLARATION .................................................................................................................................. 4 
ACKNOWLEDGEMENTS ................................................................................................................. 5 
TABLE OF CONTENTS ..................................................................................................................... 6 
LIST OF T ABLES .............................................................................................................................. 10 
LIST OF FIGURES ............................................................................................................................ 12 
CHAPTER 1 ....................................................................................................................................... 13 
INTRODUCTION ........................................................................................................................... 13 
Background to the Study ............................................................................................................. 15 
Urological Symptoms ............................................................................................................................ 16 
Current Definition of Interstitial Cystitis ............................................................................................... 18 
Commonalities between FM and IC ...................................................................................................... 19 
Significance of the Study ............................................................................................................. 19 
Current Bladder Research Emphasis ...................................................................................................... 20 
Social and Economic Impact ................................................................................................................. 21 
Health Related Quality of Life ............................................................................................................... 22 
Health Outcome Measures ..................................................................................................................... 23 
Purpose of the Study ................................................................................................................... 2 5 
Research Questions ..................................................................................................................... 2 5 
Summary ..................................................................................................................................... 25 
CHAPTER 2 ....................................................................................................................................... 26 
LITERATURE REVIEW ....................................................................................................................... 26 
Introduction ................................................................................................................................ 26 
Fibromyalgia .............................................................................................................................. 28 
Diagnosis ............................................................................................................................................... 30 
Demographics ........................................................................................................................................ 32 
Key Symptoms of Fibromyalgia .................................................................................................. 34 
Pain ........................................................................................................................................................ 34 
The Pain of Fibromyalgia ................................................................................................................. 35 
Overview of the Pain ofFibromyalgia ............................................................................................. 36 
Chronic Pain and Its Impact ............................................................................................................. 38 
Gender-related Differences in the Experience of Pain ...................................................................... 39 
Pain of Urogenital Origin ................................................................................................................. 40 
Pain Outcomes .................................................................................................................................. 40 
Fatigue ................................................................................................................................................... 41 
Non-restorative Sleep and Insomnia ...................................................................................................... 43 
Cognitive Dysfunction ........................................................................................................................... 45 
Associated Disorders and Other Symptoms of Fibromyalgia ..................................................... 45 
Irritable Bowel Syndrome ...................................................................................................................... 46 
Temporomandibular Joint Dysfunction ................................................................................................. 48 
Chest Wall Symptoms ........................................................................................................................... 48 
Restless Leg Syndrome .......................................................................................................................... 49 
Headaches .............................................................................................................................................. 49 
Autonomic and/or Neuroendocrine Dysfunction ................................................................................... 49 
Other Findings ....................................................................................................................................... 50 
Psychosocial Implications .......................................................................................................... 50 
Etiology of Fibromyalgia ............................................................................................................ 54 
Etiology of Bladder Symptomatology in FM ......................................................................................... 60 
- 6 -
Hypotheses Explaining Fibromyalgia .................................................................................................... 64 
Treatment /Management of FM .................................................................................................. 66 
Patient Education ................................................................................................................................... 69 
Exercise ................................................................................................................................................. 71 
Pharmacological Treatment of FM ........................................................................................................ 74 
Cognitive Behavioural Therapy ............................................................................................................. 79 
Fibromyalgia and Bladder Symptoms ......................................................................................... 81 
Urinary Definitions ................................................................................................................................ 82 
Lower Urinary Tract Symptoms ....................................................................................................... 83 
Bladder Sensation Definitions .......................................................................................................... 84 
Genital and Lower Urinary Tract Pain ............................................................................................. 84 
Urogenital Pain Syndromes .............................................................................................................. 85 
Symptom Syndromes Suggestive of Lower Urinary Tract Dysfunction .......................................... 86 
Measuring Signs Suggestive of Lower Urinary Tract Dysfunction .................................................. 86 
Urodynamic Observations and Conditions ....................................................................................... 87 
Lower Urinary Tract Symptoms .................................................................................................. 87 
Urinary Frequency ................................................................................................................................. 88 
Urinary Urgency .................................................................................................................................... 89 
Nocturia ................................................................................................................................................. 89 
Bladder Pain .......................................................................................................................................... 92 
Fibromyalgia Bladder Irritability and Interstitial Cystitis ......................................................... 93 
Interstitial Cystitis .................................................................................................................................. 95 
Fibromyalgia and Pelvic Symptomatology ............................................................................... 101 
Fibromyalgia and Chronic Pelvic Pain ................................................................................................ IOI 
Fibromyalgia and Vulvodynia ............................................................................................................. 104 
Fibromyalgia and Sexuality ................................................................................................................. I 07 
Measurement of Urological Symptoms ..................................................................................... I 08 
The Interstitial Cystitis Symptom and Problem Index ......................................................................... 110 
Summary ................................................................................................................................... 111 
CHAPTER 3 ..................................................................................................................................... 112 
FRAME OF REFERENCE ............................................................................................................ 112 
Theoretical Framework ............................................................................................................ 112 
The Theory . . . .. . .. . . . . . . . . . . . .. . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . I 12 
The Framework .................................................................................................................................... 115 
Multi factorial Etiology of Fibromyalgia .............................................................................................. 117 
Central Nervous System Hyperexcitability .......................................................................................... 117 
Neurogenic Inflammation .................................................................................................................... 119 
Increased Peripheral and Visceral Nociception ................................................................................... 120 
Neuroendocrine Disturbances .............................................................................................................. 12 I 
Autonomic Nervous System Dysfunction ............................................................................................ 122 
The Measurement Model ........................................................................................................... 12 3 
CHAPTER 4 ..................................................................................................................................... 126 
METHODOLOGY ........................................................................................................................ 126 
Introduction .............................................................................................................................. 126 
Research Plan ........................................................................................................................... 126 
Methodology Phase I ................................................................................................................ 127 
Design .................................................................................................................................................. 127 
Why Focus Groups as the Data Collection Method? ........................................................................... 128 
Population and Sample ........................................................................................................................ 129 
Recruitment ......................................................................................................................................... 129 
The Focus Groups ................................................................................................................................ 130 
Data Collection and Protocol ............................................................................................................... 131 
Data Analysis ....................................................................................................................................... 132 
Methodology Phase II. .............................................................................................................. 135 
Design .................................................................................................................................................. 135 
Population and Sample/ Inclusion and Exclusion Criteria .................................................................. 136 
Recruitment ......................................................................................................................................... 13 7 
Data Collection and Protocol ............................................................................................................... 138 
Data Analysis ....................................................................................................................................... 140 
Ethical Considerations (Phase I and Phase II) ......................................................................... 141 
- 7 -
CHAPTER 5 ..................................................................................................................................... 143 
RESULTS AND DISCUSSION: PHASE!. ................................................................................... 143 
Introduction .............................................................................................................................. 143 
Who Participated? .................................................................................................................... 143 
Demographic Characteristics of the Focus Group Participants .............................................. 143 
Non-Bladder Symptoms ............................................................................................................ 144 
Emerging Themes ..................................................................................................................... 145 
The Physical Impact ofFibromyalgia .................................................................................................. 145 
The Emotional Impact ofFibromyalgia ............................................................................................... 147 
The Social Impact ofFibromyalgia ..................................................................................................... 149 
The Psychological Impact ofFibromyalgia ......................................................................................... 150 
Bladder Symptoms .................................................................................................................... 152 
The Impact of Urinary Frequency ........................................................................................................ 153 
The Impact of Urinary Urgency ........................................................................................................... 157 
The Impact ofNocturia ........................................................................................................................ 159 
The Impact of Bladder Pain, Burning, Discomfort or Pressure ........................................................... 163 
Stress Urinary Incontinence and Urge Urinary Incontinence ............................................................... 165 
Vulvodynia ................................................................................................................................ 166 
The Impact of Urogenital Symptoms ......................................................................................... 168 
Chronicity of Symptoms of FM ................................................................................................. 170 
Conclusion ................................................................................................................................ 17 3 
CHAPTER 6 ..................................................................................................................................... 174 
FINDINGS-PHASE II ................................................................................................................. 174 
Introduction .............................................................................................................................. 174 
Demographic Profile of Participants ........................................................................................ 17 4 
Internal Consistency Reliability of the Interstitial Cystitis Symptom and Problem Index ........ 178 
The Symptom Index ................................................................................................................... 179 
The Problem Index .................................................................................................................... 180 
The Combined Symptom and Problem Index ............................................................................ 180 
Factor Analysis ......................................................................................................................... 181 
Fibromyalgia Bladder Index ..................................................................................................... 183 
Internal Consistency Reliability of the Fibromya/gia Bladder Index ....................................... 187 
Internal Consistency Reliability of the Bladder Urgency and Pain Subsca/e ........................... 187 
Internal Consistency Reliability of the Bladder Frequency and Nocturia Subscale ................. 188 
Test-Retest Reliability of the Fibromyalgia Bladder Index ....................................................... 189 
Concurrent Validity .................................................................................................................. 191 
Descriptive Statistics of the Sample Population ....................................................................... 193 
Fibromyalgia Bladder Index ................................................................................................................ 193 
The Kings Health Questionnaire .......................................................................................................... 194 
The Fibromyalgia Impact Questionnaire ............................................................................................. 197 
MOS SF-36 Health Survey .................................................................................................................. 198 
The Vulva/ Symptom Assessment Scale ..................................................................................... 202 
Predictive Ability of Urinary Symptoms and Problems on the Fibromyalgia Bladder Index ... 207 
CHAPTER 7 ..................................................................................................................................... 217 
DISCUSSION: PHASE II. ............................................................................................................. 217 
Introduction .............................................................................................................................. 217 
The Fibromyalgia Bladder Index .............................................................................................. 218 
Bladder Urgency and Pain Subsca/e ........................................................................................ 218 
Bladder Frequency and Nocturia Subscale .............................................................................. 219 
Reliability and Validity of the Fibromyalgia Bladder Index ..................................................... 220 
Participants' Characteristics .................................................................................................... 2 21 
Impact of Bladder Irritability and Fibromyalgia on Participants ............................................ 223 
The Vulva/ Symptom Assessment Scale ..................................................................................... 225 
Is there a Clinical Definition for Bladder Irritability in Women with Fibromyalgia? .............. 228 
Strengths of the Study ............................................................................................................... 2 31 
Limitations of the Study ............................................................................................................ 2 3 2 
CHAPTER 8 ..................................................................................................................................... 233 
RECOMMEND A TIO NS AND CONCLUSIONS ......................................................................... 233 
- 8 -
Introduction .............................................................................................................................. 233 
Recommendations ..................................................................................................................... 234 
Further Refining of the Fibromyalgia Bladder Index ........................................................................... 234 
Use of the Fibromyalgia Bladder Index in FM Assessments ............................................................... 235 
Education ............................................................................................................................................. 237 
Intervention Studies Specifically for Urological Symptoms/Impact of FM ......................................... 238 
Development and Psychometric Testing ofa Vulval Symptom/Impact Index .................................... 239 
Conclusion ................................................................................................................................ 240 
REFERENCES ................................................................................................................................. 242 
APPENDICIES ................................................................................................................................. 268 
Appendix A: Interstitial Cystitis Symptom and Problem Index (ICSIIICPI) ............................. 269 
Appendix B: Draft algorithm for the treatment of painful bladder syndrome (including IC) ... 2 71 
Appendix C: Interview guide - Phase 1 .................................................................................... 272 
Appendix D: Phase 1 Information Sheet ................................................................................... 273 
Appendix E: Recruitment Letter from Dr. to Patient (at consultation) ..................................... 275 
Appendix F: Phase I Consent Form .......................................................................................... 276 
Appendix G. Demographic Questionnaire ................................................................................ 277 
Appendix H: Fibromyalgia Impact Questionnaire (FIQ) ......................................................... 279 
Appendix I: Kings Health Questionnaire .................................................................................. 281 
Appendix J: Medical Outcomes Study 36-Short Form Health Survey (SF-36) ......................... 285 
Appendix K: Vulva/ Symptom Assessment Scale ....................................................................... 290 
Appendix L: Recruiting Information Letters for Rheumatologists ............................................ 292 
Appendix M: Recruiting Notices for Rheumatology Consulting Rooms ................................... 294 
Appendix N: Media Release for Study Recruitment .................................................................. 295 
Appendix 0: Phase 11 Information Sheet ................................................................................. 297 
Appendix P: Phase II Consent Form ........................................................................................ 300 
Appendix Q: Bladder Diary ...................................................................................................... 301 
Appendix R: Urological Screening Assessment ........................................................................ 305 
- 9 -
LIST OF TABLES 
TABLE 1: THE DEMOGRAPHIC PROFILE OF STUDY PARTICIPANTS. FREQUENCY AND PERCENT AGE 
DISTRIBUTION OF STUDY PARTICIPANTS ACCORDING TO DEMOGRAPHIC VARIABLES ....... 174 
TABLE 2: THE DEMOGRAPHIC PROFILE OF STUDY PARTICIPANTS. FREQUENCY AND PERCENTAGE 
DISTRIBUTION OF STUDY PARTICIPANTS ACCORDING TO DISEASE VARIABLES ................. 177 
TABLE 3: THE SYMPTOM INDEX: ITEM MEAN, STANDARD DEVIATION AND POSSIBLE SCORE RANGES 
··········································································································································· 179 
TABLE 4: THE PROBLEM INDEX: ITEM MEAN, STANDARD DEVIATION AND POSSIBLE SCORE RANGES 
··········································································································································· 180 
TABLE 5: ITEM AND FACTOR LOADINGS> 0.40 AND EXPLAINED VARIANCE FOR Two COMPONENTS 
BASED UPON PCA V ARIMAX ROTATION ............................................................................ 182 
TABLE 6: THE Two SUBSCALES OF THE FIBROMY ALGIA BLADDER INDEX ......................................... 183 
TABLE 7: THE FIBROMYALGIA BLADDER INDEX-BLADDER URGENCY AND PAIN SUBSCALE ........... 185 
TABLE 8: THE BLADDER URGENCY AND PAIN SUBSCALE: ITEM MEAN, STANDARD DEVIATION AND 
POSSIBLE SCORE RANGES .................................................................................................. 187 
TABLE 9: BLADDER FREQUENCY AND NOCTURIA SUBSCALE: ITEM MEAN, STANDARD DEVIATION AND 
POSSIBLE SCORE RANGES .................................................................................................. 188 
TABLE 10: CONCURRENT VALIDITY OF THE FIBROMY ALGIA BLADDER INDEX: PEARSON CORRELATION 
COEFFICIENTS BETWEEN THE FIBROMY ALGIA BLADDER INDEX, KINGS HEALTH 
QUESTIONNAIRE AND THE FIB ROMY ALGIA IMPACT QUESTIONNAIRE ................................ 191 
TABLE 11: THE FIBROMYALGIABLADDERINDEX: DESCRIPTIVE STATISTICS ..................................... 194 
TABLE 12: THE KINGS HEALTH QUESTIONNAIRE DOMAINS. DESCRIPTIVE STATISTICS: ITEM MEAN, 
STANDARD DEVIATION AND POSSIBLE SCORE RANGES ..................................................... 195 
TABLE 13: THE KINGS HEALTH QUESTIONNAIRE INDIVIDUAL QUESTIONS ON BLADDER PROBLEMS AND 
IMPACT. DESCRIPTIVE STATISTICS: SAMPLE SIZE, ITEM MEAN, STANDARD DEVIATION AND 
POSSIBLE SCORE RANGES .................................................................................................. 196 
TABLE 14: THE FIBROMYALGIA IMPACT QUESTIONNAIRE. DESCRIPTIVE STATISTICS: SAMPLE SIZE, 
ITEM MEAN, STANDARD DEVIATION AND POSSIBLE SCORE RANGES ................................. 197 
TABLE 15: FIBROMY ALGIA IMPACT QUESTIONNAIRE. RESULTS FROM FIVE INDEPENDENT STUDIES ON 
FIB ROMY ALGIA. DESCRIPTIVE ST A TIS TICS: SAMPLE S IZE, MEAN AGE, MEAN TOTAL FIQ 
SCORE, STANDARD DEVIATION AND MEAN DURATION OF FM .......................................... 198 
TABLE 16: THE SF-36 QUESTIONNAIRE. DESCRIPTIVE STATISTICS: SAMPLE SIZE, ITEM MEAN, 
STANDARD DEVIATION AND POSSIBLE SCORE RANGES ..................................................... 199 
TABLE 17: CURRENT FM STUDY DESCRIPTORS FOR THE SF-36, AUSTRALIAN FEMALE POPULATION SF-
36 NORMS, UNITED STATES OF AMERICA FEMALE POPULATION SF-36 NORMS, 
DESCRIPTORS FOR THE SF-36 FM PARTICIPANTS IN CHRONIC DISORDER POPULATION 
STUDY (USA). DESCRIPTIVE STATISTICS: SAMPLE SIZE, ITEM MEAN, STANDARD 
DEVIATION AND POSSIBLE SCORE RANGES ........................................................................ 200 
TABLE 18: THE VULVAL SYMPTOM ASSESSMENT SCALE. DESCRIPTIVE STATISTICS: SAMPLE SIZE, 
ITEM MEAN, STANDARD DEVIATION AND POSSIBLE SCORE RANGES ................................. 202 
- 10 -
TABLE 19: THE VULVAL SYMPTOM ASSESSMENT SCALE ITEM AND FACTOR LOADINGS> 0.40 AND 
EXPLAINED VARIANCE FOR Two COMPONENTS BASED UPON PCA VARIMAX ROTATION. 205 
TABLE 20: REGRESSION ANALYSIS: PAIN AND URGENCY SUBSCALE. VARIABLES ENTERED .............. 208 
TABLE 21: REGRESSION ANALYSIS: PAIN AND URGENCY SUBSCALE. MODEL SUMMARY .................. 208 
TABLE 22: REGRESSION ANALYSIS: FREQUENCY AND NOCTURIA SUBSCALE. VARIABLES ENTERED 210 
TABLE 23: REGRESSION ANALYSIS: FREQUENCY AND NOCTURIA SUBSCALE. MODEL SUMMARY .... 210 
TABLE 24: IMPACT OF THE HIGHEST 25% OF SCORES (SCORE> 51) ON THE PREDICTORS OF THE 
BLADDER URGENCY AND PAIN SUBSCALE. ITEM MEAN, MEDIAN, STANDARD DEVIATION 
AND POSSIBLE SCORE RANGES ........................................................................................... 212 
TABLE 25: IMPACT OF THE LOWEST 25% OF SCORES (SCORE< 24) ON THE PREDICTORS OF THE 
URGENCY AND PAIN SUBSCALE. ITEM MEAN, MEDIAN, STANDARD DEVIATION AND 
POSSIBLE SCORE RANGES .................................................................................................. 213 
TABLE 26: IMPACT OF THE HIGHEST 25% OF SCORES (SCORE> 57) ON THE PREDICTORS OF THE 
FREQUENCY AND NOCTURIA SUBSCALE. ITEM MEAN, MEDIAN, STANDARD DEVIATION AND 
POSSIBLE SCORE RANGES .................................................................................................. 215 
TABLE 27: IMPACT OF THE LOWEST 25% OF SCORES (SCORE< 36) ON THE PREDICTORS OF THE 
FREQUENCY AND NOCTURIA SUBSCALE. ITEM MEAN, MEDIAN, STANDARD DEVIATION AND 
POSSIBLE SCORE RANGES .................................................................................................. 216 
- 1 1  -
LIST OF FIGURES 
FIGURE 1: OVERLAP OF SENSORY URINARY SYMPTOMS IN INTERSTITIAL CYSTITIS (IC) AND 
FIBROMYALGIA (FM) ......................................................................................................... 114 
FIGURE 2: THEORETICAL FRAMEWORK ............................................................................................... 116 
FIGURE 3: ETIOLOGICAL HYPOTHESIS FOR FIBROMYALGIA. ADAPTED FROM CLAUW (1995A) ........... 118 
FIGURE 4: FIBROMYALGIA URINARY SYMPTOMS AND IMPACT MEASUREMENT MODEL ..................... 125 
FIGURE 5: THE TETHERING EFFECT OF NON-BLADDER SYMPTOMS ON WOMEN WITH FIBROMYALGIA 
........................................................................................................................................... 145 
FIGURE 6: PROPORTION OF WOMEN IN THE Focus GROUPS WITH VARY ING URINARY FREQUENCY .. 156 
FIGURE 7: IMPACT OF URINARY FREQUENCY ON WOMEN IN THE Focus GROUPS .............................. 156 
FIGURE 8: PROPORTION OF WOMEN IN THE Focus GROUPS WITH VARYING URINARY URGENCY ...... 159 
FIGURE 9: IMPACT OF URINARY URGENCY ON WOMEN IN THE Focus GROUPS .................................. 159 
FIGURE 10 :  PROPORTION OF WOMEN IN THE Focus GROUPS WITH NOCTURIA ................................... 162 
FIGURE 11: THE IMPACT OF NOCTURIA ON WOMEN IN THE Focus GROUPS ....................................... 162 
FIGURE 12: PROPORTION OF WOMEN IN THE Focus GROUPS WITH BLADDER 
PAIN/BURNING/PRESSURE/DISCOMFORT ........................................................................... 164 
FIGURE 1 3 :  IMPACT OF BLADDER PAIN/BURNING/PRESSURE/DISCOMFORT ON WOMEN IN THE Focus 
GROUPS .............................................................................................................................. 165 
FIGURE 14: THE INCREASED TETHERING EFFECT AND IMPACT OF NON-BLADDER AND UROGENITAL 
SYMPTOMS ON WOMEN WITH FM, DEPICTING ILLNESS IN THE FOREGROUND ................... 169 
FIGURE 15: THE INCREASED TETHERING EFFECT AND IMPACT OF NON-BLADDER AND UROGENITAL 
SYMPTOMS IN FM, DEPICTING WELLNESS IN THE FOREGROUND ....................................... 172 
FIGURE 16: TEST-RETEST OF THE URGENCY AND PAIN SUBSCALE OF THE FIBROMY ALGIA BLADDER 
INDEX .......•.................•...................•................................................................................... 189 
FIGURE 17: TEST-RETEST OF THE FREQUENCY AND NOCTURIA SUBSCALE OF THE FIBROMYALGIA 
BLADDER INDEX ................................................................................................................ 190 
FIGURE 18: TEST-RETEST OF THE COMBINED SUBSCALES OF THE FIBROMYALGIA BLADDER INDEX . 190 
FIGURE 19: VISUAL SUMMARY OF THE DISTRIBUTION OF VULVAL SYMPTOMS .....•............................ 203 
FIGURE 20: VISUAL SUMMARY OF THE DISTRIBUTION OF VULVAL SYMPTOM IMPACT ....................... 204 
FIGURE 21: PLOT OF PARTICIPANTS' SCORES ON BOTH VSAS FACTORS ............................................ 206 
- 12 -
CHAPT ER l 
INTRODUCTION 
Issues and challenges in relation to the measurement of genitourinary 
symptoms in women with Fibromyalgia (FM) are the primary themes of this thesis. 
The research was initiated because of my association with and clinical knowledge of 
symptomatology of patients who had disabling urological symptoms in conjunction 
with their FM. Many of these patients had not been looked at critically in a clinical 
setting. There has been little recognition of or intervention for the management of 
these urological symptoms in the population of Fibromyalgia women who already 
experience multiple non-bladder symptoms. This study will provide important 
information for women experiencing the disabling urogenital symptomatology of 
FM. 
The research activity in bladder and urological conditions has been expanded 
by the establishment of various foundations supported by health care workers, 
researchers and patients through out the world. The USA Coalition for Urological 
Research and Education (CURE) (Interstitial Cystitis Association, 2003), the USA 
Coalition for Improved Bladder Health (National Association for Continence, 2003), 
the Fishbein Foundation and the Interstitial Cystitis Association (Interstitial Cystitis 
Association, 2004) all attest to the bother of urological symptoms in afflicted 
patients. The lack of progress in some areas has evoked new strategies such as the 
initiative by the National Institute of Diabetes and Digestive and Kidney Disease 
(Urology Times, 2004) where a new paradigm for Interstitial Cystitis (IC) looks at it 
as a chronic pain syndrome. 
There are interesting new developments within the urological area, especially 
the increase of knowledge in the biology of up-regulation of sensory processing, 
central sensitisation and the possibility of some bladder conditions being visceral 
pain syndromes rather than end organ diseases. This is an area that needs to be 
- 13 -
revisited to facilitate further knowledge as it has the potential to change the way 
clinicians consider the condition of FM and its associated bladder symptomatology. 
The women in this study are a group of disenfranchised people who have a 
challenging condition, whose non-bladder FM symptoms cohabitate with bladder 
symptomatology that impacts on their quality of life. Their needs need to be 
addressed. 
FM with its debilitating musculoskeletal pain has come under renewed 
evaluation by rheumatologists and health specialists. However, evaluation of 
urogenital symptoms and their impact in this debilitating chronic condition has not 
been undertaken. For a comprehensive evaluation in quality of life issues with 
multiple systems disease, specific and directive measurement tools are required. 
This study explores these issues of lower urinary tract sensory symptoms in 
Australian women who have been diagnosed with the condition of FM. Although 
irritable bladder symptoms are listed as an associated symptom of the condition of 
FM, there is little in the literature on these symptoms of urinary urgency, urinary 
frequency, nocturia and bladder pain and their resultant impact on the quality of life 
of these women. One of the aims of this study is to quantify the impact of these 
bladder symptoms on the quality oflife of Australian women with FM. 
Interstitial cystitis (IC) is a condition of uncertain etiology that results in 
chronic bladder pain, urinary frequency, nocturia and urgency. O'Leary, Sant, 
Fowler, Whitmore and Spolarich-Kroll ( 1 997) have designed and validated the 
Interstitial Cystitis Symptom Index and Problem Index (ICSVICPI) to capture the 
most significant voiding and pain symptoms and assess how problematic these 
urinary symptoms are for patients with interstitial cystitis. Research by Clauw, 
Schmidt, Radulovic, Singer, Katz and Bresette ( 1 997a) suggests that the conditions 
of interstitial cystitis and FM have a significant overlap in symptomatology. 
This study was undertaken to validate this Interstitial Cystitis Symptom Index 
and Problem Index (Appendix A) for use within a population of women diagnosed 
with FM who exhibit lower urinary tract sensory symptoms. 
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Background to the Study 
FM is recognised as a distinct rheumatic disorder. It is a chronic non­
degenerative, non-inflammatory, non-progressive systemic pain condition of 
unknown etiology. It is a complex syndrome characterised by pain amplification, 
diffuse musculoskeletal pain and systemic symptoms. The American College of 
Rheumatology (ACR) classification criteria was outlined for the diagnosis of FM in 
1990 (Wolfe, Symthe, & Yunus, 1990). The diagnostic criteria for FM require 
patients to have wide spread pain of at least three months duration in combination 
with at least 1 1  of 18 specified tender points. Patients diagnosed with FM also 
present with a variety of other symptoms. 
A group of international FM experts issued the Copenhagen Declaration in 
1992 that was adopted by the World Health Organisation in 1993 (Wallace & 
Wallace, 1999). They recognised the use of the criteria of the American College of 
Rheumatology for research purposes, but at the same time recognised and defined 
FM as part of a wider spectrum. This spectrum included headache, irritable bladder, 
irritable bowel syndrome, painful menstrual periods, temperature sensitivities, 
atypical patterns of numbness and tingling, exercise intolerance, complaints of 
weakness, persistent fatigue, stiffness and non-restorative sleep (Wallace & Wallace, 
1999). Other associated symptoms included gastrointestinal complaints, chest pain, 
skin problems, restless leg syndrome, dizziness, cognitive disorders, environmental 
sensitivity and depression. These multifactorial symptoms of FM contribute to the 
delay in the diagnosis of FM and increase the dilemma of its unknown etiology. 
Current research is attempting to unearth a more sophisticated diagnostic marker than 
the above criteria for the diagnosis of this syndrome. 
Wolfe, Ross, Anderson, Russel and Herbert ( 1995) determined that FM 
affects between 3% and 5% of the population (according to the American College of 
Rheumatology classification criteria), that females outnumber males by a ratio of 
about 6 to 1 and that the prevalence of the syndrome increased with age. The median 
age for the onset of FM is from 29 years to 3 7 years although formal diagnosis is 
more often from 35 years to 53 years (Boissevain & McCain, 199 1). Buskila and 
Neumann (1997) noted a striking familial prevalence of FM with the prevalence in 
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female relatives being much higher. The mechanism of FM is thought to involve a 
complex interaction between neuroendocrine factors and central pain mechanisms 
with increased sensitivity in pain pathways. Symptoms of FM can be grouped 
according to their organ system (Clauw et al., 1997a). These organ groups include 
genitourinary, musculoskeletal, neurological, gastrointestinal, cardiopulmonary and 
others. 
Urological Symptoms 
From the genitourinary group, irritable bladder symptoms similar to the 
irritative bladder symptoms of interstitial cystitis (IC) are listed as one of the 
associated disorders of FM (Littlejohn, 1996). These symptoms include urinary 
frequency, urinary urgency, nocturia and pelvic pain in the absence of infection. 
Paira (1994) found that 38 of 212 patients (18%) with FM met the criteria for the 
definition of female urethral syndrome with symptoms of urinary frequency, dysuria, 
supra pubic pain and urethral discomfort. Wolfe and colleagues (1990), in their study 
on signs and symptoms of FM reported that 26.3% of his sample experienced urinary 
urgency. In a study by Wassem, McDonald and Racine (2002) on FM patient 
perspectives on symptoms, irritable bladder symptoms were reported in greater than 
70% of the 54 respondents. 
Clauw and colleagues (1997a) considered the relationship between FM and 
IC. Interstitial cystitis is a complex inflammatory condition of the bladder. Although 
the pathophysiology of the condition is not fully understood, it is known that there is 
altered epithelial permeability, mast cell activation and sensory afferent nerve 
upregulation within the bladder (G. R. Sant & Theoharides, 1999b). Z. S. 
Wisniewski (personal communication, September 3, 2004) describes the typical 
history of a woman with IC as one who presents with pain on a full bladder with 
ensuing frequency. As a consequence of this, some fibrosis of the bladder can occur 
with the bladder shrinking down to a smaller contracted form that encourages 
increased urinary frequency and urgency. Bladder and/or pelvic pain on bladder 
filling are a major part of the urological profile of these women. 
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The study on IC and FM (Clauw et al., 1 997a) showed the prevalence of 
genitourinary symptoms within three groups, patients with FM (n = 60), patients with 
IC (n = 30) and a control group (n = 30). These results show the prevalence of a 
bladder fullness sensation at 38%, 80%, and 7%, urinary urgency at 45%, 80% and 
1 3%, pelvic pain at 45%, 77% and 7%, dyspareunia at 1 8%, 50% and 7%, burning 
with urination at 6%, 40% and 0% and vaginal pain with insertion or removal of a 
tampon at 1 5%, 23% and 3% respectively. 
In a randomised community survey of 3395 non institutionalised adults, 
White, Speechley, Harth and Ostbye (1 999a) identified clinical features that 
distinguished FM from other chronic widespread pain. They included in the study 
100 FM cases, 76 widespread pain controls (PC) and 1 35  general controls (GC). 
From a list of 4 1  presented symptom items, the prevalence of urinary frequency (> 
5x/day) was recorded at 32% (FM), 23.7% (PC) and 7.5% (GC). Pain with urination 
was recorded for 6% of those with FM, 2. 7% of those with widespread pain and none 
for those in the general control group. 
Clauw and colleagues (1 997a) speculated that central neurological 
mechanisms that have been suspected to contribute to the pathogenesis of FM may 
be the same type of mechanisms operative in IC, which until now has been primarily 
considered to be a bladder disorder. Clauw and colleagues found that patients they 
studied with interstitial cystitis displayed diffusely increased peripheral nociception 
as seen in FM, nociception being the electrochemical process through which humans 
perceive pain. Erickson, Morgan, Ordille, Keay and Xie (2001 ) extended the inquiry 
into non-bladder symptoms related to interstitial cystitis. Their findings were very 
similar to those of Clauw and colleagues (1 997), but it is not known whether any of 
the non-bladder symptoms found associated with interstitial cystitis were directly 
related to the pathophysiology. Research on neurological etiological factors rather 
than bacteriological etiology in the area of bladder and pelvic pain is becoming more 
evident. 
IC like FM is a condition of unknown etiology that is treatable but not 
curable. For patients with IC, the most common symptoms include the irritative 
symptoms of urinary frequency, urinary urgency and pelvic pain. Pain can be 
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experienced within the pelvis, bladder, urethral and vaginal areas. IC is a complex 
inflammatory condition of the bladder and is seen as a major portion of the "painful 
bladder" disease complex that includes a large group of urologic patients with 
bladder and/or pelvic pain and irritative voiding symptoms with negative urine 
cultures (Hanno, 1 992). Hanno also lists FM as an associated disease with IC 
because of the over representation of FM in the IC population. 
Current Definition of Interstitial Cystitis 
In Japan in 2003, international experts met at the inaugural International 
Consultation on Interstitial Cystitis (Ueda, 2003) to define areas of agreement and 
differences in their approach to IC and to determine a uniform IC definition. The 
original definition of the Division of Kidney, Urologic, and Hematologic diseases of 
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) for 
IC was developed in 1989 and was intended mainly for research purposes to ensure 
that a homogenous group of patients with IC were available for IC studies. The 
original diagnostic criteria have been found to be too restrictive for clinical purposes 
with the resultant potential for misdiagnosis and under diagnosis of many patients 
with IC (Diokno, Homma, Sekiguchi, & Yasuyuki, 2003 ). Hanno ( 1 994b) found that 
90% of patients meeting the original NIDDK criteria were considered by IC experts 
to have the disease, but 60% who did not meet these criteria were also thought to 
have IC. Many IC patients were therefore excluded from research studies with only 
the most severely affected patients included. These original criteria have been 
described as a de facto definition (Hanno, 1994b ). 
The main objectives of this International Consultation on Interstitial Cystitis 
in 2003 were to define the basic symptoms that encompass the condition of IC and to 
develop a more appropriate terminology that represents this symptom complex. 
Discussion from the workshops indicated that chronic pelvic pain may not always be 
recognised as an essential component of the symptom complex. The final consensus 
from the 2003 International Consultation on Interstitial Cystitis adopted the term 
IC/CPPS to signify the symptom complex of chronic pelvic pain (CPPS), with 
urinary urgency and / or urinary frequency (Diokno et al. ,  2003). A draft algorithm 
for the treatment of painful bladder syndrome (including IC) was developed at the 
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International Consultation on Interstitial Cystitis in Monaco in August 2004 
(Appendix 8). This Consultation group also worked on a definition and review of the 
painful bladder. This latest version will be published in December 2004 (A. 
Rosamilia, personal communication, September 8, 2004). 
Commonalities between FM and IC 
As with FM, the majority of IC patients are female. The demographic 
features, associated features and response to tricyclic compounds are very similar in 
both conditions. One epidemiological study (Koziol, 1 994) showed that the main 
symptoms in women with IC were frequency (92%), urgency (92%) and pelvic pain 
(70%). Physical assessment found vaginal and suprapubic tenderness. Bladder charts 
revealed an average number of 2 1  voids per 24 hours with an average interval of 2.6 
hours between voids over night. Some authors refer to the FM associated disorder of 
irritable bladder syndrome as "interstitial cystitis" (Littlejohn, 1 996). 
Alagiri and colleagues ( 1 997) undertook a study to determine the prevalence 
of concomitant disease in individuals with IC and compared these results with the 
general population. They concluded that IC has an unexplained association with 
certain other chronic diseases and pain syndromes including FM. Within this survey 
of 2682 patients with IC, 25% reported having comorbid FM. Another study (Aaron, 
Burke, & Buchwald, 2000) investigated the frequency of ten clinical conditions 
among three groups of patients with chronic fatigue syndrome (CFS), FM and 
temporomandibular disorder (TMD). The patients with FM had a significantly 
greater number of symptoms characteristic of IC compared with the patients with 
CFS and TMD or control subjects. 
Significance of the Study 
Despite the emerging evidence on commonalities between FM and IC and the 
listing of bladder irritability as a symptom of FM, there appears to be little discussion 
between the medical specialities on the issue of bladder symptomatology in FM. 
Rosamilia and Dwyer (2000) suggest that many women with lower urinary tract 
sensory disorders present after having unsuccessfully trailed antibiotics for their 
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urinary symptoms. This unsuccessful treatment and a failure to cultivate 
uropathogens will often lead the clinician to consider an alternative diagnosis in the 
realm of non-infective sensory disorders of the lower urinary tract. Rosamilia and 
Dwyer (2000) suggest that women presenting with irritative urinary symptoms 
should be assessed both gynaecologically and generally. A short rheumatological list 
of questions on FM symptoms could assist in the urological identification of possible 
FM sufferers within this group of women. 
Perhaps the lack of a general assessment of women with FM for these non­
infective sensory disorders of the lower urinary tract is because bladder irritability is 
one of the less common symptoms of the FM condition. Ang and Wilke ( 1999) 
describe two types of non-specific symptoms groups of FM. They describe the first 
group of symptoms as fatigue, non-restorative sleep, distress and morning stiffness 
occurring in 75% of patients. They describe the less common symptoms occurring 
between 25% and 50% of patients as irritable bowel syndrome, urinary frequency, 
headache, subjective swelling, diffuse paraesthesia, psychological distress and 
functional disability. 
Research on issues related to these less common symptoms of FM such as 
lower urinary tract symptoms is needed to increase the awareness and knowledge 
development of the health professional regarding the disability and frustration that 
these less distinguishing symptoms may cause to patients. Hunt (1995) poses the 
question as to whether there is a void in the research in relation to bladder irritability. 
Hunt (1995 : 440) refers to the importance of psychological factors and stress in 
bladder functioning and cites Smith in the Chinese proverbial description of the 
bladder as ' the mirror of the soul' . 
Current Bladder Research Emphasis 
The Division of Kidney, Urologic, and Hematologic diseases of The National 
Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) within the United 
States of America recognises that IC represents only one of a number of symptom 
complexes of chronic pain of bladder origin. In July 2000 the NIDDK invited 
applications for investigators to use ongoing prospective cohort studies, clinical 
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trials, and large patient databases to design epidemiological, quality of life, and 
health resource utilisation studies for chronic pelvic pain of bladder origin and IC 
(Kusek & Nyberg, 2000). 
This research is providing information on the broader, more inclusive 
disorder of the symptom complex of chronic pelvic pain, and associated symptoms of 
urinary frequency and urgency. This research project on the epidemiology of chronic 
pelvic pain of the bladder and IC has attracted significant funds as the magnitude and 
the impact of the burden of chronic pelvic pain of the bladder symptom complex on 
the health of the US population is not known. In January 2004 the NIDDK 
announced a request for applications for a study entitled Interstitial Cystitis / Painful 
Bladder Syndrome: Epidemiology (Interstitial Cystitis Association, 2004a). The 
funding is a $ 1 ,000,000 per year grant for a period of 5 years. These on going 
research grants and international consultations on IC demonstrate the clinical need to 
assess bladder symptomatology in these disabling conditions. 
Social and Economic Impact 
The increased consultation and research funding within the area of bladder 
pain and irritability reflects the need within both professional and community groups 
to view bladder health as a priority area of health research. This focus on bladder 
health increases the significance and relevance of all current research in this specific 
area. A recent survey by the John Hopkins Bloomberg School of Public Health in the 
United States (G. Anderson, 2003) found that chronic health conditions in that 
country were a major concern. The survey found that the majority of physicians, 
policy makers and the public were concerned that the nation's health care system was 
not appropriately meeting the needs of people with chronic disease. This was a 
significant survey where the attitudes of 1 ,74 1 physicians, 1 ,663 adults from the 
general public and 1 55 health policy makers were sampled. 
A study on the service utilization costs for FM patients has shown that the 
annual cost per FM patient in the United States of America is $2,274 US (Wolfe et 
al., 1 997a). Rates of hospitalization occurred at approximately once a year and 
outpatient medical visits at 9.8 times per year. When alternative treatments were 
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added, the total outpatient service was once per month. This report confirms that 
patients with FM report more symptoms and comorbid and/or associated conditions 
that other patients with rheumatological conditions. The resultant impact on medical 
budgets and personal costs to patients for the treatment of FM is substantial. 
Health Related Quality of Life 
Health-related quality of life (HRQOL) is a multidimensional construct 
referring to an individual's  perceptions of the effect of a health condition or disease 
and its resultant treatment (Lose et al. , 1 998). Kelleher, Cardozo, and Toozs-Hobson 
( 1 995) describe quality of life as an abstract concept that encompasses a person's 
perception of their physical, psychological and social well being and further describe 
quality of life as a subjective phenomenon influenced by culture, beliefs, self -
concepts and life's goals and expectations. Currently there is an increasing interest in 
the development of health scales and indices for measuring subject 's assessment of 
their symptoms and for their measuring quality of life. Health related quality of life 
(HRQOL) is one of several elements being studied in the field of medical outcome 
research according to Penson and Litwin ( 1 997). They describe HRQOL as 
encompassing a wide range of human experience but emphasise the involvement of 
the patient's  perception of their own health and ability to function in life. 
The impact of lower urinary tract symptoms on the quality of life on women 
has been well documented over recent years. Pinnock and Marshall ( 1 997) have 
shown that the impact and bothersomeness of lower urinary tract symptoms on 
quality of life in an Australian community is a major reason for people seeking 
medical help. It is important to determine the increased impact and bother that these 
urinary symptoms could have, not only on the financial impact to the sufferer but 
also on the quality of life of a person already coping with the many other symptoms 
of FM. 
Bernard, Prince and Edsall (2000) reported a significant reduction in the 
quality of life in FM patients. In their study of 270 subjects with FM, most rated their 
present quality of life as 4.8 on a O to 1 0  scale compared to a score of 8.6 prior to 
having FM. They estimated their future quality of life as 9.6 in the absence of FM. A 
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recent study on health related quality of life in multiple musculoskeletal diseases 
(Picavet & Hoeymans, 2004) has shown that subjects with musculoskeletal diseases 
had significantly lower scores on all SF-36 health status dimensions than subjects 
without musculoskeletal disease. In this study, the worst health related quality of life 
patterns were found for FM, osteoarthritis of the hip, osteoporosis and rheumatoid 
arthritis. 
Asbring (2001)  in her study on the affects of chronic illness such as FM on 
women found that the illness can cause a radical disruption in a woman's biography 
and that the illness has profound consequences for her identity, especially in relation 
to her work and social life. A study by Schaefer (1995) of women living with FM 
reveals how women attempted to gain control of their illness, their symptoms, as they 
struggled to maintain a balance in their life. Validating the Interstitial Cystitis 
Symptom and Problem Index (ICSVICPI) within the FM population will enable 
accurate assessment of the impact of one group of these symptoms, the urinary 
symptoms of FM. 
Health Outcome Measures 
Dunkl, Taylor, McConnell, Alfano and Conaway (2000) assessed the 
responsiveness of FM clinical trial outcome measures, and found the Fibromyalgia 
Impact Questionnaire to be the most responsive measure to perceived clinical status. 
Bennett (2001 )  commented on this study and wrote of the need to develop outcome 
measures. Bennett remarked on the need for accurate quantification of relevant 
symptoms and physical findings in FM for defining improvement in clinical trials. 
The measurement approaches used to assess HRQOL are generic or specific 
(condition-specific or patient-specific). Generic scales allow for comparisons 
between different demographic and cultural groups as well as across different 
disorders, severities of disease and interventions (Patrick & Deyo, 1989). McHorney, 
Ware, Lu and Sherbourne (1994) comment that these scales can also be used to 
measure the burden of illness of populations with chronic medical conditions as 
compared with normals. The use of the generic scale also enables meta-analysis to 
produce the combined results of different studies. Condition-specific or patient-
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specific questionnaires do not have to cover a large range of disorders that may be 
inappropriate or irrelevant for one specific problem. There are therefore more 
specific and relevant questions to detect changes in the patient's condition (Streiner 
& Norman, 1 996). 
The Interstitial Cystitis Symptom Index and Problem Index (ICSI/ICPI) is a 
condition-specific instrument designed to measure the impact of the symptoms of 
urinary frequency, urinary urgency, nocturia and bladder pain in patients with IC. 
Condition-specific instruments should include the measurement of the presence of a 
symptom and the bothersomeness of the symptom. O'Leary and colleagues ( 1 997) 
have developed such an outcome measure for IC where the different items of urinary 
pain, nocturia, urgency and frequency symptoms and their bothersomeness are 
combined in a symptom and problem index. 
This ICSI/ICPI was developed to measure lower urinary tract symptoms and 
their impact in patients with IC. Because there is not a precise consensus definition 
of what constitutes the disease of IC, it is important to have a scientifically validated 
instrument to evaluate symptoms. O'Leary and colleagues ( 1 997) commented on the 
plethora of new therapies for the treatment of IC and the need for reliable and valid 
outcome measures. Their development of the ICSI/ICPI was the result of the critical 
need to have a uniform and reliable method to evaluate these symptoms. The authors 
of the index comment that apart from its adjunct role in clinical decision making, the 
ICSI/ICPI will be valuable to future researchers in this area. This instrument has only 
been validated within the IC population. 
Currently there is no validated instrument available for the assessment of 
significant bladder irritability and bladder pain or for the assessment of how 
problematic these symptoms are within the FM population. Such an instrument 
would enable rheumatologists, urologists and medical practitioners to quickly detect 
specify and assess the bothersomeness of the urinary symptoms for the FM patients 
and enhance referral to appropriate health professionals for management. A validated 
instrument for measuring these lower urinary tract symptoms and their impact will 
also be a valuable research tool, an objective quantifiable measure, especially where 
intervention is directed at improving the management of this problem. 
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Purpose of the Study 
The purpose of this study is to investigate the impact and measurement of 
bladder irritability symptoms in Australian women who have been diagnosed with 
the condition of FM. This study will test the ICSI/ICPI within the female FM 
population for reliability and validity. 
Research Questions 
To validate the ICSI/ICPI instrument within a population of women 
diagnosed with the condition of FM who exhibit sensory urinary symptoms. 
To establish the measured impact of lower urinary tract sensory symptoms on 
the quality of life of women with FM. 
Summary 
This is the first Australian study to seek quantification of lower urinary tract 
sensory symptoms and their impact on women diagnosed with FM and to validate an 
outcome measure for the symptoms and symptom impact. The investigation plans to 
increase awareness and discourse within the health professions about the disability 
and frustration that these less distinguishing features of FM can present .  The 
validation of a condition specific outcome measure for documenting a patient's 
assessment of her symptoms and for measuring her health related quality of life is a 
step to provide accurate quantification of symptoms for bladder bother in patients 
with FM. 
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CHAPTER 2 
LITERATURE REVIEW 
Introduction 
Current literature on the condition, symptoms, diagnosis, associated disorders 
and demographics of Fibromyalgia syndrome (FM) are examined in this chapter. The 
key FM symptoms of pain, stiffness, fatigue, insomnia and cognitive dysfunction, as 
well as the psychosocial implications of FM, are discussed. Current theories and 
models on the etiology of FM and possible etiological theories of bladder 
symptomatology in FM will be considered. 
Treatment options and recommendations for the management of FM will be 
considered, with a focus on the role of patient education, exercise, pharmacological 
treatment and cognitive behavioural therapy. Specific attention is given to the 
urogenital symptoms associated with FM and their connection with interstitial 
cystitis (IC), chronic pelvic pain, and vulvodynia. Current literature on measures of 
health status and their development in regard to FM are also included in this 
literature review. The issues and challenges in relation to the measurement of 
genitourinary symptoms in women with FM are the primary themes of this thesis. 
This research was initiated because of the lack of such measurement tools for these 
genitourinary symptoms. This research will provide important information to women 
with these disabling symptoms. 
This review will be an extensive review on the available areas of literature 
covering the wide range of symptoms, etiological possibilities and treatment 
management strategies of FM because all of these areas may be associated with, or 
impact on, the urogenital influence of FM on women. 
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In January 2002, the World Health Organisation launched the Bone and Joint 
Decade. The naming of this decade was initiated in response to the identification of a 
world epidemic of musculoskeletal disease (Hazes & Woolf, 2000). The World 
Health Organisation World Global Burden of Disease Project reported that the 
musculoskeletal conditions represented more than half of all chronic conditions 
(Dieppe, 1998). The Australian Coordinator of the Bone and Joint Decade (Brooks & 
Hart, 2000) recognised that many musculoskeletal conditions produce chronic pain, 
disability and a decrease in the quality of life. They commented that the Bone and 
Joint Decade will attempt to bring together research, education and service to 
improve the life of millions of Australians who suffer each week from these 
conditions. Littlejohn and Morand (2002) concluded that, with the impetus that this 
Bone and Joint Decade will bring to research in rheumatic disease, the medical 
profession can expect greater understanding of disease mechanisms with a 
subsequent increase in treatment options. 
More specific to FM is the development of one of the largest international 
FM research centres at the University of Michigan Centre for Chronic Pain and 
Fatigue Research. The report of the Senate Appropriations Committee of the USA 
has urged the National Institute of Health (NIH) to increase the emphasis on the 
neurological aspects of FM and to encourage new partnerships in FM research 
between the two NIH institutes. The report also encourages studies for drugs and 
biologicals which are Fibromyalgia-specific (Liller, 2002) . 
The USA Coalition for Urological Research and Education (CURE) 
encourages and funds research that will improve the care of patients with urological 
conditions. The Coalition emphasises not only the individual suffering and the 
financial burdens involved with urological conditions, but also the fact that 
urological research is the most under-funded research area in their nation (Interstitial 
Cystitis Association, 2003). The Coalition for Improved Bladder Health is another 
partnership that was formed with the aim of increasing awareness of bladder and 
pelvic health issues and includes a diverse collaborative group of health professional 
organisations. 
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The Fishbein Foundation and the Interstitial Cystitis Association (ICA), also 
piloting research programs in the United States, are providing large financial grants 
for research areas such as the epidemiology of IC and abnormalities in sensory 
nerves in the bladder of IC patients (Interstitial Cystitis Association, 2004). The 
National Institute of Diabetes and Digestive and Kidney Disease (NIDDK) 
announced in 2004 applications for a large scale five-million-dollar study entitled 
' Interstitial Cystitis/Painful Bladder Syndrome: Epidemiology' (Urology Times, 
2004). It is against this backdrop of advances in rheumatic and urological disease 
research and increasing awareness that the current study on Fibromyalgia and 
bladder irritability has evolved. 
Fibromyalgia (FM) has mainly been the domain of the rheumatologist until 
now, with the primary focus on pain management. This horizon is expanding with 
multiple health specialities now having input into the research and intervention 
strategies for the many facets of this multi-dimensioned disorder (Busch, Schachter, 
Peloso, & Bombardier, 2002b ). This literature review will include the primary and 
associated symptoms of this condition with particular focus on one of the associated 
symptoms, the urogenital symptoms. The lack of research specifically in the area of 
the genitourinary symptoms of FM, and the measurement and impact of these 
symptoms, is apparent. Recent research into the etiological factors contributing to 
FM and consideration of studies in the area of effective treatment and management 
will act as background to further discussion of these urogenital symptoms. 
Fibromyalgia 
Fibromyalgia is a chronic musculoskeletal pain syndrome characterised by 
widespread pain and predictable tenderness at numerous anatomical sites, together 
with other characteristic clinical manifestations (Wolfe et al., 1990). The World 
Health Organisation has classified FM in the International Classification of Diseases 
as non-articular rheumatism. It is thought to be a pain amplification syndrome related 
to increased sensitivity of dynamic components of the pain system (Littlejohn, 1996). 
Fibro refers to the fibrous tissue of ligaments and tendons, myo refers to muscle and 
algia refers to pain (Jain et al., 2004). 
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Bennett (2002d) describes the current paradigm of FM as a complex pain 
syndrome in which abnormalities of central sensory processing interact with some 
peripheral pain generators and psychoneuroendocrine dysfunction, generating a wide 
spectrum of symptoms and distress. The classic primary symptoms of FM are the 
diffuse pain, fatigue, stiffness and non-restorative sleep. Associated symptoms 
include morning stiffness, gastrointestinal symptoms, genitourinary problems, 
paraesthesia, temperature sensitivity, thoracic pain and dysfunction, cognitive 
disorder, vestibular problems, oesophageal dysmotility, headaches, restless leg 
syndrome, dizziness and anxiety. 
Littlejohn (200 I )  distinguishes between two different types of chronic 
musculoskeletal pain syndromes, one involving pain generation and the other being 
pain amplification. The pain generation syndromes include the myofascial pain 
syndrome and segmental spinal dysfunction. The pain amplification syndromes 
include FM, regional pain syndrome and complex regional pain syndrome. 
The International Association for the Study of Pain, in its classification of 
chronic pain, defines FM as diffuse musculoskeletal aching and pain with multiple 
tender points (Merskey & Bogduk, 1994). They describe the syndrome as chronic 
with remissions being uncommon. Jain and colleagues (2004) in the Canadian 
Consensus Document on FM classify FM as one of the large group of soft tissue pain 
syndromes. They describe the soft tissue pain syndromes as characterised by pain 
from the periarticular structures located outside of joint capsule and periosteum, 
namely ligaments, tendons, fascia, bursae and muscles. 
FM associates with significant disability. Kaplan, Schmidt and Cronan (2000) 
have demonstrated that patients with FM obtain lower scores on a validated measure, 
the Quality of Well Being Scale, than patients diagnosed with chronic obstructive 
airways disease, rheumatoid arthritis, atrial fibrillation, advanced cancer and some 
other chronic diseases. This is indicative of the quality of well being and the 
significant disability experienced by people with FM. 
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Diagnosis 
In 1990, the American College of Rheumatology published criteria (Wolfe et 
al., 1990) for classification of patients as having FM. These criteria are also often 
used for clinical diagnosis. The criteria comprise widespread pain defined as pain on 
the left and right sides of the body, as well as above and below the waist, for three 
months duration, together with the presence of abnormal tenderness on digital 
palpation, at 1 1  or more out of 18 specifically designated sites. These sites are 
deemed 'tender points' when 4 kilograms of palpation pressure induces pain. For a 
'tender point' to be positive, the subject must experience the palpation as painful and 
not just tender. These classification criteria are research based and are validated and 
rigid. The tender points of the classification criteria are as follows: 
• Bilateral occiput at the suboccipital muscle insertion. 
• Bilateral low cervical at the anterior aspects of the intertransverse spaces at 
C5-C7. 
• Bilateral trapezius at the mid point of the upper border. 
• Bilateral supraspinatus at origins above the scapula spine near the medial 
border. 
• Bilateral second rib at the second costochondral junctions just lateral to the 
junctions on the upper surfaces. 
• Bilateral lateral epicondyle 2cm distal to the epicondyles. 
• Bilateral gluteals in the upper outer quadrants of buttocks in anterior fold of 
the muscle. 
• Bilateral greater trochanter posterior to the trochanteric prominence. 
• Bilateral knee at the medial fat pad proximal to the joint line. 
• Axial skeletal pain in the cervical spine, anterior chest, thoracic spine or 
lower back must also be present. 
These classification criteria were designed as a tool to standardise research 
into FM. The ACR classification criteria have pain at the centre of their definition. 
They do not encompass the other symptoms of sleep disturbance, fatigue, cognitive 
dysfunction, psychological distress, irritable bowel, irritable bladder and other 
concurrent symptoms. Crofford and Clauw (2002a) suggest that by excluding 
symptoms other than pain, the ACR criteria fail to encapsulate the essence of the FM 
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syndrome. These authors recognise that one of the strengths of these criteria, from a 
research point of view, is that FM patients who meet the ACR criteria are at the 
extreme end of the pain and tenderness spectrum. 
A diagnosis is fundamental to managing any medical condition, but it can be 
particularly problematical when dealing with patients who suffer with chronic and 
musculoskeletal pain (King, 2004). King describes a diagnosis as a process whereby 
data provided by or gained from the patient are integrated with scientific knowledge 
to identify the nature and cause of a medical condition. King offers four distinct 
diagnostic strategies each with a distinct rationale. These include: the Gestalt or 
'heuristic' method that is a product of a rapid process of pattern recognition that is 
based on the clinician's previous experience; the hypothetico-deductive strategy 
where a short list of possible diagnostic alternatives is considered; the exhaustive 
diagnostic strategy involving a comprehensive assessment of all aspects of the 
patient and his/her symptomatology; and the algorithm strategy providing an 
evidence-based algorithm with rational alternatives. 
Many clinicians see a need to develop better criteria for clinical diagnosis in 
the community, recognising that the ACR classification criteria address only two 
domains of this multi-faceted disorder, namely pain and tenderness. Because of the 
growing recognition of the need for better information about all of the objective 
abnormalities in people with FM, and the need for an integrated approach to the 
diagnosis, a Canadian consensus document on FM has been developed (Jain et al., 
2004). An expert subcommittee from Health Canada established the terms of 
reference and selected the Expert Medical Consensus Panel representing treating 
physicians, teaching faculty and researchers (Jain et al., 2004). This consensus 
document includes a clinical case definition, diagnosis and management of FM. 
Russell (2004) sees the development of this document as the next step in a 
longer term plan. He comments that, since the development of the ACR 1990 
Classification Criteria for the Fibromyalgia Syndrome, it has been apparent that it is 
necessary to determine what to include in a clinical case definition for use in 
community medicine. This clinical case definition from Health Canada will be 
refined and validated by the international scientific community and it will be of 
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interest to the FM community of both health care professionals and patients to follow 
its influence within Canada and within other international medical communities. 
Demographics 
FM is a disease of various age groups, affecting more women than men. It is 
the third most common diagnosed rheumatic disorder after osteoarthritis and 
rheumatoid arthritis. FM affects between 2% and 6% of the population. A 
community prevalence study by Wolfe, Ross, Anderson, Russel and Herbert ( 1 995) 
has shown the overall prevalence at 3 .4% in women and 0.05% in men. This study 
showed an even higher prevalence 7% in older women between the ages of 65 and 79 
years. Prevalence shown in the London Fibromyalgia Epidemiology Study (White et 
al., 1 999a) was 4. 9% for women and 1 .6% for men. 
Male patients have been shown to have fewer symptoms, fewer tender points, 
less common 'pain all over' symptoms, fatigue, morning fatigue and irritable bowel 
symptoms than women (Yunus, Inanici, Aldag, & Mangold, 2000). The reasons for 
this variation are unclear but seem multifactorial. Yunus (2002b) describes these 
gender differences as a composite of biology, psychology and sociocultural factors. 
Gijsbers ( 1 997) suggests that although women may be constitutionally more prone to 
pain than men, their attitudes to pain allow women to report on their pain in a way 
less likely to be biased by psychosocial issues. Gijsbers also suggests that the 
essential difference between the sexes is that women are more discriminating than 
men in their perceptions of pain-related sensations and that they develop a repertoire 
of strategies that help them cope with pain more efficiently. 
The usual age range at diagnosis of FM is 34 to 53 years although the age at 
onset is usually between 29 to 3 7 years (Boissevain & McCain, 1 99 1  ). It has been 
diagnosed in children and older people. The prevalence of FM increases with age and 
is commonly associated with comorbid disorders (Wolfe et al. , 1 995). Patients can 
endure many years of pain and associated dysfunction before a correct diagnosis is 
made. 
Although the majority of FM patients experience pain and fatigue, there is no 
obvious tissue damage identified on clinical evaluation. Kramis ( 1 998) describes FM 
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as ' pain without tissue pathology' ,  which undermines the individuals' credibility and 
interferes with all aspects of their life. Wagner ( 1997) describes chronic pain as 
having no function and being destructive both physically and psychologically. The 
definition for pain set out by the International Association for the Study of Pain 
(Merskey & Bogduk, 1994) defines pain as an unpleasant sensory and emotional 
experience associated with actual or potential tissue damage, or described in terms of 
such damage. This definition fits the pain of FM very well. Wolfe and colleagues 
(1997a) concluded that patients with established FM, who were followed in a tertiary 
hospital setting for seven years, showed markedly abnormal scores for pain, 
functional disability, fatigue, sleep disturbance and psychological status. 
Littlejohn ( 1996) has stated that the commonness of the problem of FM, 
together with its potential for serious disability, makes it a major cause of loss of 
health quality for the individual and a significant economic loss to the community. A 
six-year prospective study of a cohort of FM patients by Baumgartner and colleagues 
(2002b) examined the long term prognosis in patients with FM. Their results showed 
that most of the symptoms remained stable. Although pain had increased, some 
aspects of the patients' quality of life had improved. An Australian two-year outcome 
study from a rheumatology community practice showed a remission in 
approximately 25% of the patients (Granges, Zilko, & Littlej ohn, 1994). Wolfe and 
colleagues (1997a) followed up 538 FM tertiary hospital referred patients over a . 
seven-year period to find that their markedly abnormal scores for pain, functional 
disability, sleep disturbance, fatigue and psychological status did not change 
significantly over that time. Fifty-nine percent of the study participants rated their 
health as fair or poor. Possibly, community-managed FM patients may have a better 
prognosis than those patients severe enough to attend tertiary institutions. 
A recent research study (Giesecke et al. ,  2003) supports the clinical 
impression that there are distinct sub groupings of FM patients. Giesecke and 
colleagues noted that although the ACR criteria for FM were used to identify people 
with pain and tenderness, these individuals were not a homogeneous group. The 
researchers recognised that, as well as patients experiencing different clinical 
symptoms, there was the influence of the biologic, psychological and cognitive 
factors on their symptom expression. One group of FM patients exhibited extreme 
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tenderness, but no associated psychological and cognitive factors. Another group 
exhibited moderate tenderness with normal mood levels. A third group exhibited 
significant mood and cognitive factor influences on their symptomatology (Giesecke 
et al., 2003) .  
Key Symptoms of Fibromyalgia 
Yunus (Baldry, 2001) divides and describes the symptoms of FM as 
musculoskeletal symptoms, non-musculoskeletal symptoms and associated 
symptoms. The musculoskeletal symptoms are listed as pain at multiple sites, 
stiffness, hurting all over and swollen feelings in soft tissue. The non­
musculoskeletal symptoms include fatigue at most times of the day, morning fatigue, 
poor sleep, and paraesthesia. Associated symptoms as listed by Yunus (Baldry, 2001 )  
include self-assessed anxiety, headaches, dysmenorrhoea, irritable bowel symptoms, 
restless leg syndrome, self-assessed depression, sicca symptoms, Raynaud' s 
syndrome and female urethral syndrome. 
Littlejohn (2001)  comments that most patients with FM experience a 
fluctuating set of symptoms occurring over months or years. He also includes the 
symptoms of cognitive dysfunction, dizziness, irritable bladder syndrome, multiple 
chemical sensitivities and neurally mediated hypotension. The main symptoms 
reported on in this literature review include the key symptoms of FM and include 
pain, non-restorative sleep and insomnia, cognitive dysfunction, autonomic nervous 
system and neuroendocrine dysfunction. 
Pain 
Until the 1 960s, pain was thought only to be a response to tissue damage. The 
medical community understood only the Cartesian view of pain at this time. Melzack 
( 1996) describes this Descartes' concept of pain as that produced by a direct 
transmission system from injured tissue in the body to a pain centre in the brain. He 
comments that this concept of pain has dominated pain therapy until recent times. 
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In 1965, the Melzack-Wall Gate Control Theory (Melzack, 1 996) suggested 
that a mechanism in the dorsal horns of the spinal cord acted as a gate that facilitated 
or inhibited the transmission of pain from the body to the brain. Melzack's Gate 
Control Theory encompassed the dynamic action of brain processes. The Gate 
Control Theory did not include the long term changes in the central nervous system 
resulting from the noxious input or other external influencing factors (Loeser & 
Melzack, 1 999). Melzack ( 1 996) commented that this theory does not explain some 
of the chronic pain conditions. 
Govind, (2004) in discussing pain management, states that "for treatment to 
be logical, rational and biologically plausible, an understanding of the mechanisms 
and an appreciation of the pathophysiology remains paramount - as exemplified by 
the successful treatment of hypertension, gastric ulcer and asthma. Devoid of this 
basic understanding, treatment may be empirical or at best a 'guesstimate"' (p. 1 ). At 
the recent International Association for the Study of Pain (IASP) Neuropathetic Pain 
Meeting, there was debate on the current IASP definition for neuropathic pain 
(Siddal, 2004). Some delegates took a broad approach of nervous system dysfunction 
to neuropathetic pain and included conditions such as FM and irritable bowel 
syndrome while others preferred a narrower definition such as evidence of a nervous 
system lesion (Siddal, 2004). There is still non-consensus on the definition of 
neuropathic pain within the confines of the International Association for the Study of 
Pain. 
The Pain of Fibromyalgia 
Bennett (2002e) identifies four major sites of pain m FM patients as 
peripheral tissues, the spinal cord, the brain and the descending modulation. These 
sites reflect the input of the peripheral pain generators, dorsal horn sensitisation, 
psychological influences and the modulating influence of the descending pathways. 
Pain therefore can be modified or influenced by various physiological and 
psychological factors. 
Pain is the primary symptom of FM and is often described as 'pain all over 
the body' . The International Association for the Study of Pain, in their classification 
of chronic pain (Merskey & Bogduk, 1 994), describe the pain of FM as widespread 
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aching of more than three months duration, perceived as deep pain and usually 
referred to muscle or bony prominences. The common areas are cervical, thoracic 
and lumbar spines. Pain in the trunk and proximal girdle is described as aching while 
distal limb pain is perceived as associated with swelling, numbness and stiffness. 
Pain intensity fluctuates daily, and although the pain can move from one area of the 
body to the other, it is usually continuous (Merskey & Bogduk, 1994). In the ACR 
1990 criteria report, 97% of patients had widespread pain. Over 75% of patients had 
pain in the cervical area, posterior thorax or lower lumbosacral area and 56% had 
pain in at least 15 of the zones when the body was divided into 30 regions (Wolfe et 
al., 1990). 
Jain and colleagues (2004), in the Canadian Consensus Document on FM, 
describe the pain of FM as any combination of burning, searing, tingling, shooting, 
deep aching, stabbing, sharp and/or feeling bruised all over. They list the 
characteristics of FM pain as allodynia, hyperalgesia, persistent pain, pronounced 
summation effects and after-reaction to repetitive stimuli and tenderness on 
examination. Other listed features of FM pain include widespread pain, non­
anatomical distribution, delay in onset following injury, pain felt in areas of 
perceived sensory deficit, diffuse arthralgia, shortness of breath and chest pain, low 
back pain, leg cramps, generalised stiffness and chronic headache (Jain et al., 2004). 
The core components of FM are chronic musculoskeletal pain and abnormal 
soft tissue tenderness, without tissue damage. Although muscle exhibits signs of 
tightness, examination does not reveal inflammation, degenerative changes or 
abnormal neurological signs. Maquet, Croisier, Renard and Crielaard (2002) 
compared muscle performance in women with FM and healthy women free of 
muscle and joint disease. The variables reflecting muscle strength, muscle fatigue, 
resistance and static muscle endurance were diminished in the FM group. 
Overview of the Pain of Fibromyalgia 
Zimmerman (1991) describes the pain of FM as a complex interaction of 
nociceptive, neuropathic and other dysregulatory central nervous system and 
psychosomatic mechanisms. Nociceptor pain results from the excitation of 
specialised nervous sensors that signal potentially harmful stimuli . Zimmerman 
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( 1 99 1 )  commented on metabolic deficiencies and neurogenic inflammation resulting 
from the release of Substance P and other neuropeptides from peripheral nerve 
endings, as possibly resulting in the chemical sensitisation of nociceptors and 
hyperalgesia. The neuropathic pain as described by Zimmerman is due to 
pathological mechanisms within the nerve cells and fibres in the peripheral and 
central nervous system. He suggests that the possible resultant neuronal 
hyperexcitability encouraged by 'a disturbed axonal transport system' may be 
causative factors of pain in FM. 
Cook, Lange, Ciccone, Liu, Steffener and Natelson (2004) discuss the 
emergence of brain imaging as an investigative tool, which has resulted in an 
increased understanding of the complexities of the nociceptive system in humans. 
The function of the nociceptive system in patients with FM was examined using 
functional magnetic resonance imaging (Cook et al., 2004). These studies concluded 
that subjects with FM were significantly more sensitive to experimental heat pain, 
and exhibited greater activity than controls, over multiple brain regions, in response 
to painful and non-painful stimuli. The authors conclude that these results provide 
support for a physiological explanation for FM pain, and comment that FM 
symptoms may be being maintained by amplified neural responses to afferent 
sensory stimuli. Their results indicate that brain responses to sensory stimuli in 
regions of the brain responsible for sensory, cognitive, and emotional aspects of the 
pain experience are increased in FM. 
Borg-Stein (2002) describes peripheral pain generators within local 
musculoskeletal, neurological and other sources as increasing in FM patients. Borg­
Stein divides peripheral pain generators into five major categories: joint and 
cartilage, enthesopathies, soft tissue pain, neuropathic pain, and visceral pain. She 
recommends a methodical search for these nociceptive peripheral pain generators, to 
decrease the total pain burden by decreasing the perpetuation of central sensitisation 
and decreasing the stimulus. She comments that FM sufferers are more able to 
participate in exercise programs if these peripheral musculoskeletal and neurologic 
pain generators are found and appropriately treated. These pain generators have 
features that distinguish them from the widespread pain of FM. 
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Chronic Pain and Its Impact 
As scientific inquiry into the neurobiology of chronic pain increases, the 
multiplicity of symptoms in FM becomes more understandable. The concept is 
emerging that FM is positioned toward the more painful end of a continuous 
spectrum of chronic pain (Bennett, 2000). 
In this area of chronic pain, Staud (2002) comments on the neuroplasticity of 
the brain where the central nervous system can learn and change, where the central 
nervous system adjusts and remodels itself if there is a need for different 
modifications or different expressions. FM sufferers fall into the category of chronic 
pain. The American Pain Society has created the phrase "Pain: The Fifth Vital Sign" 
to increase the awareness of pain treatment among health professionals (Clark 2004). 
They are encouraging health professionals to consider pain as the fifth vital sign and 
to assess patients for pain every time they check for pulse, blood pressure, core 
temperature and respiration. Jackson (2002) also refers to pain as the fifth vital sign. 
She describes chronic pain as the type of pain that does not serve any known purpose 
and that has outlived its usefulness, and describes chronic pain as a signalling system 
stuck on the 'on' position. 
Blyth (2003) believes that chronic pain such as musculoskeletal conditions 
and injury should be a recognised health priority in the public health arena in 
Australia. He describes chronic pain as waiting on the sidelines to be recognised. 
Though there is evidence on the efficacy of treatments for chronic pain, the health 
care policy on chronic pain is minimal in Australia (Blyth, 2003). 
Chronic pain can affect people's identity, interrupt behaviour, interfere with 
functioning and affect their sense of who they are (Harris, Morley, & Barton, 2003). 
Harris and colleagues (2003) have shown that depression and adjustment problems, 
in chronic pain patients, can result from extended interference with social roles and 
personal identity rather than momentary frustrations. McCracken and Eccleston 
(2003) recommend the acceptance-based approach to chronic pain rather than the 
coping strategies that have been dominant in clinical and research areas. Their 
research results from a chronic pain study have shown that the 'coping with chronic 
pain' variables were weakly related to acceptance of pain and unreliably related to 
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pain adjustment, while the 'acceptance of chronic pain' was associated with less 
pain, disability, depression and pain-related anxiety (McCracken & Eccleston, 2003). 
Two independent cross-sectional studies on the acceptance of pain (Viane et 
al., 2003) have confirmed the value of acceptance of pain in predicting well-being in 
patients suffering from chronic pain. The researchers found that the acceptance of 
chronic pain was strongly related to engagement in normal life activities and the 
recognition that pain may not change. They conclude that the acceptance of chronic 
pain is best envisaged as the shift away from pain to non-pain aspects of life, 
together with a shift away from the search for a cure and acknowledging that their 
pain may not change (Viane et al., 2003). 
Staud (2002) refers to pain as not just a biological phenomenon, but as a 
psychological and social phenomenon. Sator-Katzenschlager, Schiesser and Kazek­
Langenecker (2003) studied the effects of effective pain reduction on mood, 
behavioural and cognitive outcome measures in chronic pain patients. Significant 
reductions in pain intensity were accompanied by improvement in behavioural and 
cognitive dimensions, while mood and psychological well-being did not improve 
(Sator-Katzenschlager et al., 2003). 
Gender-related Differences in the Experience of Pain 
In the United States of America and other Western cultures, more women 
than men seek medical advice for symptoms of functional pain disorders (Chang & 
Heitkemper, 2002). The authors of a study on gender differences in irritable bowel 
syndrome suggest that influencing factors may be gender-related differences in 
visceral sensitivity, central nervous system pain processing, neuroendocrine, and 
autonomic nervous system and stress reactivity. Research in this area (Naliboff et al., 
2003b) has shown that different areas of the brain are stimulated in reaction to pain 
depending on the gender. In response to the same painful stimulus, the female brain 
showed greater activity in the emotion-based limbic system, while in men, the 
analytical-based centres of the cognitive regions resulted in greater activity (Naliboff 
et al., 2003b ). This issue of gender-related pain differences might be relevant to FM 
sufferers, because the majority of sufferers are female. 
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Hoffinan and Tarzian (2001) have commented that even though women more 
readily seek treatment for pain than men, they are less likely to receive it. The 
authors comment on several important questions around the biological origins of 
pain, gender differences related to pain and possible gender bias in the treatment of 
pain. They note the differences in the psychological factors influencing pain in how 
men and women attribute different meaning to their experience of pain. 
Pain of Urogenital Origin 
Pain of urogenital origin is a specific field in the area of chronic pam 
conditions. There are many specialities and multi-disciplinary centres for the 
management of pain involved with research into pain from the urinary tract. These 
include urologists, urogynaecologists, gynaecologists, surgeons, anesthesiologists, 
neuroscientists, psychologists and physiotherapists amongst many health 
professionals. It is recognised that many patients who experience pain of urogenital 
origin often suffer immensely and without the benefit of specific pain relief strategies 
(International Association for the Study of Pain, 2000). Researchers (Wesselmann, 
Burnett, & Heinberg, 1997) explain pain syndromes of the urogenital and rectal areas 
as well described but poorly understood and under-recognised focal pain syndromes. 
They list vulvodynia, orchialgia, urethral syndrome, penile pain, coccygodynia, 
prostatodynia, perineal pain, proctalgia fugax and proctodynia in this list of pain 
syndromes. The etiology of these pain syndromes often remains unknown. 
Pain Outcomes 
Bennett (2000) describes some of the possible end results of chronic pain as 
depression, marital relationship issues, vocational problems, medication dependency, 
sleep disorders, physical fatigue, personality changes, functional disability, 
emotional fatigue, painful movements, muscle deconditioning and stress increases. 
A recent Australian study (Oldroyd et al., 2003) explored the views of 
general medical practitioners on the care of the patient with a chronic disease. This 
qualitative study revealed consistent themes regarding the complexity of chronic 
disease management. Tension from the differences between the patients and their 
general practitioners' goals for care, time-consuming aspects of care and the lack of 
structure preventing the practitioner from being involved in structured 
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multidisciplinary care of their patients were all included in the emerging themes. 
Recommendations from the study included changes to assist the medical general 
practitioners in moving from acute care to providing longer term care as part of a 
multi-disciplinary team (Oldroyd et al., 2003). 
Fatigue 
The International Association for the Study of Pain describes fatigue as 
affecting 80% of people with FM and describes its severity as severe enough to 
interfere with daily activities (Merskey & Bogduk, 1994). Wolfe, Hawley and 
Wilson (1996) describe fatigue as a poorly understood symptom that is prevalent in 
several rheumatic conditions. Fatigue for FM patients is often worse in the morning 
with many of them experiencing unrefreshed sleep. Jain and colleagues (2004) note 
that the type of mechanism that generates fatigue can classify fatigue and assist in its 
assessment. They refer to the following classification in assessing fatigue: structural 
fatigue, muscular fatigue, arousal fatigue, motivational fatigue, oxygenation fatigue 
and metabolic fatigue. 
Nicassio, Moxham, Schuman, and Gevirtz (2002) evaluated the three 
predictors of fatigue in patients with FM as depression, sleep quality and pain. Their 
findings indicate a dysfunctional, cyclical pattern of heightened pain and non-restful 
sleep underlying the experience of patients' fatigue. In a study to determine diurnal 
rhythm characteristics of pain, stiffness and fatigue in patients with FM, the ratings 
of pain, stiffness and fatigue were found to be significantly correlated and revealed 
diurnal and possible weekly rhythmicity (Bellamy, Sothern, & Campbell, 2004). A 
structured, evidence-based review of all available literature on the coexistence of 
fatigue and pain has been completed (Fishbain et al., 2003). Of the 1 7  reports that 
met the quality criteria, 94. 1 % indicated there was an association between fatigue 
and pain. Additionally, 100% of a subgroup of 13 reports indicated there may be an 
etiological relationship between fatigue and pain (Fishbain et al., 2003). The 
researchers recommend that future research directions consider these possible 
mechanisms for the relationship between fatigue and pain. 
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Soderberg, Lundman and Norberg (2002) clarified the meaning of fatigue and 
tiredness as narrated by women with FM and healthy women. These results inform 
us that tiredness and fatigue are experienced differently by women with FM 
compared to healthy women who experience fatigue. For women with FM, the 
findings revealed four major themes: the body as a burden, an interfering obstacle, an 
absent presence and being in hope of alleviation. For healthy women, the main theme 
was of needing natural recovery. This study has shown that fatigue experienced and 
narrated by women with FM is quite different from the experience of tiredness as 
explained by healthy women. 
The majority of patients with FM and all patients with chronic fatigue 
syndrome experience fatigue (Clauw & Chrousos, 1997b ). These two conditions 
share overlapping clinical features. These authors suggest that current studies have 
not shown that poor sleep is the primary cause of these illnesses. However, the 
authors attribute some of the symptoms and physiological abnormalities to poor sleep 
such as the disruption of the circadian secretion of hormones released during sleep. 
Guymer and Clauw (2002) describe fatigue as one of the most prevalent 
features of FM, affecting between 76% and 8 1  % of patients. For management of the 
fatigue, they suggest a multi-modal treatment model that incorporates both 
pharmacological and non-pharmacological methods. The non-pharmacological 
methods include patient education on sleep hygiene, exercise management, energy 
expenditure and activity pacing. Pharmacological treatment includes the tricyclic 
antidepressants and serotonin reuptake inhibitors. Arnold, Keck and Welge (2000) 
undertook a meta-analysis and review of antidepressants for use in FM. Nine of 
sixteen trials were suitable for meta analysis. When compared with placebo, the 
tricyclic medications were associated with effect size larger than zero for all 
measurements. The largest effect was apparent in sleep quality. The authors 
recommend further randomised, double blind, placebo-controlled parallel designs 
where the antidepressants are administered at therapeutic dose ranges (Arnold et al. ,  
2000). 
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Non-restorative Sleep and Insomnia 
The International Association for the Study of Pain describes sleep 
disturbance as affecting 75% of people with FM and describe the feeling on waking 
as unrefreshed and tired (Merskey & Bogduk, 1994). Patients are encouraged to 
develop good sleep hygiene, to maintain low impact exercise, to pace their daytime 
activities, to slowly wind down activity in the evening, to use a supportive mattress 
and pillow, and to effectively manage any psychological problems. They are 
encouraged to continue with low dose tricyclics antidepressants or other prescribed 
medication where appropriate. Moldofsky (2002) suggests that tricyclic drugs may 
provide long term benefit for improving sleep, but queries the continuing benefit of 
these medications beyond one month in the reduction of pain. Growth hormone is 
reported to improve symptoms, but the high economic cost and the need for an 
injection restrict its use (Moldofsky, 2002). 
Research to characterise the patterns of electroencephalographic sleep and its 
association with sleep and pain in people with FM concluded that alpha intrusion 
during sleep can be of different patterns (Roizenblatt, Moldofsky, Benedito-Silva, & 
Tufik, 2001) .  Roizenblatt and colleagues (2001) detected three distinct patterns of 
alpha sleep activity in FM patients: phasic alpha that was simultaneous with delta 
activity in 50% of patients, tonic alpha that was continuous through non-REM sleep 
in 20% of patients and low alpha activity in 30% of patients. The authors report that 
83 .7% of control subjects exhibited low alpha activity. The phasic alpha intrusion 
pattern correlated better with clinical manifestations of FM (Roizenblatt et al., 2001). 
Electroencephalographic evidence of rapid alpha wave intrusion into slower 
delta wave deep sleep periods in FM patients are shown to be significantly greater 
than in controls (Boissevain & McCain, 1 991  ). Shaver, Lentz, Landis, Heitkemper, 
Buchwald and Woods ( 1997) found on polysomnography, that FM patients had more 
level I transitional sleep, more sleep-state changes and a higher sleep fragmentation. 
Studies by Affleck, Urrows, Tennen, Higgins and Abeles (1996) showed that, with 
FM patients, one night of poor sleep was followed by a significantly more painful 
day and another poorer night's sleep. Tryptophan, an amino acid that is the precursor 
of serotonin, is a significant neurotransmitter in the pathways related to level IV 
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sleep. The reduced concentration of tryptophan in relation to other plasma amino 
acids suggests an abnormality in serotonin metabolism (Bennett, 1 993). 
Italian researchers (Sarzi-Puttini et al . ,  2002) evaluated daytime hypersomnia 
m patients affected by FM (n=30) and found that the occurrence of daytime 
hypersomnia in these patients is linked to a greater severity of FM symptoms and 
evidence of greater polysomnographic alterations. Patients with daytime 
hypersomnia displayed a higher number of tender points (p < 0.0 1 ), a higher 
subjective pain score (p < 0.05) and more fatigue (p < 0.05). These patients had 
significantly less effective sleep than FM patients with no daytime hypersomnia (p < 
0.05), with a lower proportion of level III sleep (p < 0.00 1 ), level IV sleep (p < 
0.00 1 )  and twice as many arousals as per hour of sleep (p < 0.0 1 )  (Sarzi-Puttini et al., 
2002). 
A common cause of sleep deprivation for FM patients is restless leg 
syndrome, an unpleasant sensation in the lower limbs resulting in an urge to 
frequently move the legs. Yunus and Aldag ( 1 996) investigated the prevalence of 
restless leg syndrome and leg cramps in FM patients to find these symptoms were 
significantly more prevalent in FM patients and in those with rheumatoid arthritis 
than in normal controls. 
It is now recognised that sleep deprivation is a very serious health and safety 
risk factor within our communities and workplaces. The research focus on sleep is 
reflected in the Woolcock Institute of Medical Research 2nd Annual Sleep Loss 
Symposium held in Sydney, Australia in November 2004. Internationally there is 
increased interest in the health issues resulting from chronic sleep loss. Lamberg 
(2004) refers to the harm on health and quality of life of 70 million individuals in the 
United States of America because of chronic sleep loss and sleep disorders. The 
United States Surgeon General, R H Carmona, is cited in Lamberg (2004) 
commenting on sleep problems costing their nation $ 1 5  billion in health care 
expenses and $50 billion in lost productivity annually. The National Centre on Sleep 
Disorders Research in the United States aims to increase recognition and treatment of 
sleep disorders to cut health costs, treat sleep disorders and improve public health 
and quality of life of sufferers (Lamberg, 2004 ) .  
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This deprivation of restorative sleep is also an area of continuing research 
specifically in the FM area as non-restorative sleep is a major symptom for FM 
sufferers that can contribute to fatigue and intensify pain. 
Cognitive Dysfunction 
Patients with FM frequently report a decline in cognitive functioning, 
memory and mental alertness. This is also referred to as neurocognitive dysfunction. 
Jain and colleagues (2004) describe this as cognitive fatigue rather than a fixed 
impairment. They list the symptoms of cognitive dysfunction as: cognitive fog; 
problems with linguistic performance; dyslexia; difficulty with writing, reading 
mathematics, word retrieval and speaking; and short term memory dysfunction. 
Researchers (Park, Glass, Minear, & Crofford, 200 1 )  evaluated FM patients for the 
presence of cognitive deficits and tested the hypotheses that these abnormalities 
would fit into a model of cognitive ageing. They concluded that cognitive 
impairment, especially memory and vocabulary deficits, were evident although they 
found that the cognitive defects were not global. Their results show that there is 
cognitive dysfunction in FM patients and that it is related to pain. 
One study on sleep, daytime symptoms and cognitive performance in patients 
with FM (Cote & Moldofsky, 1 997) concluded that, rather than an impairment in 
accuracy, the cognitive performance of FM patients was affected by a slower speed 
in information processing, possibly due to pain, non-restorative sleep and mental 
fatigue. Sephton, Studts, Hoover, Weissbecker, Lynch, Ho, McGuffin and Salmon 
(2003) investigated the biological and psychological factors associated with memory 
function in FM. Although the authors suggest that their interpretation of results is 
limited by the lack of contrasting data from an age-matched healthy sample, the 
study suggests that hypocortisolism and depressive symptoms are factors underlying 
the cognitive deficits in FM. 
Associated Disorders and Other Symptoms of Fibromyalgia 
Clauw ( 1 995a) comments on the significant overlap between FM and other 
systemic illnesses/syndromes such as somatoform disorders, chronic fatigue 
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syndrome and Persian Gulf Syndrome. He lists these overlapping conditions as 
headaches, irritable bowel syndrome, temporomandibular dysfunction, non-cardiac 
chest pain, myofascial pain syndrome and urogenital symptoms. Clauw, when 
interviewed by Meisler (2000), described a spectrum of regional syndromes that 
involve different areas of the body in which there is a bidirectional relationship with 
FM. These include migraines, interstitial cystitis, non-cardiac chest pain and mitral 
valve prolapse. The ACR Criteria for the Classification of FM (Wolfe et al., 1 990) 
includes the following as symptoms: sleep disturbance, ' pain all over' ,  fatigue, 
morning stiffness > 15  minutes, anxiety, headache, prior depression, irritable bowel 
syndrome, sicca symptoms, urinary urgency, dysmenorrhea history and Raynaud's  
disease. Some of these associated disorders and symptoms will now be considered. 
Irritable Bowel Syndrome 
Irritable bowel syndrome and FM share many similarities. Both conditions 
are defined and diagnosed by symptom-based criteria. Both are defined as a 
symptom complex. There is no biological marker for either condition and the 
pathophysiologic basis for both is still unclear. In 1989, a group of investigators and 
experts on functional gastrointestinal disorders proposed a set of criteria known as 
the 'Rome' criteria. An updated set of criteria, the 'Rome II' was first published in 
2000 (Fennerty, 2003). Fennerty describes the criteria as useful in ensuring similar 
patients are enrolled in clinical research projects, but adds they are much less useful 
as a diagnostic tool in clinical practice. Similar to the criteria for FM, this 
classification criterion is research-based and is validated and rigid. The other criteria 
mentioned for the diagnosis of FM are the diagnostic criteria, which are clinically 
based, non-validated and ' softer' . Fennerty (2003) adds that, because of the 
limitations of the existing diagnostic criteria for IBS, the 'Rome III' criteria will soon 
need to be developed. 
The American Gastroenterology Association (AGA) medical position 
statement list three interrelated factors that affect the symptoms of IBS (American 
Gastroenterological Association, 2002). These include altered gut reactivity, a 
hypersensitive gut with enhanced visceral perception and pain and dysregulation of 
the brain-gut axis which may be associated with an increased stress reactivity and 
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altered perception and modulation of visceral afferent signals. This medical position 
statement also acknowledges that IBS adversely affects the health-related quality of 
life of patients. This includes impairment of their physical, emotional and psycho­
social roles to a degree that exceeds that found in patients with other medical 
conditions (American Gastroenterological Association, 2002). Olden (2003) 
comments on the progress in IBS research in finding enhanced visceral 
hypersensitivity in the colon and rectum as well as altered processing of signals to 
the brain and raises the question as to which neurotransmitters play a role in the 
altered processing of neural sensation in IBS patients. The similarities between the 
research paths of both FM and IBS are significant and noticeable. 
One study (Sperber et al. ,  1 999) has shown that FM and IBS co-exist in many 
patients. In their IBS study, 25 of the 79 IBS patients (3 1 .6%) and 3 of the 72 
controls (4.2%) had FM. Irritable bowel syndrome is a functional disorder of the 
gastrointestinal tract that presents as chronic abdominal pain and changed bowel 
function without evidence of laboratory or structural abnormalities on routine testing 
(Sperber et al., 1999). A further study by Sperber and colleagues (2000) evaluated 
the use of the Functional Bowel Disorder Severity Index (FBDSI) as a measure of 
the severity of disease among patients with IBS. This study included FM patients 
with IBS. An association was found between the FBDSI and IBS patient status with 
IBS non-patients, patients with IBS only and patients with both IBS and FM having 
increasingly severe scores. 
The Visceral Sensitivity Index (VSI) has been developed and validated as a 
reliable, valid measure of gastrointestinal symptom-specific anxiety (Labus et al., 
2004). Labus and colleagues acknowledge that anxiety, related to gastrointestinal 
sensations and symptoms, may play a significant role in the pathophysiology and 
health outcomes of patients with IBS. This 15-item scale may be useful for clinical 
assessment and treatment outcome studies. In the first prospective study of its kind, 
researchers have indicated that familial aggregation of IBS may occur (Kalantar, 
Loche, Zinsmeister, Beighley, & Talley, 2003). These findings need to be replicated 
in larger studies. The authors state that further studies will need to carefully evaluate 
the roles of intrafamilial, environmental and inherited factors in the etiology of these 
conditions. 
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Veale, Kavanagh, Fielding and Fitzgerald ( 199 1) suggest that primary FM 
and IBS may be different expressions of a common pathogenic process. The authors 
suggest that abnormalities of the central nociceptive processing may be present in 
IBS. They describe visceral hypersensitivity or decreased pain thresholds to 
distension of the gut as biological markers for IBS. Their studies suggest that patients 
with IBS may have cutaneous hyperalgesia similar to that experienced by patients 
with FM. In a prospective case-controlled study (n= 32), urinary frequency and 
urgency and the urodynamic findings of detrusor instability were significantly more 
common in women with irritable bowel syndrome (p < 0.05) (Monga, Marrero, 
Stanton, Lemieux, & Maxwell, 1997). The authors comment that these findings are 
indicative of an irritable bladder in the irritable bowel syndrome supporting the 
concept that irritable bowel syndrome may be part of a more generalised disorder of 
smooth muscle. 
Temporomandibular Joint Dysfunction 
A majority of FM patients suffer with temporomandibular joint dysfunction 
syndrome (Silver & Wallace, 2002). The authors found that symptoms associated 
with this dysfunction included teeth grinding, jaw clenching, and spasm in the 
temporomandibular joints with resultant localised pain and headaches. One study 
(Rhodus, Fricton, Carlson, & Messner, 2003) on the prevalence and profile of oral 
symptoms in an FM population has shown that there was a significant prevalence in 
temporomandibular dysfunction in an FM population (67.6%) compared to controls 
(20%) (p < 0.001). 
Chest Wall Symptoms 
Chest pain, palpitations and discomfort of the costochondral margins and 
chest wall are common in people with FM (Silver & Wallace, 2002). Cetin and Sivri 
(2001) have shown that dyspnea is a common symptom for patients with FM. The 
authors note that it is not associated with pulmonary function, but rather chest wall 
discomfort and pain. Studies suggest that FM patients have a significantly increased 
incidence of mitral valve prolapse with a greater than 20% incidence compared to 
2% recorded with healthy controls (Freed et al. ,  1999). This may be due to the 
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dysautonomia in FM causmg diffuse smooth muscle dysmotility that could be 
responsible for some of the associated FM symptoms such as mitral valve prolapse 
and non-allergic rhinitis (Clauw, 1995a). 
Restless Leg Syndrome 
Silver and Wallace (2002) describe restless leg syndrome as periodic limb 
movement disorder or nocturnal myoclonus and associate it with the alpha anomaly 
in non REM sleep in FM patients. This restless leg syndrome is found m 
approximately 15% of people diagnosed with FM (Silver & Wallace, 2002). 
Headaches 
Silver and Wallace note that over half of patients with FM experience 
headaches, and that many of these patients experience these headaches daily or many 
times per week. Wassem, McDonald and Racine (2002) found that headaches were 
one of the listed symptoms of FM, reported in greater than 70% of 54 study 
respondents. Kim (2004) cites Bernstein's study from the American Headache 
Society Annual Meeting in 2004, where three quarters of FM patients were shown to 
have chronic headaches ( n= 100). The survey from the department of anaesthesiology 
at the University of Pittsburgh has shown that 76% of FM patients had regular 
headaches and, of those, 21  % had migraine with aura and 27% had migraine without 
aura. Kim (2004) cites Bernstein in describing headaches as an integral part of FM 
for these patients, a part of the pain dysregulation of FM syndrome. 
Autonomic and/or Neuroendocrine Dysfunction 
Petzke and Clauw (2000) present an overview of findings of studies that 
assess aspects of the sympathetic nervous system function in FM. These reviewed 
studies included the areas of muscle sympathetic activity, microcirculation, heart rate 
variability, tilt table testing, endogenous pain modulation and biochemical markers 
(Petzke & Clauw, 2000). Jain and colleagues (2004) list autonomic dysfunctions as 
dizziness, neurally mediated hypotension and vertigo, loss of thermostatic and 
vasomotor stability, neurogenic or trophic oedema, sicca syndrome, cardiac and 
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respiratory irregularities, intestinal irregularities and bladder dysfunction. Also listed 
are the neuroendocrine dysfunctions of loss of adaptability and stress tolerance, 
weight gain, hypothyroidism, and dysmenorrhoea. Also listed are associated signs 
such as musculoskeletal asymmetry and muscle dysfunction. 
Other Findings 
Cold intolerance is a common symptom of FM. Wolfe and colleagues ( 1990) 
have shown that approximately 30% of FM patients experience this cold intolerance 
and that some may develop Raynaud's disease. Multiple sensitivities can result from 
the disordered sensory processing in people with FM with many sensations being 
amplified (Slotkoff, Radulovic, & Clauw, 1997). Dizziness is also a common 
symptom experienced by patients with FM. 
Recent findings from a genetic linkage study (Weissman, Gross, Fyer, & 
Heinman, 2004) indicate a possible syndrome in some families with panic disorder. 
This syndrome includes bladder problems such as IC, thyroid disorders, chronic 
headaches/migraines and mitral valve prolapse. Weissman and colleagues (2004) 
suggest that the range of symptom disorders includes disorders associated with IC 
such as FM, celiac disease and irritable bowel syndrome and further suggest that 
many or all of these conditions may share underlying pathophysiologic features. 
Swezey and Adams ( 1999) investigated the associations of bone mineral 
density and osteoporosis in patients with FM and healthy controls. The researchers 
concluded that in this study FM was frequently associated with osteoporosis and 
recommended appropriate prophylactic strategies. Further studies are necessary to 
consider the impact of the lack of exercise due to pain and fatigue on the decreased 
bone mineral density. 
Psychosocial Implications 
Physical trauma or emotional stress can trigger and/or exacerbate the 
symptoms of FM. Crofford and Clauw (2002a) state that as well as the 
neurobiological mechanism, behavioural factors can have an effect in symptom 
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expression in some FM patients. The effects of pain and other symptoms of FM can 
result in changed behaviour patterns and coping skills. These non-biologic factors 
play a major role in symptom expression in all rheumatic diseases, not just FM 
(Crofford & Clauw, 2002a). Jain et al (2004) refer to the common assertion that FM 
symptoms result from an underlying depression or other psychological issues, but 
state that this is not supported by available data. 
Psychosocial health is often used as an umbrella term under which diverse 
research inquiries are carried out (Martikainen, Bartley, & Lahelma, 2002). The 
Oxford English Dictionary defines ' psychosocial' as ' pertaining to the influence of 
social factors on an individual's mind or behaviour, and to the interrelation of 
behavioural and social factors' (Simpson & Weiner, 1 989). Schaefer ( 1 995) writes of 
the psychosocial aspects of living with FM in describing acceptable ways of living 
with the pain and discomfort of FM as a struggle to find balance. 
Soderberg, Lundman and Norberg (1999), in their study on women's 
experience of living with FM, showed women with FM lived lives significantly 
influenced by their illness. This study of women's experiences of living with FM was 
defined according to the themes of loss of freedom, threat to integrity and struggles 
to achieve relief and understanding. This loss of freedom embraced a body in pain, 
suffering from fatigue and from a loss of energy, living a changed life every day and 
having economic restrictions. The theme of threat to integrity emerged from the loss 
of credibility and the invisibility of the illness, together with the lack of knowledge 
about FM and a negative societal attitude. Women's struggle to achieve 
understanding and relief reflected the need to find an explanation for the condition, 
to seek relief and to plan one's daily life in accordance with the illness (Soderberg et 
al., 1 999). 
Researchers Soderberg and Lundman (2001 )  further considered transitions 
experienced by women with FM. These transitions are described as transitions in 
patterns of daily living, family life, social life, working life and learning to live with 
the changes caused by FM. The authors referred to FM as the "choreographer of 
activities and relationships" (p.617). In this study by Soderberg and Lundman 
(200 l ), women described these transitions as invisible to almost everyone except 
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themselves, but felt that other people viewed them as healthy beings. "It is like 
living in two different worlds simultaneously, the world of the sick and the world of 
the healthy" (p. 6 1 7). 
Mannerkorpi, Kroksmark and Ekdahl (1 999) have shown how patients with 
FM experience their symptoms in everyday life and they illuminated qualitative 
differences in FM patients' experiences and their management of symptoms. The 
study findings reveal four different patterns of perceiving and managing symptoms: 
Struggling, where patients perceived they managed their lives by mobilising their 
psychological and physical strength to manage pain and fatigue; Adapting, where 
patients perceived they managed their day by planning their activities on the basis of 
their assumptions of limitations; In despair, where patients despaired because they 
could no longer cope with their pain and life situations; Giving up, where patients 
had given up many activities of daily life and felt that symptoms dominated their 
lives (Mannerkorpi et al., 1 999). 
Toombs (1 992) writes of the taken-for-grantedness of daily living being 
interrupted by illness, as well as the experience of illness as a loss of wholeness. 
Toombs describes this loss of wholeness as not just the recognition of specific 
symptoms, but rather as a profound loss of total body integrity where the painful 
body disrupts the fundamental unity between one' s  body and one's self. For patients, 
the contradiction between their perception of their illness and the lack of medical 
objective findings, together with the long investigative periods, is very stressful 
(Hendriksson, 1 995). Being given a diagnosis is a relief, but presents the new stress 
of managing this chronic, incurable condition. 
FM and chronic fatigue syndrome (CFS) have an elusive etiology. There are 
no objective measures and both conditions are difficult to diagnose (Asbring & 
Narvanen, 2002). Accordingly, the potential for stigmatisation of women with these 
conditions needs evaluation. Asbring and Narvanen (2002) investigated whether 
women experienced their illness as stigmatising and examined the strategies women 
used in avoiding such compartmentalisation. Their findings have shown that the 
women felt they were being challenged by others about the truthfulness of their 
illness experience, and their moral character was being questioned. They also 
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described the 'psychologising' of their symptoms as stigmatising (Asbring & 
Narvanen, 2002). This is compounded by the lack of objective findings that can 
verify a physical illness that can encourage health care professionals to consider 
psychological factors as the precipitators of the illness. 
Asbring and Narvanen (2004) interviewed 1 2  women with FM and 1 3  women 
with CFS in a study defining the potential for the patients to gain control over their 
situation during the health care process, and to have some influence on the outcome 
of this process. The women described various strategies they utilised with health care 
providers to influence this process. These strategies included gaining control through 
knowledge, and using power strategies such as changing doctors, not following 
advice, confrontation, persuasion and insistence in directing treatment wishes. 
The stress of diagnosis and management of FM has a profound effect not only 
on the women diagnosed, but also on their family members. A study from the 
husband's  perspective of living with a woman with FM (Soderberg, Strand, Haapala, 
& Lundman, 2003) identified several themes: increasing responsibility and work in 
the home; being an advocate for and supporting the wife; learning to see the 
woman's changing needs; changing relationship between spouses; changing 
relationship with friends and relatives; deepening relationship with the children; and 
lacking information and knowledge about FM. 
A recent Australian study (Infante et al., 2004) explored the perceptions of 
patients with chronic conditions about the nature and quality of their care in general 
practice. Participants in the study included 76 consumers in 12  focus groups in two 
Australian states. The results of the study described three emerging priorities. The 
first centred on the quality of doctors, including their technical competence, 
interpersonal skills, consultation time for patients and continuity of care. The second 
priority was for the general practitioners to develop closer links with consumer 
organisations and support groups and to pass the information to their patients. Many 
participants felt that their general practitioners were 'good' at the management of the 
condition, but were 'weak' in recognising the emotional impact of chronic illness. 
There was also the expectation that the practitioners should not only know the 
medical side of a condition, but also the psychological and social impacts of the 
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disease. Participants also emphasised the need for general practitioners to continue 
professional development especially with respect to management and treatment of 
chronic illness. In a disease like FM, where the diagnosis has no pathological 
quantification, there is a sense of helplessness and/or disempowerment in doctors to 
treat a condition they are not sure exists. 
Etiology of Fibromyalgia 
The etiology of FM is multifactorial but specific etiology is still elusive. FM 
has been subjected to scientific scrutiny in the past 1 0  years with more than 1 000 
publications produced in peer-reviewed journals. The majority of people with FM 
enjoyed a relatively pain-free and active lifestyle before the onset of FM symptoms. 
Buskila and Neumann ( 1 997) have shown that the prevalence of blood relatives of 
patients with FM being diagnosed themselves with FM was 26% with the prevalence 
in female relatives being 4 1  %. The mean tender point counts of both young male and 
young female relatives in this study were significantly higher than in controls, being 
6. 1 vs. 0.2 (p < 0.0 1 )  in males and 4.4 vs. 0.4 (p < 0.0 1 )  in females. The mean tender 
point counts of adult relatives were even higher than controls with 4.0 vs. 0.04 (p < 
0.0 1 )  for males and 1 0.3 vs. 0.28 (< 0.0 1 )  for females. Buskila and Neumann 
concluded that patients with FM do have a higher prevalence of FM and more tender 
points than an age-matched group within the general population. They conclude that 
this trait is the result of genetic and environmental factors. 
The symptoms of FM reflect alterations in pain perception, mood and sleep 
and may be a stress-related illness as its onset often coincides with a stressful 
situation, either physical or psychological (Pillmer, Bradley, Crofford, Moldofsky, & 
Chrousos, 1 997). Abnormalities in pain perception occur such as allodynia, which is 
pain with innocuous stimulation, and hyperalgesia, which is an increased sensitivity 
to pain stimuli. Both of these abnormalities are present in patients with FM. Recent 
attention for an explanation of this pain is on the central nervous system, rather than 
on peripheral causes. 
The main symptom of FM is chronic widespread pain. At the 1 oth World 
Congress on Pain, FM was frequently referred to as the classic example of the 
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' central pain state' . This indicates that peripheral tissue causes of pain cannot be 
easily identified in most FM patients and suggests that most of the action is at the 
level of the spinal cord and above (Bennett, 2002a). Researchers are therefore 
focusing more on the role of the central nervous system rather than on the 
musculoskeletal system in an effort to explain the symptoms of FM. A disorder of 
the central processing of sensory information from the nociceptor and 
mechanoreceptor systems can result in numerous neurophysiological changes that are 
observed in FM sufferers. 
Tissue damage does not need to be present for a patient to experience pain. 
Schug (2002) suggests that pain should not be considered to be acute or chronic, but 
rather as physiological or pathological pain. He describes physiological pain as 
having only a biological function like pulling away from heat to protect the body and 
pathological pain as having no biological function as healing is complete. Schug 
observes that spontaneous pain occurring in the absence of an apparent stimulus is 
caused by the upregulation of the lack of inhibition and that pain sensitisation is an 
exaggerated response to pain. Littlejohn (1998) describes FM as the result of central 
sensitisation, an increase in the excitability and responsiveness of neurones in the 
spinal cord. This central sensitisation leads to an increase in the activities in higher 
brain centres and is perceived as more intense and prolonged pain. This 
hyperexcitability is mediated by the activation of neurones with N-methyl-D­
aspartate (NMDA) receptor sites by some excitatory amino acids (Pillmer et al., 
1997). The release of these amino acids and their effect on the dorsal horn neurones 
are increased by some neuropeptide transmitters like dynorphin, Substance P (SP) 
and calcitonin gene-related peptide (Pillmer et al., 1 997). 
Bennett ( 1 998a) uses the terminology "disordered sensory processing" to 
encompass the concept of allodynia where light touch evokes severe pain. He 
suggests this non-nociceptive pain is usually dependent on central sensitisation that 
has been induced by prior or ongoing nociception and that an understanding of this 
non-nociception pain is relevant to the current understanding of FM. Different 
treatment strategies from those used to treat nociceptive pain are required for the 
treatment of non-nociceptive pain. 
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Bennett (2002a) comments that an understanding of the detailed mechanisms 
of neurochemical receptor interactions will be central to the development of new 
drugs for treating chronic pain conditions. As a rheumatologist, Bennett (2002a) is 
increasingly convinced that FM is primarily a neurological disorder that is presenting 
as a musculoskeletal pain syndrome. 
Staud (2002) sought to obtain evidence that input into central nociceptive 
pathways is abnormally processed in individuals with FM. It was concluded that 
central pain processing is abnormal, that pain memory is increased, that FM pain 
correlates with heat and mechanical 'wind-up' ,  and that these differences are due to 
clearly established biological mechanisms (Staud, 2002). This is one reason why pre­
emptive analgesia is currently of great interest to pain researchers, because 
pretreating with an analgesic agent, peripheral and central sensitisation associated 
with major tissue insult or disease may decrease (Sidebotham, Schug, & Petcu, 
1997). These authors state that unrelieved pain can be the most distressing of human 
conditions and should attract the time and effort of medical researchers. 
Nociception is activity induced m neural pathways by stimuli that are 
potentially harmful. Nociception is not a passive, one-directional process, but a 
complex interaction between ascending and descending pathways that has the ability 
to alter the relationship between stimulus and response (Rao, 2002). Nociceptive 
stimuli from the periphery are relayed to the central nervous system via either 
unmyelinated C fibres or myelinated Ao fibres that terminate in the dorsal horn. 
These fibres synapse with dorsal horn interneurons and projection neurones (Rao, 
2002). Willis and Westlund (1997) explain that a subset of dorsal horn neurones 
project supraspinally via the spinothalamic tract and other pathways, thus forming 
the basis of pain perception in the brain. 
The neuropharmacology of the dorsal horn neuron is complex, with 
excitatory and inhibitory neurotransmitters present. The complicated detailing of 
these neurotransmitters and the research findings in relation to chronic pain are far 
beyond the scope of this literature review. However, Substance P-mediated 
neurotransmission has been the subject of animal studies replicating chronic pain 
(Rao, 2002). Rao remarked that the role of Substance P-mediated neurotransmission 
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in human nociception processing is controversial. Substance P is a neuropeptide 
stored in the secretory glands of sensory nerves and is released by axonal 
stimulation. Substance P has multiple biological effects that include stimulation of 
muscle, pain nociception, immune cell functions, plasma extravasation and many 
other inflammatory effects (Luber-Narod et al., 1 997). Several studies (Russel et al., 
1 994; Vaeroy, Helle, Forre, Kass, & Terenius, 1 988) have shown that the 
neuropeptide Substance P occurs in the cerebrospinal fluid of patients with FM two 
to three times higher than in control subjects. Substance P lowers the threshold of 
synaptic excitability, which allows for the unmasking of normally silent interspinal 
synapses (Coderre, Katz, Vaccarino, & Melzack, 1 993). De Vane (2001)  describes 
the physiological role of Substance P as a modulator of nociception that is involved 
in the signalling of the intensity of noxious or aversive stimuli. 
Recent genetic studies with mice and the development of Substance P 
antagonists have redefined this neurotransmitter as an integral part of the central 
nervous system pathways implicated in psychological stress (De Vane, 2001 ). 
Current research focus is on clinical applications of Substance P antagonists to 
enhance treatment of diseases linked with emotional response and with the 
interpretation of sensory input into the brain (De Vane, 2001 ). 
The concept of neurogenic inflammation is based on the release of Substance 
P and related peptides by an axon reflex mechanism. Saban, Saban, and Bjorling 
(1 997) investigated peptide-induced release of inflammatory mediators by the 
urinary bladder and concluded that the peptides evaluated induced changes that may 
directly regulate the participation of these peptides in the pathogenesis of cystitis. 
Callsen-Cencic and Mense (1 997) also questioned whether alterations in the 
expression of neuropeptides and nitric oxide synthase in the neuronal pathways to the 
bladder might be involved in the hyperexcitability of the bladder with the 
development of cystitis. 
Rao (2002) describes how the behavioural state of central sensitisation may 
be the result of alterations in the ascending or descending neural pathways of the 
brain and spinal cord. Behbehani ( 1 995) describes the major components of the 
descending nociceptive system. He describes the periaqueductal gray as a central 
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structure in this linkage, linking the cortex and other higher structures with the dorsal 
horn and processing both ascending and descending nociceptive information. The 
monoamines, serotonin and noradrenaline, have a central role in this descending 
modulation. The place of the descending system in chronic pain is a subject for 
current research in seeking answers for management for chronic pain in FM. Rao 
(2002) cites a number of studies showing reduced spinal noradrenaline outflow 
results in chronic hyperalgesic states in laboratory animals. 
As well as neurotransmitter abnormalities, hormonal and biochemical 
abnormalities are detectable in patients with FM (Clauw, 1 995a). Insulin-like growth 
factor I (IGF 1/somatomedin C) is a hormone produced in the liver, primarily in 
response to the growth hormone. Most patients with FM have low serum levels of 
IGF I. Bennet (1 993) suggests a disruption of the neuroendocrine axis that controls 
growth hormone production could be the link between disturbed sleep and muscle 
pain because this hormone is produced mainly during level IV sleep. Studies have 
shown that treating these patients with human growth hormone leads to an 
improvement of symptoms (Bennett, Clark, & Walczyk, 1 998b). Bennett (2004) 
notes that suboptimal growth hormone secretion, resulting in a state of adult growth 
hormone deficiency, may occur in chronic inflammatory disease, chronic 
corticosteroid use and FM. He describes the need to evaluate the under - and over­
secretion of growth hormone for practising rheumatologists. 
The hypothalamic-pituitary-adrenal (HP A) axis has been described as a 
complex brain-to-body pathway involving the hypothalamus, pituitary and adrenal 
glands. Adler, Kinsley, Hurwitz, Mossey, and Goldenberg ( 1 999) describe the HPA 
axis, and the autonomic nervous system, as the major pathways for the body's 
responses to stressful conditions such as pain, exercise, trauma or infection. Both 
systems are influenced by genetic factors, environmental factors and chronic illness 
(Adler et al., 1 999). Crofford and colleagues (1 994) examined basal and stimulated 
HP A axis and related hormone levels in patients with FM. Their results showed that 
HP A function is altered in patients with FM. Crofford (2002b) refers to the evidence 
of the HP A axis involvement in acute and chronic pain and questions whether the 
HP A axis abnormalities in FM reflect pre-existing vulnerability to the FM spectrum 
of the disease or if chronic somatic symptoms as seen in FM alter HP A axis activity. 
- 58 -
Further studies by Adler and colleagues (1999) have shown that patients with FM 
have an impairment of the hypothalamic-pituitary portion of the hypothalamic­
adrenal axis and the sympathoadrenal system. This results in reduced 
adrenocorticotrophic hormone (ACTH) and epinephrine responses to hypoglycaemia. 
Neeck and Riedel (1 999) postulate that the distortion of the hormonal pattern 
m FM patients can be attributed to hyperactivity of the corticotropin-releasing 
hormone (CRH). The authors suggest that this hyperactivity is driven and sustained 
by the stress from chronic musculoskeletal pain and/or by changes in the CNS 
mechanism of nociception. Neeck and Riedek ( 1 999) concluded from their studies of 
the entire endocrine profile of sixteen FM patients and seventeen controls that the 
pattern of hormonal deviations in patients with FM is a CNS adjustment to chronic 
pain and stress and is a specific entity of FM. 
Martinez-Lavin (2002) suggests that dysautonomia may play a central role in 
the pathogenesis of FM because autonomic nervous system (ANS) dysfunction is 
frequently found in patients with FM. Martinez-Lavin describes the ANS as a 
dynamic system with intense and instantaneous onset of action and dissipation that 
works closely with the endocrine system, especially the hypothalamic-pituitary­
adrenal axis and the growth hormone axis. Because the ANS regulates the function 
of most of the organs and systems of the body, it is the main homeostatic system. 
Martinez-Lavin (2002) proposes a pathogenic model of 'sympathetically maintained 
pain' suggesting that the hyperactive sympathetic nervous system can result in 
constant fatigue, morning stiffness, sleep disorders, intestinal irritability and other 
FM symptomatology. Raj ,  Brouillard, Simpson, Hopman and Abdollah (2000) have 
shown abnormal responses to two tests of autonomic nervous system functioning in 
patients with FM. The authors comment that further research is needed to ascertain if 
dysautonomia has an influence in the pathogenesis of FM or if dysautonomia results 
from FM. 
Using neuroimaging to measure the change in regional cerebral blood flow 
produced by pain in patients with FM, Bradley, McKendree-Smith, Alberts, Alarcon, 
Mountz and Deutsch (2000) identified lower than normal blood flow levels to two 
major pain processing areas in the brain, the thalamus and the caudate nuclei. 
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Kwiatek, Bamden, Tedman, Jarrett, Chew, Rowe and Pile (2000) confirmed, in their 
work using single-photon-emission computed tomography (SPECT) brain scans on 
cerebral blood flow, that there is reduced regional cerebral blood flow (rCBF) in the 
right thalamus as well as the pontine tegmentum in the brain stem of patients with 
FM. The authors conclude that the pathophysiological significance of these changes 
in FM patients needs to be clarified with further research. 
Because FM patients suffer other symptoms, such as sleep abnormalities, 
fatigue, irritable bowel and bladder symptoms and others as well as pain, Clauw and 
Chrousos (1997b) and Littlejohn (1996) question how the pathophysiology of these 
other symptoms is related to central sensitisation. Various hypotheses have been 
considered and published by researchers but this is still an ongoing area of active 
debate and research as knowledge in the area of pain medicine continues to grow. 
Etiology of Bladder Symptomatology in FM 
Al-Chaer (2000) describes visceral pain as having the capacity to become the 
consuming focus of one's life. Al-Chaer describes the clinical impact of pain from 
internal organs (visceral pain) as outweighing somatic pain because of the high 
incidence of algogenic (pain causing) conditions, which affect the viscera, and the 
tendency of these conditions to be chronic or recurrent. McMahon (2004) describes 
the sensory innervation of the viscera as serving a number of important functions, 
including the transmission of visceral sensations such as pain. He comments that the 
transduction properties of visceral afferents are not stable and can be altered by 
numerous factors. These altered properties of all neurobiological systems are 
described as forms of plasticity. McMahon (2004) describes the functionally relevant 
forms of plasticity in the context of visceral sensory neurones as those that affect the 
encoding and transmission of sensory information, and comments on the increased 
excitability of sensory neurones causing functional consequences and contributing to 
chronic pain states. 
Butrick (2004) describes the visceral silent afferents as all having the capacity 
to transmit pain. He notes that 10% of the afferents are silent in the skin compared 
with 30%-80% of the visceral afferents being silent. These silent afferents can 
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become active with prolonged stimulation and have a major role in tissue 
sensitisation (Butrick, 2004). Cervero (1 994) states that the bladder does have the 
highest neural density and the greatest proportion of silent C-fibres of any viscera. 
Cervero and Laird ( 1999) question the conventional view of visceral pain as 
simply a variant of somatic pain, based on the belief that a single neurological 
mechanism is responsible for all pain. The authors acknowledge that the two 
pathways have much in common, but note that there are important differences. They 
comment on the lack of specialised clinicians with expertise in the management of 
visceral pain leading to a range of treatment by a range of specialists treating visceral 
pain as a symptom and not as a distinct neurological entity. 
Cervero and Laird ( 1 999) comment that, although the mechanisms of visceral 
pain differ between organs and organ systems, there are two common principles that 
apply to visceral pain. The first is that, because neurological mechanisms of visceral 
pain differ from those mechanisms in somatic pain, the findings from somatic pain 
cannot therefore be extrapolated to visceral pain. The second principle is that the 
perception and psychological processing of visceral pain is different from that of 
somatic pain. Cervero and Laird refer to five important clinical characteristics of 
visceral pain as: not all viscera are sensitive to pain; it is not always linked to visceral 
injury; it is diffuse and poorly localised; it is referred to other locations; and it is 
accompanied by motor and autonomic reflexes such as nausea and muscle spasm. 
Cervero and Laird (1999) refer to the challenge to established paradigms on 
the transmission of visceral pain, stating that there are two distinct classes of 
nociceptive sensory receptors that innervate internal organs. The first class of 
receptors has a high threshold to natural, mainly mechanical stimuli, where stimulus 
intensity and nerve activity are evoked entirely by stimuli within the noxious range. 
These high threshold receptors have been identified in a number of organs and organ 
systems, including the ureter, urinary bladder and uterus. The second class of 
receptors has a low threshold to natural, mainly mechanical, stimuli where nerve 
activity of these low threshold receptors is evoked by stimulation of different 
intensities from innocuous to noxious (Cervero & Laird, 1999). These receptors have 
also been described in organs, including the urinary bladder (Cervero & Laird, 1 999). 
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Cervero and Janig (1992) also suggest that a large component of the afferent 
innervation of internal organs consists of afferent fibres that are usually quiescent 
and become activated only when inflammation is present. This theory proposes that 
these sensory receptors contribute to the signalling of chronic visceral pain, with long 
term alterations of spinal reflexes and abnormal autonomic regulation of internal 
organs. 
Overall, visceral pain is not the focus of this FM study. However, the 
symptoms of visceral pain from the urogenital system are to be considered. Although 
both irritable urinary symptoms and irritable bowel syndrome are listed as associated 
symptoms of FM, more research is being undertaken in the area of irritable bowel 
syndrome than in the urogenital pain arena. Cervero and Laird (1999) cite a number 
of studies lending support to the hypothesis that functional abdominal syndromes 
such as irritable bowel syndrome may be the result of visceral hypersensitivity that 
causes patients to become more aware of gastrointestinal activity. These authors 
suggest that this heightened awareness could be the result of sensitisation of the 
peripheral nociceptors or of some alterations of the central processing that result in 
an increase in the activation of visceral nociceptive pathways. 
Costa, Glise and Graffer (2004) acknowledge that, through neural 
information from the viscera, the central nervous system plays an important role in 
health and disease, but that not much of the visceral afferent information reaches our 
conscious experience, except in circumstances where it produces unpleasant 
sensations such as pain, discomfort and nausea. 
Giamberardino, De Laurentis, Affaitati, Lerza, Lapenna and Vecchi et (2001 ), 
from the Department of Medicine and Aging from the University of Chieti, in Italy, 
researched the clinical observation that algogenic conditions of one internal organ 
can affect reactivity to painful stimuli of other visceral areas, with over-lapping of 
sensory projections. Results indicate that algogenic conditions of the female 
reproductive organs enhance pain and referred hyperalgesia from the urinary tract. 
The authors point out that the female reproductive organs, and the urinary tract, have 
common sensory projections to spinal cord segments. Giamberardino and colleagues 
(2001) suggest increased afferent signals from one visceral domain, such as the 
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reproductive organs, towards the central nervous system, increase the excitability of 
viscero-visceral convergent neurones in the spinal cord. This then results in the 
central effect of the input from the second internal organ, the urinary tract being 
amplified and resulting in 'viscero-visceral hyperalgesia' . These researchers have 
provided evidence of an interaction of sensory nerves from different viscera resulting 
in the development of pain symptoms. 
Ishigooka, Zermann, Doggweiler, Schmidt, Hashimoto and Nakada (2001) 
explored the potential of chronic bladder irritation in an animal model, resulting in 
central sensitisation. Bennett (2001) states that the understanding of visceral pain 
leading to central sensitisation is gaining ground in both the clinical and 
experimental arenas. He comments that this is of particular importance to 
rheumatologists who endeavour to treat and manage the associated symptoms of FM 
such as irritable bowel and bladder syndromes. 
Researchers (Yoshimura, Seki, Chancellor, de Groat, & Ueda, 2002) 
hypothesise that in some chronic bladder conditions, the hyperexcitability of the C­
fibre afferent pathways, which during bladder filling are normally silent, may be the 
mechanism for bladder pain and urgency. Yoshimura and colleagues (2002) consider 
C-fibre afferent pathways in urinary frequency and pain in painful bladder 
syndromes as targets for treatment of this condition. Their focus is on the modulation 
of activity of bladder afferent pathways, preventing bladder pain by interfering with 
the steps involved in altering C-fibre activity. Yoshimura and colleagues (2002) 
suggest that a mechanism by which pain is induced involves chronic tissue 
inflammation that can lead to some functional changes in C-fibre afferents, and that 
the normally silent fibres appear to have specific functions in signalling noxious 
events in the bladder. Their study concludes that the hyperexcitability of C-fibre 
afferent pathways is likely involved in pain associated with painful bladder 
syndrome. This area of urogenital pain is a major focus for pain researchers in this 
early 21st century. 
Felson, (2003/2004) as president for the Society for Basic Urological 
Research, comments he is encouraged by the research on pain and sensory 
mechanisms in both bladder processes, sensation and pain, and urothelial cell 
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function. Felson describes their urological societal research as attempting to 
understand the fundamental disease processes as this is what translates into 
treatments and cures. 
Hypotheses Explaining Fibromyalgia 
Chaitow (2003) summarises a number of hypotheses explaining the evolution 
of FM. He refers to the chronobiological hypothesis by Moldofsky, the genetic 
hypothesis by Goldstein, the integrated hypothesis by Bennett, the nociceptive 
hypothesis by Wolfe and the stress hormone hypothesis by Goldenberg and Adler. A 
brief synopsis of each hypothesis is delineated here. 
Moldofsky's chronobiological hypothesis suggests that FM is the result of 
altered biological rhythms, including diurnal physiological functions and 
environmental influences, together with psychosocial and behavioural influences 
(Chaitow, 2003). Goldstein's hypothesis considers a genetic predisposition in the 
etiology FM. Chaitow (2003) lists a number of studies where genetically acquired 
traits such as joint hypermobility and mitral valve prolapse are reported as more 
common in the FM population than in the general population. There are also 
indications of familial tendencies in the development of FM. Bennett's integrated 
hypothesis (Chaitow, 2003) considers blending both the central and peripheral 
nervous system etiologies. The nociceptive hypothesis by Wolfe (Chaitow, 2003) 
proposes pain amplification resulting from chronic pain stimulus, progressing under 
the influence of genetic factors, somatic disease, sleep disturbance and psychological 
factors with the evolution of FM. 
Clauw and Williams (2002) present a model that unifies some studies and 
hypotheses on the role of altered central nervous function. The model, known as the 
Chronic Multisymptom Illness (CMI}, is described by the authors as the constellation 
of stress-mediated symptoms and syndromes that can occur in two forms within the 
individual. The first form is described as a systemic or widespread symptom 
expression and includes FM and chronic fatigue syndrome (CFS). The second format 
is described as single organ or single region symptom expression and includes 
conditions such as migraine or tension headaches and irritable bowel syndrome. 
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Clauw ( 1 995a) also presents a unifying hypothesis to describe the spectrum 
of symptoms and syndromes that are associated with FM. He comments that, 
although multiple non-rheumatic features initially seem unrelated, they can be 
divided into four categories based on the underlying cause and clustering of cohorts 
of patients. Clauw describes these four categories as: neurologic as seen in sleep 
disturbance, paresthesias, vestibular and cognitive symptoms and mood disturbances; 
smooth muscle dysmotility as seen in irritable bowel, bladder symptoms, and 
migraine headaches; increased skeletal muscle tone as seen m myalgias, TMJ 
syndrome and tension headaches; and irritative or inflammatory symptoms as seen in 
cystitis, rhinitis, and pharyngitis. Clauw ( 1 995a) postulates that a different effector 
arm of the nervous system results in specific symptomatology mediating each group 
of symptoms. This integrated hypothesis is the basis of the theoretical framework for 
this thesis. 
In detailing this integrated hypothesis, Clauw ( 1 995a) suggests that 
genetically vulnerable individuals may be asymptomatic throughout life until a 
'triggering' event, although some may have always been aware of some of the allied 
conditions such as migraines or cystitis. Many may stop exercising as a result of this 
' triggering' event and that may increase the symptoms. Clauw describes the resultant 
adaptive stress response activating both the hypothalamic pituitary adrenal (HP A) 
axis and the sympathetic system. 
Clauw ( 1 995a) states that once the latent CNS hyperactivity is apparent then 
all or some of the effector arms of the central nervous system can be involved. Clauw 
suggests that an elevated ratio of excitatory to inhibitory neuromodulators is 
responsible for this spectrum of conditions, the region of the central nervous system 
being affected being reflected in the symptomatology. More than one of the effector 
arms of the central nervous system can be activated at any one time. Clauw ( 1 995a) 
cites studies by Mayer and Raybold, White, Stevens and Upton and Whorwell, 
Lupton, Erduran and Wilson in demonstrating this concurrent activation by studies 
on irritable bowel syndrome where there is both diffuse smooth muscle dysmotility 
of the intestines, oesophagus, bladder and bronchus as well as increased visceral 
nociception. The literature discussed in the etiology of bladder symptomatology in 
this thesis indicates both neurogenic inflammation and increased visceral nociception 
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are involved in the irritative and bladder pain sensations in women with FM. Because 
several arms of the nervous system contribute to specific symptoms, Clauw (1995a) 
suggests that a multi-disciplinary approach for examining symptoms and systems 
concurrently is more likely to provide effective treatments. 
It is obvious from the various hypotheses that there are numerous evolving 
concepts in the etiology of FM. In summary, the evolution of understanding of the 
plasticity of the nervous system, the interaction between somatic and visceral 
pathways and the expansion of information on neurotransmitters are together 
increasing our understanding of etiological factors in the development of FM and 
therefore in management strategies. 
Treatment /Management of FM 
Clauw (2000) commented that not all health care professionals are interested 
in the diagnosis and management of patients with FM while others see the FM 
patient as difficult. Clauw suggests that this perception of difficulty may be because 
the physician is unable to improve the condition of the patient, or their demands 
exceed the physician's  capabilities. He recommends the early diagnosis of FM, 
before the chronicity of the condition results in dysfunction and disability. 
Millea and Hollaway (2000) suggest that the physician's  supportive 
counselling skills and openness to try new treatment strategies with refractory cases 
are an important part of the management strategy for FM. Bauman, Fardy and Harris 
(2003) discuss patient-centred care being about the sharing of the management of an 
illness between the patients and their doctor and the evidence of this patient-centred 
care having a favourable impact on chronic health conditions, including chronic 
musculoskeletal conditions. The main features of this patient-centred care, featuring 
doctor-patient interaction, include shared goal setting, with written management 
plans, supportive community-based programs with a focus on health promotion and 
healthy lifestyles. Effective patient-centred care results in a partnership between the 
doctors and patients where the patients can talk freely about the emotional and 
psychological issues related to their chronic condition and not just the associated 
physical symptoms. 
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The pain of FM is not caused by peripheral inflammation, but rather by a 
central nervous system defect and therefore different treatment interventions are 
necessary (Clauw, 2000). The author encourages extended medical consultations 
with FM patients until there is an understanding on the part of the physician of the 
problems the patients are experiencing and for the patients to understand that the 
treatment will involve patient participation. 
There is no one specific treatment for FM. Once the patient is diagnosed with 
FM, the treatment should be individualised, with regular assessment to monitor 
treatment efficacy. The condition is managed by a number of specific approaches to 
address the symptoms. This multimodal approach includes education, psychological, 
exercise and medication regimes. Education about the condition is paramount and it 
is extremely validating for the patient to receive a diagnosis usually after a long 
search for an answer to their pain and the impact of associated symptoms. Although 
FM is not life threatening, it is a quality of life threatening condition, and treatment 
and management must focus on all aspects of appropriate medical and self­
management techniques. The approach to address specific symptoms is imperative. 
One example is the symptom of bladder irritability. Education on normal bladder 
function, good bladder habits and bladder management strategies would be included 
for women with these specific bladder symptoms. 
A six-year prospective study of a cohort of patients with FM has shown that 
some symptoms of FM can persist for years, but some aspects of quality of life 
improve over time because of coping strategies patients can develop with or without 
professional assistance (Baumgartner, Finckh, Cedraschi, & Vischer, 2002a). A 
longitudinal study (Fitzcharles, DaCosta, & Poyhia, 2003) examining the outcome of 
FM with standard medical care was favourable, with almost half of the sample 
reporting clinically meaningful improvement . The authors suggest that, because of 
the current thinking on the pathogenesis of FM of central dysregulation of the pain­
processing mechanisms, it may be possible that with time there could be a resetting 
of the pain threshold. Fitzcharles and colleagues (2003) suggest that some treatment 
interventions may facilitate the shift of this pain threshold towards normal. 
- 67 -
Littlejohn and Walker (2002b), in considering a realistic approach to 
managing patients with FM, note that, because FM probably arises from a disordered 
neurophysiology, the effects embrace thoughts, emotions and cognitions because of 
the influence of central control inputs. The biopsychosocial model of pain combines 
the notions that, at the physiological level, changes are initiated by trauma or 
pathology, whilst at the psychological level variables are reflected in the attention to 
internal sensations and this attention and behavioural responses can be influenced by 
social and environmental variables (Nicholas, 2000). The Council of the Australian 
Pain Society has recently published a paper on Pain Management Programs for 
Chronic, Persistent or Long Lasting Pain (Speldewinde & O'Callaghan, 2002). This 
program is based on the bio-psycho-social model as the authors state that simple 
analgesics, opioids and interventional techniques often help with the nociceptive 
component, but do not always address the larger psychological aspects of an 
individual's suffering. 
Bennett (2002e) also emphasises a rational approach to the management of 
FM by adopting a holistic approach based on the bio-psycho-social approach to 
management. He discourages treating the diagnosis of FM as a unified entity, but 
rather recommends that attention be given to twelve separate management issues. 
These are listed as diagnosis and evaluation, education, pain, fatigue, sleep, 
psychological disorders, endocrine dysfunction, dysautonomia, deconditioning, 
cognitive dysfunction, the existential crisis and associated syndromes. Bennett 
(2002e) states that the concept that FM symptomatology results from the 
amplification of incoming sensory impulses has revolutionised the understanding of 
FM and created a more rational approach to treatment. 
A review of multi-disciplinary treatment studies for patients with FM (Oliver, 
Cronan, & Walen, 2001) has shown that these programs are generally effective. 
Based on these findings, the authors have recommended that future researchers 
utilise reliable and valid measures designed for patients with FM. Creamer, Singh, 
Hochberg and Berman (2000) have shown that a non-pharmacological intervention 
for FM that included education, relaxation, and Qi Gong movement therapy weekly 
for eight weeks resulted in significant improvement in signs and symptoms in FM. 
Results from an evaluation on comparing the efficacy of pharmacological and non-
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pharmacological treatments of FM by Rossy and colleagues ( 1999) have shown that 
the optimal intervention for FM includes exercise and cognitive behavioural therapy 
as well as appropriate medications for the symptoms of sleep deprivation and pain. 
A pilot study by Pfeiffer and colleagues (2003) to determine the effects of a 
1 .5-day multi-disciplinary outpatient treatment program for FM has shown that 
improvements compared favourably with those results from longer interventions. 
The program was divided into an introductory program including education on FM 
and self-management techniques, occupational therapy focusing on energy 
conservation and ergonomics and physiotherapy focusing on stretching techniques, 
posture, body mechanics, strength, endurance and aerobic exercise. The efficacy of 
the program was assessed by the use of validated outcome measure assessment tools. 
This short intervention program (n=78) did show a significant improvement on the 
Fibromyalgia Impact Questionnaire score (5 1 .3 - 44.7, p < 0.002) but did not 
significantly improve depression (p < 0.06), life fulfilment (p < 0.53) and physical 
impairment (p = 0. 1 1  ). 
Sprott (2003) notes that because subgroups within the FM population have 
been determined, uniform recommendations for treatment cannot be given. He 
recommends individual adapted measures to accommodate the differences between 
FM sufferers within the subgroups. Sprott (2003) asks the question as to why FM 
patients respond differently to different treatments. He suggests it may be due to the 
differences in the etiological pathogenic mechanisms within the identified FM 
subgroups and lists these as disturbances in the inhibitory system, neuro-endocrine 
disturbances, neuropeptide disturbances and decreased secretion of growth hormone. 
Sprott reminds us that treatment regimes are based on an unknown etiology and that 
a long term effective intervention must focus on managing the symptoms associated 
with FM. 
Patient Education 
Understanding the implications of a diagnosis of FM is very important for the 
patients who often have spent many years, many dollars and emotional energy 
seeking a diagnosis or a solution for their pain and dysfunction. It is important that 
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patients understand what FM is, that it is not life threatening, that there is no 'cure,' 
that it is non inflammatory, that they may always be symptomatic and that they must 
take responsibility for their own well being and FM management. Patient education 
on FM is available through many resources, support, education and pain management 
groups. 
Ramos-Remus, Salcedo-Rocha, Prieto-Parra and Galvan-Villegas (2000) 
report that the prevalence and morbidity rate of rheumatic diseases are increasing 
with non-medical causes playing an important role in the morbidity and disability of 
patients. They suggest because the maj ority of rheumatic diseases have no cure and 
many have poor outcomes that contributing factors to this may include comorbid 
conditions, drug side effects and the non-medical causes of morbidity. In addressing 
this issue, the authors suggest that the outcome of chronic disease may be influenced 
by the action of the person with the disease as much as by the health professional and 
therefore suggest that chronic diseases may respond to lifestyle modification as well 
as medical intervention. 
Hill ( 1997) defines patient education as any combination of learning 
experience designed to improve patients' behaviours and, as a result, improve their 
health status and long term outcome. Ramos-Remus and colleagues (2000) define 
self-management as activities that a person undertakes to improve health, to prevent 
disease and to decrease the chance of illness. They detail the goal of self­
management programs as remodelling interpretative structures to improve the 
patients' behaviours and to increase their self-efficiency. The authors describe 
interpretive structures as those a person uses to interpret and respond to any event. 
They further describe these structures as culturally acquired within a personal, 
cultural, social, political and economic environment and as significant personal 
factors in the knowledge, attitudes and behaviour used by individuals. This 
interpretive framework within the disease context is described as the way society and 
patients perceive, categorise or give meaning to a disease (Ramos-Remus et al., 
2000). 
The timing of any patient education program is important. Ramos-Remus and 
colleagues (2000) recommend that patients with chronic disease should commence 
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these programs following adequate time for the reaction of diagnosis, denial period 
and acceptance of the disease. They describe patient education as a strategy rather 
than one program and recommend that education is implemented as programs and 
assessed as interventions. The aim is to reshape the interpretive structures of patients 
and not just to provide educational information. 
A study on the impact of a health education program on the quality of life of 
persons with FM (Bosch, Saenz, Valls, & Vinolas, 2002) has shown that health 
education modified the patients' perception of quality of life, reduced their pain, 
increased their understanding of FM and reduced dependence on the health system. 
Another prospective randomised study (Langer, Ehlebracht-Konig, & Mattussek, 
2003) demonstrated that patient education leads to an improvement of knowledge, 
self-efficacy, self-help activities, improvement in helplessness and pain, and reduces 
both temporary and permanent disability. 
Jain and colleagues' (2004) recommendations for patient education include 
being informed about FM and sources of support, knowing of early warning systems 
to prevent crashes, establishing a simple, serene, slow and supportive environment, 
relaxation and stress management, keeping the body warm, conserving energy, and 
avoiding aggravating factors. Patients are encouraged to establish personal 
boundaries, to maximise sleep and maintain a balanced diet. 
Patient education extends into the arena of pain management. Cooper, Booker 
and Spanswick (2003) discuss one strategy for education in pain management to 
improve pain outcomes for patients that differs from the routine clinical practice. 
Rather than their focus being on the abolition of pain, it is on the restoration of 
function despite pain. Patients are made aware that activity-related pain does not 
equate with activity-related tissue damage, allowing them to confidently reintroduce 
physical activity into their daily routines (Cooper et al., 2003). 
Exercise 
Exercise is always recommended as part of the prescription for the 
management of FM. For many FM patients, fear that movement of an already painful 
body will increase their pain and disability often prevents them from undertaking 
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exercise training and/or programs. Jain et al (2004) have stated that exercise must be 
specific to the pathophysiology of FM and that the exercise intensity should be 
adapted to the patients' individual capacity and limitations. Individualised exercise 
programs should include warm up and cooling times, stretching, strength training, 
endurance training to increase conditioning, balance, pacing and patient control over 
the intensity and duration of the exercises (Jain et al., 2004). Clauw (2000) 
recommends a step approach towards exercise intervention, beginning with a non­
demanding and short exercise period. 
The Cochrane Musculoskeletal Group (Busch, Schachter, Peloso, & 
Bombardier, 2002a) systemically reviewed the efficacy of exercise training as a 
treatment for FM. They concluded that supervised exercise training does have 
beneficial effects on physical function and symptoms in patients with FM. A recent 
study (Richards & Scott, 2002) concluded that prescribed aerobic exercise is a 
simple, effective, inexpensive and available treatment for FM. However, the 
researchers found that compliance to an exercise program is a problem that may need 
to be addressed by cognitive behavioural therapy and the provision of explanations 
for initial increase in symptoms. 
Gowans, deHueck, Voss and Richardson (1999) evaluated the efficacy of a 
six-week exercise and educational program for patients diagnosed with FM. The 
randomised controlled trial study (n=4 l )  showed that short term exercise and 
educational programs could produce some immediate and sustained benefits for 
patients. The subject's physical function was assessed by a modified six-minute walk 
test with a significant improvement in the intervention group (p < 0.05). Similarly the 
program increased the intervention group subjects' sense of well being as indicated 
by the visual analog scale in the Fibromyalgia Impact Questionnaire (FIQ) that 
measured 'days felt bad' (p < 0.05). The intervention group also showed significantly 
greater decreases in morning fatigue as measured by the FIQ visual analog scale that 
gauged fatigue on waking (p < 0.05). It is difficult to monitor whether the benefits 
were related to the exercise, education or both, because both interventions were 
given. The authors reflect that further studies will be needed to show if such gains 
can be improved and sustained for sufficient time to be clinically beneficial to FM 
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patients. Further studies are also needed to distinguish between the effects of each 
intervention. 
Gowans and deHueck (2004) recommend further investigation into the 
benefits of low intensity exercise and the development of strategies for long term 
compliance with exercise regimes by people with FM. The authors also encourage 
enhanced access to community exercise programs and progression exercise 
instruction specific for people with FM. 
Persell (2002) determined that a 1 2-week graded aerobic exercise plan 
resulted in more improvement in a validated self-rated change in global impression 
scale and decreased tender point counts compared with a relaxation and stretching 
program for adults with FM (n= 1 36). For the primary outcome, the improvement in a 
validated self-rated change in global expression scale, 24/69 patients (35%) in the 
exercise group and 1 2/67 ( 1 8%) in the relaxation group improved (p = 0.03). 
Similarly, a study by Gandhi, DePauw, Dolny and Freson (2002), examining 
the effects of a 1 0-week (20 session) exercise program on quality of life of women 
with FM (n = 2 1 ), concluded that significant improvements were made in the range 
of motion (p = 0.0003) and in the FIQ scores (p = 0.0049) of the exercise groups, but 
the tender point count and the tender point severity scales were unaltered. This area 
of research between physical activity and health-related quality of life and outcomes 
is complex. Although the beneficial effects of participating in regular exercise are 
known, the dose response relationships between physical activity and health-related 
quality of life are unclear (Brown et al. , 2004). 
One influence on exercise prescription could be the fatigue factors that 
accompany FM. Bujak, Mikdashi, Kalappa, Keyser, and Handwerger (2002) 
considered aerobic capacity in their studies of people with FM. Aerobic capacity is 
determined by measuring peak oxygen intake. If a person scores more than 27% 
below their expected oxygen intake, they are considered to have functional aerobic 
impairment. In this study, functional aerobic impairment was observed in 6 of the 1 1  
FM study participants, but in none of the 1 1  controls. Bujak and colleagues (2002) 
are continuing to look for molecular mechanisms underlying this impairment to 
develop interventions that may improve aerobic capacity. 
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The majority of patients who have experienced the symptoms of FM for some 
time tend to be deconditioned muscularly because of their inability to exercise 
without exacerbating the pain. Although the exercise emphasis for FM management 
has been mainly on aerobics, a recent pilot study (Rooks, Silverman, & Kantrowitz, 
2002) has shown that a program of progressive strength training and cardiovascular 
exercise was safe and well tolerated in women with FM. This study also showed that 
the introduction of progressive strength exercises, together with cardiovascular 
endurance training, did not exacerbate their FM symptoms. Patient characteristics 
that may impact on the success of an exercise program for FM and similar conditions 
have been listed by Ambrose, Lyden and Clauw (2003) as: a readiness to adopt a 
new exercise regime that may increase pain at the beginning; the ability to accept 
self-management for their FM; unrealistic expectations; fear of an increase in pain 
and fatigue; and past experiences with exercise and social support. 
Recommendations from the 61h International Conference on Chronic Fatigue 
Syndrome, Fibromyalgia and Related Illnesses included a low level aerobic interval 
exercise as an exercise alternative for people with FM (Lapp, 2003). This exercise 
regime involves exercising for 3 to 5 minutes followed by the same time period 
resting to allow the body to recover and then exercise and rest again. This option for 
exercising is often more palatable for the FM sufferer who can experience a flare up 
of symptoms due to excessive exercise (Lapp, 2003). 
For women with bladder irritability symptoms associated with FM, their 
ability to exercise is often inhibited by the anxiety of urinary urgency and urinary 
frequency. The fear of not being able to get to the toilet in time to void, the anxiety 
of an urge or stress incontinent episode and/or the increased pressure and pain on the 
bladder resulting from exercising, all contribute to poor compliance to any exercise 
program. To date, there have been no studies on the effect of exercise specifically on 
the bladder irritability symptoms of FM. 
Pharmacological Treatment of FM 
Clauw (2000) comments that, in clinical practice, the view is widely held that 
the interventions of education, exercise and cognitive behavioural therapy are more 
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effective when they are combined with symptom-based pharmacological therapy. 
Barkhuizen (200 1 )  lists symptoms amenable to pharmacological therapy as pain, 
sleep disturbance, mood disturbance, fatigue and associated disorders. Until there is a 
clearer understanding of the pathophysiologic mechanisms causing the symptoms of 
FM, pharmacological treatment should be aimed at individual symptoms 
(Barkhuizen, 200 1 ). He suggests guarding against polypharmacy and prescription for 
symptoms that impact on activities of daily living and quality oflife. 
Barkhuizen (2001 )  notes that, even though evidence-based medicine dictates 
that the use of medication should be based on the results of randomised placebo­
controlled clinical trials, FM poses a challenge to researchers because it is a complex 
disorder with multiple symptoms, lacking clear etiology and objective physical 
findings. Jain and colleagues (2004) anticipate that the optimal therapy for FM in the 
future will be the use of a limited cocktail of low dose medications which each target 
a specific receptor known to be involved with the pathogenesis of FM. Duggan 
(2002), in his presentation on Central Transmitters: Prospects for Pain Control, spoke 
of the most centrally acting drugs affecting brain function by their action at the 
synapses by modifying the release, action or inactivation of neurotransmitters. 
Russel (2003) describes FM as a syndrome that is underserved by the medical 
profession and the pharmaceutical industry. He asks questions regarding the 
management of FM, such as what kinds of biochemical and physiological changes 
predispose people to developing FM and can these changes be manipulated by 
physiological or psychological interventions? Russel also asks which steps in the 
nociceptive process could be altered to produce clinical benefits. For now, the 
complexity of FM defies pharmacological cure or significant relief of symptoms. 
Anti-inflammatory medicines are non-effective in reducing pain, as FM is not 
an inflammatory disease. A trial of non-steroidal anti-inflammatory drugs is often 
used to manage peripheral pain such as that resulting from osteoarthritis. Narcotic 
medications are controversial in the management of FM and other chronic pain 
conditions. There does remain some concern about the addictive properties of 
opioids. They may increase cognitive dysfunction or gastrointestinal problems and 
remain a controversial topic for treatment of FM (Barkhuizen, 200 1 ). 
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Analgesic therapy includes the use of tricyclics antidepressants with 
documented analgesic effects (Goldenberg, Mayskiy, & Mossey, 1996). A meta­
analysis of nine studies on the use of antidepressants in FM (Arnold et al., 2000) 
found a moderate improvement in pain and sleep and a modest improvement in 
fatigue, tenderness and stiffness. Another meta-analysis of 1 3  published, good 
quality, randomised, placebo-controlled trials (O'Malley, Balden, Tomkins, Santoro, 
& Kroenke, 2000) suggests that antidepressants reduce the symptoms of FM. The 
authors have suggested further research to assess the relative efficacy of different 
types of antidepressants as well as whether the efficacy is independent of an effect on 
depression. Lawson (2002) suggests that tricyclic medications are most effective 
when administered with other therapies such as selective serotonin reuptake 
inhibitors which affect the modulation of the neurotransmitters, serotonin and 
noradrenaline. 
The selective serotonin reuptake inhibitors have been shown to have a 
minimal effect on pain in FM, but some benefit in the emotional component of pain 
and mood disorders (Jung, Staiger, & Sullivan, 1997). Sleep hygiene measures are 
usually implemented before medication for poor sleep patterns. Medication to 
improve sleep includes pure sedatives acting on benzodiazepine receptors, sedating 
antihistamines and sedating antidepressants (Barkhuizen, 2001 ). 
Data presented by Crofford and Arbor (2002c) showed improvement in the 
core symptoms of FM of pain, sleep and fatigue from a double-blind, placebo­
controlled study on the new drug pregabalin. This study involved 529 patients 
diagnosed with FM. Pregabalin-treated patients trialling 450mg/day for eight weeks 
showed significant improvements in pain compared to those who received placebos. 
Jancin (2004) cites Buskila at the annual 2004 European Congress of Rheumatology 
in describing pregabalin as an efficient agent that gives significant improvement in 
the widespread pain, sleep disruption and fatigue due to FM. Buskila commented that 
these improvements and a good safety profile were as much as could be expected of 
any proposed therapy, given the gaps in the current understanding of the basis of FM 
(Jancin, 2004). Crofford (2002c) speaks of the need for new treatment options that 
are both effective and well tolerated because of the debilitating and difficult to treat 
symptoms of FM. 
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Many of the available medications for pain have been developed for lessening 
acute rather than chronic pain. Mechanisms that lead to chronic pain are different 
from those of acute pain. Clauw, when interviewed by Meisler (2000), suggested 
that, within the next three to five years, we can expect to see new classes of 
medications that will be developed for the management of chronic pain alone. 
Clauw, presenting at the 2003 American College of Rheumatologists Annual 
Scientific Meeting (Ross, 2003), has suggested that the drug milnacipran, which was 
in its phase II clinical trial and had shown to provide statistically significant 
improvement of pain in FM, could dramatically change the way FM is treated. The 
phase II study was a 12-week randomised, double-blind, placebo-controlled trial at 
several centres across the United States of America (n=l 25). The results showed 
37% of FM patients reported a 50% reduction in pain compared to 14% of placebo 
patients (Franklin, 2003). Further studies need to be completed to confirm these data. 
Milnacipran belongs to a group of drugs known as SNRis (serotonin norepinephrine 
reuptake inhibitors). Milnacipran is a dual acting reuptake inhibitor that acts on two 
neurotransmitters, norepinephrine and serotonin, which are involved in the central 
modulation and processing of chronic pain (Kranzler, 2003) .  
Littlejohn (2004) comments that pharmacological information to date 
suggests that drugs such as duloxetine, a serotonin and norepinephrine reuptake 
inhibitor, may be more efficacious in the treatment of FM. A recent randomised, 
double blind, 12-week trial (Arnold et al., 2004) has shown that duloxetine-treated 
patients improved significantly more (p = 0.027) on the total score of the 
Fibromyalgia Impact Score (FIQ) but not on the FIQ pain score (p = 0. 130). In this 
trial, the intervention group also showed a significant decrease in Brief Pain 
Inventory average pain severity scores (p = 0.008), Brief Pain Inventory average 
interference from pain score (p = 0.004), number of tender points (p = 0.002), and 
FIQ stiffness score (p = 0.048) (Arnold et al., 2004). The duloxetine-treated patients 
also significantly improved in mean tender point pain threshold (p = 0.002), Clinical 
Global Impression of Severity (CG I-Severity) scale and Patient Global Impression of 
Improvement (POI-Improvement) scale (p = 0.033) (Arnold et al., 2004). The men in 
this study did not show any significant improvement on any efficacy measures. The 
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researchers recommend further studies to study the long term efficacy of duloxetine 
in FM. 
Recent trials of duloxetine have also shown it to be effective for women with 
stress urinary incontinence (Cardozo, 2004). Cardozo refers to duloxetine as the first 
pharmacological agent that has been developed in large randomised controlled trials 
for the management of stress incontinence in women. Michel and Peters (2004) 
describe lower urinary tract function as being tightly managed by a complex neural 
network. They describe the pelvic nerves as suppliers of key signals for micturition, 
and the hypo gastric and pudenda! nerves as suppliers of key signals for urine storage. 
Urethral closure depends on an intact striated urethral sphincter that is innervated by 
the pudenda! nerve. The tone and contraction of the striated urethral sphincter is 
increased by the central neurotransmitters of serotonin and noradrenaline. 
Duloxetine, as a powerful and balanced serotonin and noradrenalin reuptake 
inhibitor, is thought to increase the concentrations of these neurotransmitters, with a 
resultant increase in the activity of the striated urethral sphincter and increased 
bladder capacity (Michel & Peters, 2004 ). Results of the randomised placebo­
controlled trials (van Kerrebroeck, 2004) show that duloxetine 80mg/day is an 
effective and safe treatment for women with urinary incontinence 
The Food and Drug Administration Arthritis Advisory Committee of the 
United States of America has proposed guidelines for use in the design trials of drugs 
for FM (Franklin, 2003). This advisory committee has recommended that trials of 
FM treatments should last at least six months and that all patients entering the trial 
should meet the 1990 diagnostic criteria set down by the American College of 
Rheumatology. The committee recommended that the drug manufacturers 
demonstrate an effective end point as indicators for the treatment for FM. This end 
point could include some improvements in pain, patient global assessment and 
function (Franklin, 2003). It was also suggested that end points for symptom-specific 
indicators for pain, sleep difficulties and fatigue be included. 
Sewitch, Dobkin, Bematsky, Baron, Starr, Cohen and Fitzcharles (2004) 
identified the determinants of medication non-adherence in women with FM (n= 
127). Sixty (47%) women were non-adherent to medication, with 20 (33 .3%) being 
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intentionally non-adherent and 24 (40%) unintentionally non-adherent. Unintentional 
non-adherence was predicted by community status, not being under a rheumatologist 
care plan, decreased disease activity, less use of instrumental coping and increased 
patient-physician discordance, while intentional non-adherence was predicted by a 
shorter time under a rheumatologist's  care and greater patient-physician discordance 
(Sewitch et al. , 2004). 
Cognitive Behavioural Therapy 
Price (2004) describes pain as having many neurological and psychological 
dimensions that are processed in the brain. This subsequently triggers pain as a 
sensation and evokes an emotional response to that pain. Price concludes that there is 
no single, all -encompassing pain response centre existing in the brain. He states that 
although pain sensations are activated by neurones in the brain, these sensations 
occur within the context of psychological and physical factors that are responsible 
for the cognitive and evaluative component of pain. Price (2004) likens the sensory 
dimension of pain being embedded in the emotional dimension in the same way that 
height is a determinant of weight. 
The Australian Association for Cognitive and Behavioural Therapy 
(Australian Association for Cognitive and Behavioural Therapy, 2004) defines 
cognitive behavioural therapy (CBT) as a focused approach to the treatment of 
different types of emotional, behavioural and psychiatric problems which assists 
individuals in identifying unhelpful thoughts and behaviours and learning healthier 
skills and habits. 
Cognitive behavioural therapy is one method used to assist patients with FM 
to cope with their symptoms and to improve their quality of life by focusing on self­
control and coping strategies. In one randomised controlled study, (Williams, Cary, 
Groner, Chaplin, Glazer, Rodriquez and Clauw, (2002), the cognitive behavioural 
therapy consisted of six hour-long group sessions with an experienced therapist that 
focused on teaching patients skills to improve their physical functioning. Results 
from this study found that 25% of the patients who had behavioural therapy 
experienced a significant increase in physical functioning after the treatment 
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compared with only 1 2% of patients who did not receive it. Both groups of patients 
had the same level of pain one year following treatment. Williams and colleagues 
(2002) suggest that previous studies have shown mixed results because of the 
differences in how the therapy was administered. Their data suggests that the 
inclusion of cognitive behavioural therapy in a medical regime for FM can benefit 
physical functioning in a subset of patients. 
A meta-analysis of 49 studies of FM treatments (Rossy et al., 1 999) found 
that cognitive behavioural therapy and exercise were superior to pharmacological 
agents. The authors conceded that it is likely that the cognitive behavioural therapy 
and exercise produced positive results because they targeted more than one 
symptom. Long term relief of symptoms is seldom achieved for patients with FM. 
The current management philosophy is to assist the patient to adapt to a lifestyle 
dispersed with pain, fatigue and numerous other associated symptoms. As noted 
previously, there is some evidence that FM can be helped but not cured by a multi­
disciplinary approach incorporating education, aerobic exercise, cognitive 
behavioural therapy and management of associated syndromes (Bennett, 2002b ). 
Nielson and Jensen (2004) examined the association between the treatment 
process variables of beliefs, and coping strategies and treatment outcomes of pain 
severity, activity level, emotional distress and life interference related to a four-week 
multi-disciplinary FM treatment program. Outcomes of the intervention resulted in 
an increased sense of control over pain, a belief that one is not necessarily disabled 
by FM, knowledge that pain is not necessarily a sign of some damage, decreased 
guarding, increased exercise, seeking support, activity pacing and use of self­
statement for coping. Nielson and Jensen (2004) observe that their findings were 
consistent with a cognitive behavioural model of FM. 
The research on the sub-grouping of Fibromyalgia patients on the basis of 
pressure-pain thresholds and psychological factors (Giesecke et al ., 2003) has 
implications for rehabilitation interventions for FM patients. Uniform 
recommendations for treatment for all FM sufferers cannot be given because of the 
diversity within the patient group (Sprott, 2003) .  Sprott recommends individual 
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adapted measures should be emphasised to differentially treat these FM subgroups 
when identified. 
Fibromyalgia and Bladder Symptoms 
Irritable bladder symptoms similar to the irritative bladder symptoms of 
interstitial cystitis (IC) are listed as one of the associated disorders of FM (Littlejohn, 
1996). These symptoms include urinary frequency, urinary urgency, nocturia and 
pelvic pain in the absence of infection. Although the focus of this current research on 
FM is not on the development of knowledge of the neurobiology of bladder pain and 
its associated symptoms of urgency, frequency and nocturia, a brief overview of 
some recent research findings related to lower urinary tract sensation is important as 
background for this study. 
Rothenberg (1999) describes FM as a condition that involves the loss of pain 
regulation in the central nervous system resulting in pain amplification. Abnormal 
levels of central nervous system neurotransmitters then result from this excessive 
pain stimulation . The imbalance of neurotransmitters affects the body's hormonal 
response to stress, resulting in abnormalities in the autonomic nervous system. 
Rothenberg comments that these abnormalities in tum affect the involuntary 
functions and that their impact contributes to conditions such as irritable bowel and 
irritable bladder. 
With all neurologic reflex mechanisms efferent activity results from afferent 
input (Fowler, 2002). Adequate sensory input is a prerequisite for conscious bladder 
control (Wyndaele & De Wachter, 2003). Sensory nerve cell bodies from the dorsal 
root ganglion project to the lower urinary tract and the spinal cord. The motor 
innervation of the bladder and urethra originates from the lumbosacral area (S2-S4) 
and travels by the parasympathetic pelvic nerves. The sensory nerves from the 
bladder run with the motor supply. Poorly localised sensations of pain and distension 
enter with the sympathetic fibres at a higher level (Abrams, 1997). 
Sensory receptors are present in the human bladder in the detrusor muscle 
and in the suburothelial layer. The sensory nerves supplying the bladder are 
myelinated A-delta or unmyelinated C-fibres (Wyndaele & De Wachter, 2003). 
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Wyndaele and De Wachter note that both the afferent A-delta and C-fibres in the 
pelvic and hypogastric nerve are able to signal non-painful sensations during bladder 
fillings and suggest that these afferents may also signal noxious events resulting in 
abnormal symptoms such as urgency and pain. They further comment on the 
plasticity of the bladder afferents where the number of active primary afferents is not 
static, resulting in changes in bladder sensation in various pathological conditions. 
Wyndaele (1998) and Wyndaele and Wachter (2002) studied cystometrical 
sensory data from a normal population during cystometric bladder filling. The 
normal pattern of bladder sensations on filling is described during cystometry as 
three distinct sensations. The first sensation is described as just that of the bladder 
filling, the second as the first desire to void and the third as a strong desire to void. A 
fourth sensation of pain can be added if bladder filling continues after the volume of 
full bladder sensation. 
Wyndaele and De Wachter (2003) report the first sensation of filling 
occurring at a mean of 40% of bladder filling and the first desire to void at a mean of 
59% of total bladder capacity. They refer to this system of sensations as warnings 
that enable us to integrate bladder function in every day life. It has been suggested 
that if this system of sensations malfunctions, where the first sensation of filling is 
absent, then the other sensations occur at significantly smaller volumes (Wyndaele, 
1993) and this may cause urgency (Klein, 1988). Wyndaele and De Wachter (2003) 
suggest that, if the sensations come at too low volumes, they may cause frequency 
and nocturia. These authors describe urgency as a pathological sensation where one 
experiences a continuous desire to void sometimes even after micturition. In many 
women diagnosed with FM, the cause for this urgency cannot be identified. 
Urinary Definitions 
The standardisation of measurements and a consensus on terminology help to 
prevent confusion, assist in understanding the pathophysiology of conditions and 
define what is normal and abnormal (van Kerrebroeck & Weiss, 1999). Urogenital 
symptoms of FM include urinary frequency, urinary urgency, nocturia, bladder 
and/or pelvic pain and vulvodynia. These urogenital symptoms associated with FM 
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are often referred to as the irritable bladder syndrome, interstitial cystitis or lower 
urinary tract symptoms. Urinary definitions used in this study will conform to the 
standards recommended by the International Continence Society except where 
specifically noted. 
The International Continence Society (ICS) is recognised as the international 
governing body for the standardising of urological terminology. The following 
urinary definitions are from the Standardisation of Terminology of Lower Urinary 
Tract Function: a report from the standardisation sub-committee of the International 
Continence Society (ICS) (Abrams et al., 2002b). These definitions are compatible 
with the WHO publication ICIDH-2 (International Classification of Functioning, 
Disability and Health) published in 2001 and the ICDl O, the International 
Classification of Disease. The following definitions are from the Standardisation of 
Terminology in Lower Urinary Tract Function from the ICS. 
Lower Urinary Tract Symptoms 
The urogenital tract symptoms of FM are lower urinary tract symptoms 
(LUTS} and are defined from the individual's perspective. Urinary symptoms as 
defined by the International Continence Society (ICS) are divided into the three 
groups of storage, voiding and post micturition symptoms. Definitions relevant to 
this study are listed here. 
Storage symptoms are experienced during the storage phase of the bladder 
and include: 
• increased day time frequency, the complaint by the patient who considers that 
she/he voids too often by day. 
• nocturia, the complaint that the individual has to wake at night one or more 
times to void. 
• urgency, the complaint of a sudden compelling desire to pass urine which is 
difficult to defer. 
• urinary incontinence, the complaint of any involuntary leakage of urine. 
• stress incontinence, the complaint of involuntary leakage of urine on effort or 
exertion or on sneezing or coughing. 
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• urge urinary incontinence, the complaint of involuntary leakage accompanied 
by or immediately preceded by urgency. 
• mixed urinary incontinence, the complaint of involuntary leakage of urine 
associated with urgency and also with exertion, effort, sneezing or coughing. 
• other types of incontinence which may be situational such as the report of 
incontinence during sexual intercourse or giggle incontinence. 
Bladder Sensation Definitions 
• Normal is where the individual is aware of bladder filling and increasing 
sensation up to a strong desire to void. 
• Increased is where the individual feels an early and persistent desire to void. 
• Reduced is where the individual is aware of bladder filling but does not feel a 
definite desire to void. 
• Absent is where the individual reports no sensation of bladder filling or desire 
to void. 
• Non-specific is where the individual reports no specific bladder sensation but 
may perceive bladder filling as abdominal fullness, vegetative symptoms or 
spasticity. 
• Voiding symptoms are experienced during the voiding phase. 
• Post-micturition symptoms are experienced immediately after micturition 
such as feeling of incomplete emptying being a self-explanatory term for a 
feeling experienced by the individual after passing urine. 
Genital and Lower Urinary Tract Pain 
Pain discomfort and pressure are part of a spectrum of abnormal sensations 
felt by an individual. The ICS terminology report recommends that genital and lower 
urinary tract pain should be characterised by type, frequency, duration, precipitating 
and relieving factors and by location as defined in the following: 
• Bladder pain is felt suprapubically or retropubically usually increasing with 
bladder filling and may persist after voiding. 
• Urethral pain is felt in the urethra and the individual indicates the urethra as 
the site. 
• Vulval pain is felt in and around the external genitalia. 
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• Vaginal pain is felt internally, above the introitus. 
• Perineal pain is felt in the female, between the posterior fourchette (posterior 
lip of the introitus) and the anus. 
• Pelvic pain is less well defined than, for example, bladder, urethral or 
perinea! pain and is less clearly related to the micturition cycle or to bowel 
function and is not located in any single pelvic organ. 
Syndromes as described in the ICS terminology report are varying 
combinations of symptoms that cannot be used for precise diagnosis. The use of the 
word, 'syndrome', is justified only if there is at least one other symptom in addition 
to the symptom used to describe the syndrome. The syndromes are functional 
abnormalities for which a precise cause has not been found. It is expected that 
appropriate assessment has excluded obvious pathologies. The ICS terminology 
report lists two syndromes, the urogenital pain syndrome and the symptom syndrome 
suggestive of lower urinary tract dysfunction. 
Urogenital Pain Syndromes 
These are all chronic conditions. Pain is the major complaint, together with 
complaints including lower urinary tract, bowel, sexual, or of a gynaecological 
nature: 
• Painful bladder syndrome is the complaint of suprapubic pain related to 
bladder filling, accompanied by other symptoms such as increased daytime 
and night-time frequency, in the absence of proven urinary infection or other 
obvious pathology. 
• Urethral pain syndrome is the occurrence of recurrent episodic urethral pain 
usually on voiding, with daytime frequency and nocturia, in the absence of 
proven infection or other obvious pathology. 
• Vulval pain syndrome is the occurrence of persistent or recurrent episodic 
vulval pain, which is either related to the micturition cycle or associated with 
symptoms suggestive of urinary tract or sexual dysfunction and where there is 
no obvious pathology or proven infection. 
• Vaginal pain syndrome is the occurrence of persistent or recurrent episodic 
vaginal pain which is associated with symptoms suggestive of urinary tract or 
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sexual dysfunction and where there is no proven vaginal infection or other 
obvious pathology. 
• Perineal pain syndrome is the occurrence of persistent or recurrent episodic 
perineal pain, which is either related to the micturition cycle or associated 
with symptoms suggestive of urinary tract or sexual dysfunction and where 
there is no proven infection or other obvious pathology. 
• Pelvic pain syndrome is the occurrence of persistent or recurrent episodic 
pelvic pain associated with symptoms suggestive of lower urinary tract, 
sexual, bowel or gynaecological dysfunction and where there is no proven 
infection or other obvious pathology. 
Symptom Syndromes Suggestive of Lower Urinary Tract Dysfunction 
Urgency, with or without urge incontinence, usually with frequency and 
nocturia, can be described as either the overactive bladder syndrome, urge syndrome 
or urgency-frequency syndrome. 
Measuring Signs Suggestive of Lower Urinary Tract Dysfunction 
The bladder diary records the times of micturitions and voided volumes, 
incontinence episodes, pad usage, fluid intake, degree of urgency, the degree of 
incontinence and other relevant information. The following measurements can be 
extracted from bladder diaries: 
• Daytime frequency is the number of voids recorded during waking hours and 
includes the last void before sleep and the first void after waking and rising in 
the morning. 
• Nocturia is the number of voids recorded during a night's sleep. Each void is 
preceded and followed by sleep. 
• Nocturnal polyuria is defined by the nocturnal urine volume >20-30% of the 
total 24 hour urine volume. 
• Twenty-four-hour frequency is the total number of daytime voids and 
episodes of nocturia during a specified 24-hour period. 
• Maximum voided volume is the largest volume of urine voided during a 
single micturition. 
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Urodynamic Observations and Conditions 
Urine flow is defined either as continuous or intermittent. The continuous 
flow curve is defined as a smooth arc-shaped curve, or a fluctuating one where there 
are multiple peaks during a period of continuous urine flow. 
• Flow rate is defined as the volume of fluid expelled via the urethra per unit 
time. It is expressed in ml/sec. 
• Voided volume is the total volume expelled via the urethra. 
• Maximum flow rate is the maximum measured value of the flow rate after 
correction for artefacts. 
• Voiding time is the total duration of micturition. 
(Abrams et al., 2002b) 
Lower Urinary Tract Symptoms 
Lower urinary tract symptoms (LUTS) can be classified as storage symptoms, 
emptying symptoms or both (Blaivas, 2000). Urinary frequency, urgency and pain 
are classified as storage symptoms. Sensory urgency is described as an 
uncomfortable need to void unaccompanied by detrusor instability. 
Within the medical literature, lower urinary tract symptomatology in the male 
population has been more extensively studied than that for the female population. An 
Austrian study (Schatzl et al. ,  2001 ) compared the prevalence and severity of lower 
urinary tract symptoms (LUTS) in both sexes and determined their effect on 
everyday life as 'bothemess' .  The women's  results (n= 1 1 9 1 )  showed the mean 
increase in LUTS from the youngest (20-39 years) to the oldest (> 70 years) age 
group was 23 .6% (3.9%/decade). In all decades, the irritative storage symptoms were 
higher in the women's group. The researchers reported that urinary urgency and 
frequency were more bothersome in older individuals, while nocturia and voiding 
symptoms were almost equally bothersome for both younger and older study 
participants. 
Gillespie (2004) reviews the literature on the generation of excessive sensory 
urges of the bladder. Urological opinion is that low bladder tone during the filling 
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phase is maintained by reducing the parasympathetic excitatory micturition reflex 
and encouraging the inhibitory sympathetic elements to facilitate 'accommodation' 
(Ruch, 1960). Gillespie explains the bladder as rhythmically active during the filling 
phase, the activity being generated in the bladder wall, and describes this as 
' autonomous' activity in the non-micturition phase. Gillespie notes that this rhythmic 
activity is an intrinsic property of the bladder wall and that the frequency and 
magnitude of these transient contractions could be affected by parasympathetic and 
sympathetic neural inputs. This autonomous activity entails waves of contraction and 
localised stretches of the bladder wall. These complex events may involve a network 
of pacemaker cells and connecting interstitial cells motivated by excitatory and 
inhibitory neural inputs (Gillespie, 2004). Modulation by central nervous system 
activity can affect the amplitude and frequency of the autonomous activity with 
resultant changes in bladder sensations. 
Lower urinary tract symptoms (LUTS) in women can produce significant 
bother and affect their quality of life (Scarpero, Fiske, Xue, & Nitti, 2003). Scarpero 
and colleagues determined whether the degree of bother caused by lower urinary 
tract symptoms correlated with a woman's quality of life and whether this varies with 
a woman's age and continence status. Using the American Urological Association 
Symptom Index (AUASI), this study has shown a strong correlation between urinary 
symptoms and problems caused by these symptoms (n=1232, p < 0.001) and also 
that the correlation existed throughout various age groups and was independent of 
their continence status. A similar pattern was shown for the correlation between 
urinary symptoms and quality of life. With the diversity of symptomatology of 
diseases such as FM that do not yet have absolute classifications or 
biological/biochemical markers, how do we give advice to people with these 
symptoms? How do we treat 'bother'? 
Urinary Frequency 
Increased urinary daytime frequency is described by the International 
Continence Society as the complaint by the patient who considers that she/he voids 
too often by day (Abrams et al., 2002b ). The incidence of urinary frequency in 
community-dwelling women (n=886) was reported at 20% (Glenning, 1985). 
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Significant correlations between urinary frequency and bother have been shown in 
another community-dwelling population (Swithinbank et al. ,  1999). In this study (n = 
2075), over 50% of women found voiding nine times a day or more was a problem 
for them. The mean age of responders was 52 years with an age range of 19-97 years. 
The authors found that the most prevalent symptoms were not necessarily the 
symptoms the women reported as being most problematic. Swithinbank and Abrams 
(2000) found only 5% of women with a voiding frequency of 1 to 6 times a day and 
17% of women who voided 7 to 8 times a day found it bothersome. 
Urinary Urgency 
Urinary urgency is described by the International Continence Society as the 
complaint of a sudden compelling desire to pass urine which is difficult to defer 
(Abrams et al., 2002b). Urgency is described as a pathological sensation that is 
experienced as a continuous desire to void, as a sensation that does not necessarily 
ebb post micturition and one that is experienced differently from the sensation of 
bladder fullness (Wyndaele & De Wachter, 2003). A large study (Swithinbank et al., 
1999) on community-dwelling women in Britain (n=2075) has shown that one of the 
most common urinary symptoms was urgency (61 %). Only 37% of these women 
with urgency reported this symptom as problematic. The authors comment that this 
study has highlighted the importance of prevalence studies on urinary symptoms as 
well as the perceived impact caused by the symptoms. This perceived impact may be 
more useful in assessing the demands for treatment. 
Treatment for sensory urgency firstly includes the treatment of detectable 
conditions. When there is no obvious abnormal pathology, a pharmacological 
approach using drugs that impair bladder sensation and/or neurotransmitters of pain 
signals may be considered (Blaivas, 2000). 
Nocturia 
Nocturia, as described by the International Continence Society, is the 
complaint that the individual has to wake at night one or more times to void (van 
Kerrebroeck & Weiss, 1999). The authors of the Standardisation of Terminology in 
- 89 -
Nocturia for the International Continence Society (van Kerrebroeck et al., 2002) 
comment that although a person may consider that one night time void is normal, 
they still do have nocturia. The authors also note that, in the situation where the 
desire to void may not be the trigger that wakes people at night yet they need to void 
when they wake, these individuals are still considered to have nocturia. 
Nocturia is a condition that is now recognised as a clinical entity in its own 
right and not a symptom of some other disorder (van Kerrebroeck et al., 2002). It has 
been reported as one of the most common causes of sleep disturbance (Middlelkoop, 
Smilde van den Doel, Neven, Kamphuisen, & Springer, 1996). Schatzl and 
colleagues (2000) have shown that the number of people with nocturia of two or 
more times increased with age: below 30 years (3 . 1  %), between 30 to 59 years 
(7 .2%) and over 60 years (26.7%). The age-adjusted extrapolation to the general 
population (> 20 years of age) of women in Austria showed that 1 1 .8% of women 
experience nocturia of two or more times and that the nocturia affects the quality of 
life of two thirds of these women (Schatzl et al., 2000). 
Weiss and Blaivas (2003) list pathological conditions such as cardiovascular 
disease, diabetes mellitus, lower urinary tract obstruction, anxiety, primary sleep 
disorders, and behavioural and environmental issues as factors that may result in 
nocturia. They attribute nocturia to nocturnal polyuria, diminished nocturnal bladder 
capacity or a combination of both factors. 
Middlelkoop and colleagues ( 1996) have reported the prevalence of nocturia 
to be 58% and 66% in women and men of 50 to 59 years and 72% and 91 % in 
women and men over 80 years of age. A recent study on nocturia and its effect on 
health-related quality of life and sleep (Coyne et al., 2003) found that nocturia was 
widely prevalent and increased with age. It was demonstrated that incremental 
increases in the number of voids per night had increased negative effects on sleep, 
symptom bother and health-related quality of life. Lose, Alling-Moller and Jennum 
(2001 )  have shown that the prevalence of nocturia is more common in parous women 
and increases with age, with more than 50% of women > or = to 80 years of age 
experiencing nocturia. The authors note that although nocturia is one of the most 
bothersome of the lower urinary tract symptoms, with a significant impact on quality 
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of life, few women seek medical assistance because they accept it as part of aging 
(Lose et al., 2001). Swithinbank and colleagues ( 1999) in their large British study (n 
=2075) found 19% of women reported nocturia as a urinary symptom with 63% 
finding the nocturia troublesome. The mean age of responders was 52 years with an 
age range of 19 to 97 years. 
The impact of nocturia on quality of life in a Dutch population has revealed 
that nocturia can lead to sleep insufficiency with subsequent decrease in mental and 
physical health. Researchers (van Dijk et al. ,  2004) selected 1 000 adults after 
stratification to complete a written questionnaire. The 8 19 respondents were 
distributed over three groups: a target group (n= 189) who were bothered by >/= one 
void per night, a reference group I (n=120) with no bother but >/= two voids per 
night and a reference group II (n=5 l 0) with 0- 1 voids per night . The results have 
shown that the perceived impact on life was highest in the target group (p < 0.05). 
The target group also showed more sleep problems and scored lower on quality of 
life scores than reference groups I and II (p < 0.05). Van Dijk and colleagues (2004) 
suggest that doctors routinely check for nocturia when patients present with sleep 
problems. This would be particularly pertinent for FM sufferers, many of whom 
already experience insomnia and unrefreshed sleep that is unrelated to their bladder 
symptomatology. 
Fiske, Scarpero, Xue and Nitti (2004) studied 1232 patients showing that as 
the number of nocturia episodes increases, the bother increases (p < 0.0001) and is 
independent of age and continence status. Fiske and colleagues (2004) propose from 
this study that clinically significant nocturia in women be classified as two or more 
episodes per night. They also suggest that two episodes of nocturia be considered 
mildly clinically significant, three episodes as moderate and four or more episodes to 
be severe nocturia. This classification system is given as a guide only in the 
diagnosis and treatment of women with nocturia. 
Kobelt, Borgstrom and Mattiasson (2003) assessed the effect of nocturia on 
productivity, vitality and utility in a selected group of professional active individuals 
with nocturia compared with matched controls. The researchers tested the hypothesis 
that a lack of sleep due to frequent sleep interruptions could decrease a person's  
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daytime energy and activity levels. The study group (n=203) with nocturia 
experienced a lower level of vitality and utility with greater impairment of work and 
activity. Symptom severity correlated with all three measures of productivity, vitality 
and utility. The women participants were more affected than the men. The 
researchers concluded that waking at night to void diminished the participants overall 
well being, vitality and productivity and resulted in a significant level of indirect and 
tangible costs (Kobelt et al., 2003). 
Walmsley and Staskin (2003) stress the importance of considering the non­
urologic etiologies in the differential diagnosis of a patient presenting with nocturia. 
The authors comment that this is even more important if the patient has failed to 
respond to lower urinary tract directed therapy or if surgery is being considered. 
Voiding diaries are an essential part of the assessment of patients with nocturia as 
they give information on low nocturnal bladder capacity, increased night time urine 
production and behavioural and environmental factors. Because of the insomnia 
already experienced by people with FM, the increased burden of nocturia may have 
an increased detrimental effect on their hours of effective sleep. As previously 
mentioned in this text, it is now recognised that sleep deprivation is a very serious 
health and safety risk factor within our communities and workplaces. The impact, 
therefore, on women already struggling with non-bladder symptoms of FM can have 
significant bother and health effects. 
Bladder Pain 
Bladder pain is felt suprapubically or retropubically, usually increasing with 
bladder filling, and may persist after voiding, while painful bladder syndrome is the 
complaint of suprapubic pain related to bladder filling, accompanied by other 
symptoms such as increased daytime and night time frequency, in the absence of 
proven urinary infection or other obvious pathology (Abrams et al., 2002b). Two 
types of pain have been described in the bladder: a sharp pain suprapubically or in 
the perineal region; a painful pressure in the lower abdomen (Wyndaele & De 
Wachter, 2003). Blaivas (2000) describes these two types of pain as one that occurs 
immediately before, during or after voiding, and the pain that is felt when micturition 
is delayed. Blaivas comments on the many other permutations of pain that may not 
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be associated with the lower urinary tract but are included with the differential 
diagnosis. 
Fibromyalgia Bladder Irritability and Interstitial Cystitis 
Data from their study examining clinical features and peripheral nociception 
in parallel cohorts of FM and IC patients suggested to Clauw and colleagues (1997a) 
a significant overlap in symptomatology in both IC and FM. A questionnaire 
questioning the presence of 4 7 different symptoms that are common in FM was 
completed by 60 FM patients, 30 IC patients and 30 controls. The authors suggest 
that the data, together with near identical common natural histories, demographics 
and response to therapy, indicate that both FM and IC may share some common 
pathogenic etiologies. 
Lutgendorf, Kreder, Rothrock, Hoffman, Kirschbaum, Sternberg, 
Zimmerman and Ratcliff (2002b) showed that the abnormalities of the hypothalamic­
pituitary-adrenal feedback system resulted in poor regulation of the inflammatory 
response. This suggests that dysregulation of the HP A feedback mechanism could 
result in inadequate regulation of inflammation in IC, allowing chronic inflammation 
to become established. In commenting on this study, Bennett (2002c) notes that, as 
IC symptoms are exacerbated by stress, dysregulation affecting the stress response 
system could contribute to the pathophysiology of IC. Bennett also comments on the 
relevance of these findings to understanding the association of FM with some other 
inflammatory states as IC is a common morbidity with the FM syndrome. 
The urogenital symptoms experienced by women with FM have numerous 
descriptive terms. Interstitial cystitis (IC) is the term often used in the literature 
describing the urogenital symptoms of FM. The irritable bladder symptoms 
experienced by women with FM are similar to the irritative bladder symptoms of IC. 
These urinary symptoms include urinary frequency, urinary urgency, nocturia and 
pelvic pain in the absence of infection with the most definitive symptom being pain. 
Sand (2004) suggests that, in all women who present with chronic pelvic pain (CPP) 
and with the urinary symptoms of urgency and frequency, IC should be suspected as 
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(Wesselmann, 2004) an isolated or concurrent etiology m the absence of other 
pathologic entities such as infection or tumour. 
Urogenital pain often goes together with voiding disturbances and sexual 
dysfunction (Wesselmann, 2000). A study on the relationship between some bladder 
symptoms and sexual activity in women (Patel et al. ,  2004) concluded that women 
who experienced urinary frequency and/or urge incontinence were less sexually 
active. The authors also noted that women who expressed a greater degree of bother 
related to abdominal pain or genital pain were less likely to enjoy sexual activity and 
were more likely to experience sexual thoughts or fantasies. As women with FM 
often experience both abdominal pain from irritable bowel symptoms and genital 
pain, this study highlights a possible impact on their capacity to sexually express 
themselves as women. 
Women with FM also experience chronic pelvic pain. Vulvodynia, 
dyspareunia and vaginismus are common and can be multifactorial (Weiss, 2000). 
Vulvodynia is a chronic pain disorder characterised by constant or recurring 
complaints of vulvar pain or discomfort. This study examines vulvodynia symptoms 
and dyspareunia and their impact on women diagnosed with FM. 
Effective outcome measures for urogenital symptoms need to be revisited and 
developed as our knowledge of these symptoms and their impact improves. This is 
important not only in the primary areas of urological disease, but also in the areas 
where urinary symptoms are associated symptoms of other conditions such as FM. 
There is currently no questionnaire available specifically to aid in assessing the 
urological symptoms or impact on women with FM. Such a questionnaire would 
assist in determining the nature of the problem, the extent and frequency of the 
symptoms, and the impact the condition has on the patients' well being and activities 
of daily life. Pre-and post-treatment validated questionnaires for these specific 
conditions can clearly indicate treatment outcomes. Such questionnaires can also be 
helpful in prevalence studies for the wider population (Graham & Dmochowski, 
2002). The current study tests the Interstitial Cystitis Symptom and Problem Index 
(ICSI/ICPI) within the FM population for reliability and validity to provide such a 
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questionnaire for this specific FM population of women with irritable bladder 
symptoms. 
Interstitial Cystitis 
Wein and Hanno (2002) describe IC as an elusive disease that evades 
diagnosis, defies a defining etiology and resists treatment. The characteristics of IC 
are similar to those of an acute urinary tract infection, being suprapubic pressure and 
pain, urgency and frequency of voiding. The most dominant symptom of IC is pain. 
Ratner (2001a), in describing a severe case, notes frequency occurring as often as 60 
bathroom visits per day and nocturia as often as every 20 to 30 minutes, leading to 
chronic sleep deprivation. Ratner (2001 b) describes patients when a diagnosis is not 
made as being left to manage severe, debilitating symptoms with no support. Failure 
to diagnose IC can lead to depression with some patients left in such pain that they 
commit suicide (Ratner, 2001a). Ratner (2001b) explains that IC can be an organ­
specific disease in some patients while it may be a systemic condition in other 
patients. A majority of patients with IC report dyspareunia (Ratner, Slade, & Greene, 
1994). 
In 2004 researchers at the University of Maryland School of Medicine 
(Interstitial Cystitis Association, 2004) completed the first total description of the 
structure of a toxin known as the antiproliferative factor (APF) which inhibits the 
growth of bladder epithelial cells. This finding may lead to a diagnostic test for IC as 
APF was found in the urine of approximately 95% of IC sufferers. 
Because of the lack of a definitive diagnostic marker and a lack of distinct 
pathophysiology for IC, a diagnosis of IC is made on a constellation of clinical 
features as well as exclusionary criteria as with FM. MaLossi and Chai (2002) have 
posed the question of how do you treat a disease that has an unknown etiology? The 
multitude of etiological theories has resulted in many different treatment regimes 
developed from a trial and error approach. It is recommended that treatment be 
guided by an objective assessment of IC symptoms (MaLossi & Chai, 2002). One of 
the validated questionnaires they recommend is the ICSI/ICPI so clinicians can 
monitor symptoms through different treatment regimes. 
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Recently in the United States of America, the Social Security Administration 
announced an official Policy Interpretation Ruling for IC for the processing of IC­
specific disability claims (Chesnut & Perilli, 2003). Instead of defining the disease in 
terms of quantifiable disease markers, a ruling emphasises the functional limitations 
that a given disease imposes on those who have the condition. It is of interest that 
this is occurring at a time when more and more syndromes like IC, IBS, vulvodynia 
and FM are being diagnosed without unique disease markers. 
Both FM and IC share common features such as similar demographics, 
irritable bowel syndrome, headaches, history and aggravating factors. Data from the 
study by Clauw and colleagues (Clauw et al., 1997a) indicate that IC and FM have 
significant overlaps in symptoms including an increased peripheral nociception. The 
authors speculate that IC that has been treated until now as a specific bladder 
condition may be part of the disorder of the central processing of sensory information 
as seen in FM. Blaivas, Chaikin, Evans and Sant (1999) reinforced this speculation at 
a symposium on the management of the painful bladder syndrome. In discussing the 
etiology of bladder pain, these presenters spoke of some patients' pain being 
mediated by central pain mechanisms in the spinal cord and other patients suffering 
chronic centralised pain 24 hours a day because of the up-regulation of the spinal 
cord. 
Ratner (2001 b) acknowledges that the relationship between IC and other 
associated related disorders will become known when the pathophysiology of each 
disorder becomes known. Ratner writes that some IC patients are at greater risk of 
developing certain disorders. She lists these disorders as irritable bowel syndrome, 
vulvodynia, FM, endometriosis, chronic fatigue immune dysfunction syndrome, 
asthma, sensitive skin and migraines. It is because of the possible common 
etiologies, that Ratner (2001 b) questions whether IC is a systemic disease in some 
patients and an organ-specific bladder disease in others. Alagiri, Chottiner, Ratner, 
Slade and Hanno (1997) have shown the twelve most common conditions associated 
with IC. Vulvodynia and FM are ranked fourth and fifth on this list of associated 
conditions. 
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Wesselmann and Burnett ( 1999) describe chronic non-malignant pain 
syndromes of the urogenital tract of longer than six months duration as well 
described, poorly understood and frustrating for both patient and physician. 
Wesselmann and Burnett are very conscious of the controversy that surrounds these 
pain syndromes and describe the controversy as ranging from questioning the 
existence of symptoms to the dismissing of the symptoms as psychosomatic. The 
authors comment strongly that much of this controversy is offset by the extensive 
available literature confirming their organicity. They acknowledge that cures for 
urogenital pain are uncommon but caution toward invasive and irreversible 
procedures. Instead, they encourage further research into neuroanatomy, 
neurophysiology and neuropharmacology (Wesselmann & Burnett, 1999). 
Falvey (200 1 )  also indicates concern for delay in diagnosis because of the 
misconception that the symptoms are psychological and notes the delay in a 
diagnosis can prevent the use of some coping strategies which may be used if a 
definite diagnosis was given. Falvey also reports on the patients with IC being very 
sensitive to sensory stimuli, with the resultant lower tolerance threshold which may 
be seen to be over-reacting to underlying pathology. Because of these factors, 
Falvey (200 1 )  encourages a conceptual shift by those who treat IC patients to 
consider that negative psychological effects are the result of, and not the cause of, the 
disease. 
Burkman (2004) comments that because the pathogenesis of IC is unclear and 
multi-factorial, this often delays diagnosis and can impact on treatment options and 
resultant quality of life for the patient. In the USA, women see an average of eight 
clinicians during a five to seven year period before obtaining an accurate diagnosis of 
IC (Curhan, Speizer, Hunter, Curhan, & Stampfer, 1999). According to Sand (2004), 
women with IC are frequently misdiagnosed with, and are treated for, either 
recurrent urinary tract infections or an overactive bladder syndrome. This may also 
be the case with FM women who have the bladder irritability symptoms of urinary 
urgency, frequency and pain. 
A population-based study among patients with Sjogren's syndrome has 
demonstrated a strong association of Sjogren's syndrome with interstitial cystitis-like 
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symptoms (Leppilahti et al., 2003). The O'Leary-Sant interstitial symptom and 
problem index questionnaire (O'Leary et al., 1997) was used to assess the symptoms 
and symptom impact. The researchers' results suggest the possibility of a shared 
etiology of the two conditions. 
Wesselmann (2001) observes that IC shares many features with other chronic, 
non-malignant visceral pain syndromes. Wesselmann advocates a different approach 
to successfully treat chronic visceral pain associated with IC. This approach 
concentrates on three separate concepts: that a spectrum of insults can lead to chronic 
visceral pain; that the different underlying pathogenic pain mechanisms may require 
different pain management strategies; that the multiple different pathogenic pain 
mechanisms may co-exist in the same patient and can require different pain 
management regimes (Wesselmann, 2001 ). It is anticipated that this conceptual 
approach to treatment may result in new insights into the pathophysiology of IC and 
the development of new treatment options for patients with IC and for patients with 
other chronic visceral pain syndromes (Wesselmann, 2001). 
Brookoff ( 1 997) discusses the consequence of bladder inflammation in IC as 
hypersensitivity of the chemosensitive afferent bladder nerves resulting in 
hyperalgesia. Following further inflammation, mechanoreceptive nerves in the 
bladder wall generate pain signals in response to a small increase in intravesicular 
pressure resulting in allodynia. With time, the persistent pain signals from the 
bladder to the central nervous system result in changes to the dorsal horn of the 
spinal cord, resulting in central sensitisation where the dorsal horn can transmit pain 
signals to the brain with minimal peripheral stimulation. Brookoff ( 1997) describes 
how, with this persistent pain over years, the pain signal becomes embedded in the 
central nervous system and the condition can become incurable. Brookoff comments 
that, although patients with severe pain from IC may not be cured, their pain can be 
eased. 
Elbadawi (1997) presents a critique of current concepts of IC and presents a 
proposal regarding the responses invoked by neurogenic inflammation. His proposal 
encompasses sensory nerve excitation, the release of neuropeptides and activated 
differential secretion of potent mast cell mediators. Radziszewski, Borkowski and 
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Majewski (2002) state that, although no etiopathogenesis-based treatment has been 
proposed for bladder conditions of interstitial cystitis, painful bladder or overactive 
bladder, it is tempting to think that these conditions may represent different 
manifestations of 'neurogenic inflammation of the bladder' where previously silent 
C-fibres may be engaged. 
Dysregulation of the hypothalamic-pituitary-adrenal axis may be linked to 
interstitial cystitis symptomatology. One study (Lutgendorf et al., 2002a) measured 
salivary and urinary cortisol levels in 48 patients with interstitial cystitis and in 35 
age-matched controls. Although salivary or cortisol levels were similar in both 
groups, in the cystitis group the morning cortisol levels were linked to less pain and 
the higher urinary-free cortisol levels represented less overall symptomatology. 
Patients with morning cortisol levels less than 1 2.5 nmol/L were almost 1 3  times 
more likely to have higher urinary urgency. As a result of these findings, the 
researchers suggest that the regulation of the hypothalamic-pituitary-adrenal axis 
may be associated with IC symptomatology. Fitzpatrick, DeLancey, Elkins and 
McGuire ( 1 993) recognised a sub-group of patients in whom interstitial cystitis and 
vulvar vestibulitis co-existed and suggested that the co-existence of these non­
infectious inflammatory syndromes involving a disorder of the urogenital sinus­
derived epithelium have a common etiology. 
Parsons and Koprowski ( 199 1 )  have shown that a variant of the interstitial 
cystitis syndrome, with decreased significant pain, can be clinically improved by 
retraining of the individual' s  voiding pattern. Chaiken, Blaivas, and Blaivas ( 1 993) 
confirm the short term effects of behavioural therapy in selected patients with 
symptoms of interstitial cystitis. The treatment consisted of diary keeping, timed 
voiding, controlled fluid intake, and pelvic floor muscle training techniques. 
Of interest is the paper by Kusek and Nyberg (2001 )  on the epidemiology of 
IC where the authors suggest a broader definition of chronic pelvic pain of the 
bladder, but recognise that specificity may be problematic, as there are numerous 
causes of chronic pelvic pain not related to the bladder. Hanno (2003) suggests that 
the current clinical definition of IC is too restrictive for clinical use and results in 
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many patients being undiagnosed and untreated. Hanno (2004) suggests that a new 
paradigm is needed through which we can view this chronic pain syndrome. 
In March 2003, a group of renowned IC specialists met in Japan for the 
International Consultation on Interstitial Cystitis to formulate a restatement of the 
diagnostic criteria for IC. As mentioned in the introduction, the final consensus from 
the 2003 International Consultation on Interstitial Cystitis adopted the term IC/CPPS 
to signify the symptom complex of chronic pelvic pain (CPPS) with urinary urgency 
and/or urinary frequency (Diokno et al., 2003). 
The original NIDDK research criteria for IC have been universally used in 
research settings and through time have become widely adopted as a definition of the 
disease, although there is disparity in clinics around the world and no consensus as to 
the best practice in diagnosing IC for clinical purposes (Payne, Terai, & Komatsu, 
2003). Payne and colleagues comment on the problem of this research criteria being 
used for clinical diagnosis having resulted in the under diagnosis of IC for many 
patients, with a resultant lack of appropriate treatment. 
The International Consultation on Interstitial Cystitis in 2003 also considered 
the current status of diagnostic markers and potential use of these diagnostic markers 
in IC for understanding the etiology and pathophysiology of IC, to enable a definitive 
diagnosis of IC and to allow for a rational treatment algorithm (Keay, Takeda, 
Tamaki, & Hanno, 2003). The most promising diagnostic marker that comes closest 
to meeting all of these criteria is the antiproliferative factor (APF) which appears to 
be made by bladder epithelial cells from IC patients, but not by asymptomatic 
controls. 
As mentioned in Chapter 1 of this thesis, The International Consultation on 
Interstitial Cystitis in Monaco in 2004 has developed a draft algorithm for the 
treatment of painful bladder syndrome, including IC. The group also worked on an 
all-encompassing definition and a review of the painful bladder. This review 
included discussions on definitions, bladder diaries, urological investigations, 
medication, trans-electrical nerve stimulation, diet, education, hydrodistension, 
neuromodulation, intravesical botulinum A, augmentation, cystectomy and referral to 
pain clinics (A. Rosamilia, personal communication, September 8, 2004). 
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As well as the International Consultation on Interstitial Cystitis being 
established, the Interstitial Cystitis Clinical Research Network (ICCRN) was formed 
in 2003 . The ICCRN is the combination of two programs from the National Institute 
of Diabetes and Digestive and Kidney Diseases (NIDDK), the Interstitial Cystitis 
Database Study and the Interstitial Cystitis Clinical Trials Group. The ICCRN was 
established by NIDDK' s division of Kidney, Urologic and Hematologic Diseases to 
develop and conduct randomised clinical trials for the evaluation of new therapies for 
IC. The ICCRN comprises 1 0  clinical centres throughout the United States of 
America, and a data coordinating centre for protocol development, quality control, 
data analysis and data management quality (National Institute of Diabetes and 
Digestive and Kidney Diseases, 2004). 
The Bladder Research Progress Review Group was also formed in the United 
States of America by the NIDDK of the National Institute of Health to examine the 
current state of bladder research in their country and to develop a plan for future 
bladder research. The significant financial investment in this research will have an 
effect on the quality of life of many people and will dramatically decrease the 
psychological, emotional, societal and financial burden of bladder disease. The aim 
of this group is to outline future critical research on the basic science of the lower 
urinary tract and clinical studies of bladder disease and conditions. This group will 
be vigorously investigating the neurovascular influences of the lower urinary system 
because the nervous and vascular systems are involved in almost every disorder of 
the lower urinary tract. 
Fibromyalgia and Pelvic Symptomatology 
Fibromyalgia and Chronic Pelvic Pain 
Establishing a differential diagnosis in this group of women with chronic 
pelvic pain is difficult. Chronic pelvic pain (CPP) can be specifically of bladder 
origin. The Standardisation of Terminology in Lower Urinary Tract Function from 
the International Continence Society (Abrams et al ., 2002b) defines pelvic pain 
syndrome as the occurrence of persistent or recurrent episodic pelvic pain associated 
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with symptoms suggestive of lower urinary tract, sexual, bowel or gynaecological 
dysfunction and where there is no other obvious pathology. The American College of 
Obstetricians and Gynaecologists (American College of Obstetrics & Gynaecology, 
2004) has recently developed new guidelines for the clinical management of chronic 
pelvic pain. Their proposed definition of chronic pelvic pain lists the symptoms of 
non cyclical pain of at least six months duration involving the pelvis, anterior 
abdominal wall, lower back and/or buttocks, with these symptoms being serious 
enough to cause disability or to need medical care (American College of Obstetrics 
& Gynaecology, 2004). Where there is no clear indication of the etiology for pain, 
treatment is directed at the relief of symptoms. 
Stone and Mountfield (2000b) offer possible etiological explanations as 
undetectable irritable bowel, the vascular pain from dilated pelvic veins, and altered 
spinal cord and brain processing of stimuli in women with chronic pelvic pain. 
Howard (2003) writes that disorders of the reproductive tract, gastrointestinal 
system, urological organs, musculoskeletal system and the psychoneurological 
system may be responsible for CPP in women. He questions why, for some women, 
these disorders lead to a chronic syndrome while with others the condition is cured 
with initial treatment regimes. Howard suggests that the different responses may be 
due to changes in visceral nerves or to altered nociceptive processing. 
Because of the different etiological possibilities for CPP, the treatment of 
chronic pelvic pain may consist of two approaches. One approach is to treat the 
chronic pain as a diagnosis and the other is to treat the disorder that is causing or 
contributing to the pain (Howard, 2003 ). This author suggests that pain is no longer a 
symptom after 4-6 months and that, after this period of time, the symptom becomes 
the disease, chronic pain. In these cases, Howard recommends the diagnosis of 
chronic pain that allows pain-directed therapies to begin with the result that the 
patient may move toward a more normal existence that is not dominated by pain. 
CPP syndromes affect an estimated 9 to 1 5  million women in the United 
States of America (Mathias, Kuppermann, Liberman, Lipschutz, & Steege, 1 996). 
Studies have shown that IC is the cause of CPP in a large number of these women 
(Burkman, 2004). Burkman describes IC as a chronic pelvic pain symptom (CPPS) 
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of bladder origin discernible by the symptoms of urinary frequency, urinary urgency 
and pelvic discomfort or pain in the absence of obvious bladder pathology such as 
bladder cancer or urinary tract infections. However, a differential diagnosis can be 
extremely difficult. 
Because of the prevalence of this CPP condition, and health costs associated 
with it, Stone and Mountfield (2000b) state that randomised controlled trials of 
medical, surgical and psychological interventions are urgently required. Pelvic pain 
in women can be either acute or chronic. The issues of undiagnosed chronic pelvic 
pain in women are significant. One study by Zondervan, Yudkin, Vessey, Dawes, 
Barlow and Kennedy (1 999) revealed that 28% of patients with chronic pelvic pain 
were never given a diagnosis. Mathias, Kuppermann, Liberman, Lipschutz and 
Steege (1 996) showed that in the United States of America 6 1  % of patients with 
chronic pelvic pain had an unknown etiology. Stones, Selfe, Fransman and Hom 
(2000a) estimate, according to a population-based estimate, that chronic pelvic pain 
affects 15% of women. 
These women, as well as experiencing pain, suffer the psychosocial impact of 
chronic pelvic pain affecting changes in mood, disruption of activities of daily living 
and relationships issues. A study by Zondervan (2001 b) has shown that there is high 
symptom-related anxiety in women with chronic pelvic pain and emphasised the 
need for more information about, and the possible causes of, this condition. The 
study known as the Oxfordshire Women's  Health Study Survey in the United 
Kingdom showed a substantial overlap between chronic pelvic pain, urogenital 
symptoms and irritable bowel syndrome. This study showed approximately half of 
the women with chronic pelvic pain had at least one other symptom; 39% had 
irritable bowel syndrome while 24% had genitourinary symptoms. 
Sand (2004) observes that CPP can result from the combination of urogenital 
syndromes such as vulvodynia and IC. The difficulty of differential diagnosis in this 
area of pelvic pain and lower urinary tract pain and symptoms is evident. The 
possible diagnostic blend of FM, chronic pelvic pain, lower urinary tract pain, 
vulvodynia and irritable bowel syndrome pain is indeed perplexing to both clinicians 
and researchers. 
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Fibromyalgia and Vulvodynia 
The International Society for the Study of Vulvovaginal Disease (ISSVD) 
(National Vulvodynia Association, 2002b) defines vulvodynia as chronic vulvar 
discomfort or pain, especially that characterised by complaints of burning, stinging, 
irritation, or rawness of the female genitalia. Vulvodynia is highly individualised. It 
can vary in its persistence and its location. Pain can be spontaneous, constant or 
intermittent, localised or diffuse. Vulvodynia can have a major impact on quality of 
life, impacting on activities of daily living and sexual activities. 
Rodke ( 1996) comments on the experiences of patients with vulvodynia who 
experience all of the problems of a chronic pain syndrome without the assurance of 
knowing what causes their pain and if there is any relief available. Pezzone (2003 ), 
in workshop discussions on vulvodynia, details chronic pelvic pain disorders, 
inclusive of those affecting the pelvis, such as irritable bowel syndrome and 
interstitial cystitis and those affecting the pelvic floor, such as vulvodynia, urethral 
syndrome and prostatodynia. He notes that many of the conditions share a common 
predisposition, a shared etiological factor and a possible cross-sensitisation via neural 
cross talk. Pezzone suggests that the frequent overlapping of irritable bowel, 
vulvodynia interstitial cystitis and other chronic pelvic pain disorders may indicate 
irregular neuronal interactions allowing the irritation of one organ to co-sensitise 
other organs. 
W esselmann (2002) questions whether there is a connection between IC and 
vulvodynia, noting that they often occur in the same patient with the conditions 
developing simultaneously or one preceding the other. The author notes that vulvar 
vestibulitis (pain at the introitus) is more commonly associated with IC. 
At the joint meeting of the American Pain Society and the Canadian Pain 
Society in Vancouver 2004, implications for the classification, assessment and 
diagnosis of women with vulvodynia were presented (Fisher, Robert, Jarrell, 
Carlson, & Taenzer, 2004). Chronic vulvar pain was described as a medical issue 
that has been neglected by the scientific community and, as a result, consensus on a 
classification system with validated terminology and diagnostic criteria does not 
exist. The authors note that the term 'vulvodynia' is used inconsistently and is 
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applied to vulval conditions with known and unknown etiologies, a former example 
being vulvar dermatoses and the latter being vulvar vestibulitis syndrome (VVS) and 
dysesthetic vulvodynia (DS). 
Fisher and colleagues (2004) considered the pain profiles of women with 
unexpected chronic vulval pain and found considerable overlap in the characteristics 
of their pain, with resultant questioning of the validity of the separate terminology 
for VVS and DV. For this current study, the terminology 'vulvodynia' is used to 
describe chronic vulvar discomfort or pain, especially that characterised by 
complaints of burning, stinging, irritation, or rawness of the female genitalia as 
described by the International Society for the Study of Vulvovaginal Disease. A 
study by Pukall, Baron, Khalife and Binik (2004) showed that women with vulvar 
vestibulitis syndrome (VVS) reported significantly higher pain intensities and 
unpleasantness ratings in response to palpation to non-genital body areas, suggesting 
that these women may have a more generalised sensory abnormality. A 
rheumatologist undertook the physical examination and the examination technique 
used was one typically used for the diagnosis for FM. 
Dyspareunia, one of the distinguishing characteristics of vulvar vestibulitis 
syndrome (VVS), is currently classified in the Diagnostic and Statistical Manual of 
Mental Disorders (DSM) as a sexual disorder rather than as a pain disorder (Pukall, 
Kao, & Binik, 2004). The DSM excludes dyspareunia from the category of Pain 
Disorder even though it meets all of the criteria for inclusion. The DSM specifies two 
types of pain, sexual and non sexual but Pukall and colleagues correctly note that 
many chronic pain conditions, such as FM, that interfere with sexual functioning are 
not classified as sexual dysfunction. Pukall and colleagues recommend that 
vulvodynia be evaluated from a pain perspective with a resultant multi-modal 
approach to treatment. 
The first epidemiological study on chronic vulvar pain by the National 
Vulvodynia Association in the United States of America (National Vulvodynia 
Association, 2002a) suggested that almost 20% of American women have suffered 
from chronic vulvar pain at some time in their lives. Some 40% of these women did 
not seek any treatment for their condition. The National Institutes of Child Health 
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and Human Development in the United States have commenced a randomised 
placebo-controlled trial on the use of tricyclic antidepressants for chronic vulvar pain 
(National Vulvodynia Association, 2002a). 
Masheb, Brondolo and Kerns (2002) conducted a multi-dimensional 
evaluation of women with chronic vulval pain. Participants (n=13 l )  included 57 
women with vulval discomfort and 74 healthy controls. Their findings suggest that 
the experience of persistent vulvar pain, rather than the level of intensity of pain, 
accounted for disturbances in functioning and feelings of well being. The analysis of 
data from standardised measures of pain severity, physical functioning and affective 
disorder confirmed the concomitant dysfunction in these domains (Masheb et al., 
2002). There was no relationship between pain severity and affective distress. Their 
findings also showed that although these women scored in the range for marital 
satisfaction, they were not as maritally satisfied as their peer group. 
There is no cure for vulvodynia. Some treatments offer symptom relief such 
as tricyclic antidepressants, anticonvulsants, nerve blocks, interferon, biofeedback 
and diet modification (National Vulvodynia Association, 2002b ). McKay, Kaufman, 
Doctor, Berkova, Glazer, and Redko (2001)  showed that electromyographic 
biofeedback of pelvic floor musculature is an effective approach to vulvar 
vestibulitis, a part of the spectrum of vulvodynia. The aim of the biofeedback 
exercises is to rehabilitate and strengthen dysfunctional pelvic floor muscles, to 
relieve ongoing spasm in the muscles and to break the cycle of chronic vulvar pain 
(Rodke, 1 996). 
A further study (R. Anderson, Wise, & Namazi, 2002) suggests that some 
patients with vulvodynia may experience improvement in vulvar and/or urinary 
symptoms following a combination of surface electromyography assisted 
biofeedback, internal myofascial release and progressive relaxation. Pudendal nerve 
blocks are also used for pain relief in women who suffer from chronic vulvar pain. If 
the women respond positively to the initial diagnostic block, then a series of 
pudendal blocks may be taken as the most appropriate therapeutic approach 
(Daneshfar, 2004). 
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Fibromyalgia and Sexuality 
FM is a chronic disease. With the genitourinary symptoms experienced by 
women with FM, the possibilities and implications of sexual difficulties or 
dysfunction are significant. Webster (2003), in her findings from a study on 
understanding the changes in sexuality experienced by women with IC, describes the 
experience of women with IC as having to make major changes in most dimensions 
of their lives. She lists the major psychological self-care strategies adopted by 
women with IC as information seeking on their condition, self-validation, being 
responsible for their own health and rejecting psychological explanations (Webster, 
2003). Webster considers broader definitions of sexuality than some, describing 
sexuality in terms of being integrated, individualised and a unique expression of 
oneself. 
Sex makes an important contribution to the quality of life in many patients 
who live with chronic disease and to their partners (Mcinnes, 2003). Mcinnes 
describes a number of biological, psychological, and social effects that can impact on 
people with chronic disease. She includes the biological alterations of sexual desire, 
sexual capacity and activity being altered through interference with neural integrity 
of the genitalia as well as medication side effects, limitations on sexual response and 
activity due to pain and fatigue and the negativity of altered body image. The 
psychological effects can include anxiety, loss of self-esteem, depression, or grief of 
the loss of the 'old' self. Mcinnes (2003) refers to the precipitation of an emotional 
crisis with alterations to sexual function and sexual relationship that result from the 
limitation or cessation of sexual activity because of chronic illness. 
Mcinnes (2003) defines sex as a vital part of day-to-day living with chronic 
illness, providing important boosters for patient's quality of life and allowing the 
patient with chronic illness to feel normal again. The improvement of doctor-patient 
communication about sexual issues, recommended by Mcinnes, places the emphasis 
on doctors for an attitudinal change towards sexual health issues, acquiring 
knowledge especially on the impact of illness on sexuality and acquiring the skills to 
implement these skills (Mcinnes, 2003) .  A study on the constructions of sexuality for 
midlife women living with chronic illness (Kralik, Koch, & Telford, 200 1 )  has 
shown that the issues of sexuality are an important health concern for women with 
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long term illness and emphasises that the women should be given the opportunity to 
openly discuss sexuality issues with their health professionals. 
Vulvodynia can have a major impact on quality of life of women with FM, 
impacting on activities of daily living and sexual activities. Vulvodynia is listed as an 
associated FM condition (Wallace & Wallace, 1 999). Vulvodynia can result in 
dyspareunia which is recognised as a sexual pain disorder (A. Graziottin, 2003 ). 
Graziottin describes the psychosexual factors of loss of libido and arousal disorders 
as associated with, or secondary to, sexual pain disorders. The author advocates that 
the psychobiology of this experience of sexual pain should be addressed with an 
integrated, comprehensive and patient-centred perspective. 
Measurement of Urological Symptoms 
This review has considered issues and challenges in relation to the 
measurement of genitourinary symptoms in this population of women diagnosed 
with FM, thereby providing an information passage through the process of this 
research. This research was initiated because of the lack of measurement tools for the 
genitourinary symptoms of this population. To assess effective intervention therapy 
for these difficult to manage urinary symptoms, it is imperative that current updated 
measurement tools are developed as our knowledge in the urological area increases. 
Scientifically validated health outcome measures were first applied to 
urological patients early in the 1 990s with the development of the new benign 
prostatic hyperplasia symptom index. This provided a better understanding of the 
patients' perception of their disease and helped optimise clinical decision making to 
achieve outcomes that mattered most to the patients (O'Leary, Barry, & Fowler, 
1 992). The authors encouraged the development of such indexes for other disease 
entities in urology that demand a quantitation of the illness experience from their 
patients' perspective. Litwin (2002) comments that, in the treatment of urogenital 
diseases, the traditional goal has been to maximise survival but now, for patients with 
non life threatening conditions, their quality of life has taken on new meaning and 
value. 
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Shojania, Mariani and Lindberg (2002) describe science as grinding slowly 
with each new observation and investigation seeking 'truth'. They describe our best 
versions of truth as coming about as a continuum, noting that in one year much is 
observed and reported, some of which lasts and some which does not. Shojania and 
colleagues (2002) also comment that, although it is sometimes difficult to separate 
those that are transient from those that have more perseverance, scientific truth is a 
moving target, a work in progress. So too are measures of health status a moving 
target. Guyatt, Kirshner and Jaeschke (1 992) speak of the health status measurement 
literature as a jungle. They referred to it as an underbush of confused terminology 
and contradictory conceptualisation. 
The ICSI/ICPI is a disease specific instrument focusing on the symptoms and 
impact of urinary dysfunction in the IC population. Most symptom questionnaires 
give a numerical score to the symptom under study. The symptom index is the group 
of items used to measure symptoms that are related (Graham & Dmochowski, 2002). 
A symptom score is the numerical value derived from the use of the index (Hines, 
1 996). Graham and Dmochowski (2002) ask how we can be confident about the 
score generating a true reflection of the symptoms. Psychometrics that measure the 
response to phenomena that is not easily quantifiable govern the development of 
such questionnaires. The validity and reliability of such questionnaires are 
determined by statistical methods. The symptom score is a reflection of the 
questionnaire used to obtain the score. The psychometric testing of the 
questionnaires provides the assurance that symptom questionnaires actually measure 
symptoms (McDowell & Newell, 1 996). 
Van der Vaart, de Leeuw, Roovers and Heintz (2003) comment that the 
consequences of symptoms for a person's  well being are also determined by the 
individual's  psychosocial adjustment to the symptoms. They note that this is 
especially true for chronic conditions that are not life threatening, but which threaten 
quality of life where the effect is felt in physical, social and emotional functioning. 
Van der Vaart and colleagues (2003) therefore recommend measurements of well 
being or health-related quality of life as well as symptom measurements in outcome 
assessments of treatment for urogenital dysfunction. The ICSI/ICPI reflects this 
- 109 -
recommendation in that it measures both the symptoms and the problems of the 
urological dysfunction of women with IC. 
The Interstitial Cystitis Symptom and Problem Index 
The Interstitial Cystitis Symptom Index (ICSI) and the Interstitial Cystitis 
Problem Index (ICPI) are dual tools for quantifying the severity and impact of 
interstitial cystitis. O'Leary, Sant, Fowler, Floyd, Whitmore and Spolarich-Kroll 
(1997) developed this index specifically for IC patients. The development of this 
index was preceded by a pilot study and a subsequent study using a longer initial 
questionnaire. These preliminary studies indicated the symptoms that best described 
IC were burning, frequency, nocturia, bladder pain and back pain. The urgency 
symptoms affected 90% of the IC patients. Seventy per cent of the IC patients had 
daytime frequency compared with 16% without IC. Eighty per cent of the IC patients 
experienced nocturia compared with 10% without IC. Ninety-six per cent of IC 
patients experienced bladder discomfort, pressure or pain compared with 27% 
reporting occasional pressure and 15% reporting pain (O'Leary & Sant, 1999). 
The final ICSVICPI captures the most important voiding and pain symptoms 
and indicates the extent of how problematic these symptoms are for patients with IC. 
The four symptoms of urinary frequency, urinary urgency, nocturia and pain are used 
in both of the indices, the symptom index and the problem index. These items 
compared well with a larger panel of items to discriminate between patients with 
interstitial cystitis and controls. O'Leary and colleagues (1997) showed excellent 
internal consistency and test-retest reliability for both questionnaires in a community 
population with a convenience sample of patients with IC. A following study 
(Lubeck, Whitmore, Sant, Alvarez-Horine, & Lai, 2001) evaluated the psychometric 
properties of the ICSI in a prospective clinical drug trial in patients with IC and was 
found to be a valid, reliable and responsive measure of IC symptoms. 
This ICSI/ICPI developed for the interstitial cystitis population will be tested 
for reliability and validity within the FM population for women who experience 
these same symptoms of urinary frequency, urinary urgency, nocturia and bladder 
pain. Recommendations by Graham and Dmochowski (2002) for such validation of 
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instruments within specific populations include adequacy of instrument testing, 
simplicity of use and application to clinical practice. 
Summary 
In summary, Rothenberg (1999) describes FM as a syndrome that involves a 
loss of pain regulation in the central nervous system that may cause pain 
amplification. The excessive pain stimulation appears to then lead to abnormal levels 
of central nervous system neurotransmitters such as serotonin, norepinephrine and 
Substance P .  The imbalance in these neurotransmitters can then produce problems 
with the body's hormonal response to stress, resulting in inappropriate levels of 
cortisol, catecholamines, growth hormones and possibly thyroid hormones. All of 
these can cause abnormalities in the autonomic nervous system. Rothenberg ( 1999) 
highlights these abnormalities as contributing to irritable bowel syndrome, neurally 
mediated hypotension, irritable bladder symptoms, vascular headaches, chronic 
fatigue and non-restorative sleep disorders. 
Littlejohn and Morand (2002) have predicted that the impetus from the 
current Bone and Joint Decade will increase research within the discipline of 
rheumatology with resultant greater understanding of disease mechanisms and a 
subsequent increase in treatment options. This research on FM and bladder 
irritability will increase our knowledge of the urinary symptoms and their impact on 
women with this condition and will extend the awareness of this problem to a more 
multi-disciplinary medical arena. The validation of the ICSI/ICPI instrument within 
the FM population will assist in determining the nature of sensory urinary symptoms, 
the extent and frequency of the symptoms and the impact these symptoms have on 
the patients' activities of daily living and quality of life. Having a validated outcome 
measure for sensory urinary symptoms in the FM population should encourage 
further intervention research into this debilitating condition. 
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CHAPT ER 3 
FRAME OF REFERENCE 
Theoretical Framework 
Theoretical frameworks provide a structure for guiding systematic enquiry 
and examining relationships amongst relevant variables. These theories and 
relationships are then validated through research and form the basis for further 
development and possible refinement of the theories (Polit & Hungler, 1 989). These 
authors describe theories as efficient mechanisms for bringing together and 
summarising known facts from various studies to more effectively explain scientific 
findings. The authors also comment that research performed within the context of a 
theoretical framework is more likely to result in effective and significant findings. 
The benefit of theoretical frameworks is that they enable a research finding to be 
presented in a more generalised and meaningful way that allows the researcher to 
combine his/her observations and facts in a more organised format. 
The Theory 
The theoretical framework and measurement model for this study on FM and 
bladder irritability is based on previous research findings and relevant theory related 
to Fibromyalgia (FM), central nervous system sensitisation, irritable bladder sensory 
symptomatology, interstitial cystitis and instrument development. The literature 
provides direction for the study design and the Interstitial Cystitis Symptom and 
Problem Index (ICSI/ICPI) instrument validation methods used within the FM 
population. 
The theoretical framework guiding this investigation is based on three 
specific areas of literature: 
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• the genitourinary symptoms of women with FM 
• the similarity of these symptoms to symptoms experienced by women with 
the condition of IC 
• the involvement of central nervous system mechanisms that contribute to the 
pathogenesis of FM that are similar to the mechanisms underlying IC. 
Although the musculoskeletal features of FM define the condition, there are 
many other symptoms that are apparent in individuals with this condition. The 
urogenital symptoms of FM are urinary urgency, urinary frequency, nocturia and 
pelvic pain. IC is a condition characterised by symptoms of urinary urgency, urinary 
frequency, nocturia and pelvic pain. Both conditions can be classified as non­
infective sensory disorders of the lower urinary tract . 
Research by Clauw and colleagues (1997a) suggests that the central nervous 
system mechanisms thought to contribute to the pathogenesis of FM may be 
operative in IC. The postulation that these conditions may share a similar etiology 
and the evidence that both conditions have similar clinical symptomatology provide 
rationale to undertake a study to validate, for use within the FM population, an 
instrument developed for the IC population. This instrument, the Interstitial Cystitis 
Symptom Index and Problem Index (ICSVICPI), has been developed and validated to 
measure lower urinary tract symptoms and their impact in patients with IC (O'Leary 
et al., 1997). 
Aaron and Buchwald (2000) noted numerous clinical conditions that share 
common symptomatology such as pain. They described the frequency of ten clinical 
conditions among patients with chronic fatigue syndrome (CFS), FM and 
temporomandibular disorder (TMD) and found that patients with FM had 
significantly more symptoms characteristic of interstitial cystitis than did patients 
with CFS or TMD. A survey by Alagiri, Chottiner, Ratner, Slade and Hanno (1997) 
also showed that of 2682 patients with IC, 25% reported having comorbid FM. This 
overlap of IC and FM symptomatology gives further impetus for this current study to 
validate an outcome measure for the FM population that has been found to be valid 
and reliable for use within the IC population. 
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Bladder symptomatology 
overlaps in IC and FM 
FM 
Figure 1: Overlap of Sensory Urinary Symptoms in Interstitial Cystitis (IC) and Fibromyalgia 
(FM) 
Currently there is no validated instrument to measure lower urinary tract 
sensory symptoms or their impact on women diagnosed with FM. Lose and 
colleagues (1998) suggest that research on lower urinary tract symptoms in adult 
women is limited by the lack of standardised outcome variables for use within this 
population. They encourage studies that lead to the development and standardisation 
of outcome measures and comment that success in this regard will enhance 
knowledge of actual treatment as well as stimulate the development of new treatment 
options. 
Often the scientific evaluation of the outcome of intervention is based on pre­
test and post-test evaluation. Lose and colleagues (1998) note that the reliability of 
some methods and measurements is often unclear, leading to inaccurate 
interpretations of the results of the intervention. They state that the reliability of a test 
depends on the accuracy and reproducibility of the method. Valid and reliable 
measurement scales not only guarantee consistency in measuring patient progress, 
but provide a basis for the development of evidence-based practice (O'Connell et al., 
2002). This study has used the ICSVICPI through two study phases to provide a 
validated and reliable tool for the measurement of sensory urinary symptoms and 
their impact in women with FM. 
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The theoretical links that describe the common pathogenic mechanisms 
between the two conditions of FM and IC provide a foundation for the psychometric 
testing of the instrument. The development of a valid and reliable instrument to 
measure these urinary symptoms will provide a means of subsequent testing 
regarding these conditions in future research. 
The Framework 
The theoretical framework underpinning this research on bladder irritability 
symptoms in women diagnosed with FM is displayed in Figure 2. The literature 
indicates that the majority of research studies on FM in the last decade have focused 
on the central sensitisation of the central nervous system, as the most likely 
etiological factor in the development of FM. An adaptation of the integrated 
etiological hypothesis proposed by Clauw (1995a) is the basis of the theoretical 
framework for this study. 
- 115 -
�
� C:
i
�
:
� ; :ve
ct
-
ion
Environment 
Genetic 
Influence 
Physical Stress 
Psychosocial 
Stress 
Neurogenic 
Inflammation 
Urinary Urgency 
Figure 2: Theoretical Framework 
Central Nervous System 
Hyperexcitability 
FIBROMYALGIA SET IN MOTION 
Increased Visceral 
N ociception 
N euroendocrine 
Disturbances 
IRRITABLE BLADDER SYMPTOMS 
Urinary 
Frequency 
- 116 -
Bladder 
Discomfort/Pain 
Inflammation 
Trauma 
Immunological 
Response 
Autonomic 
Dysfunction 
Nocturia 
Multifactorial Etiology of Fibromyalgia 
The following discussion gives direction and momentum to this theoretical 
framework, commencing with the multifactorial etiology of FM. Many factors 
impact on the human system to initiate and to maintain the central nervous system 
hyperexcitability state seen in FM. These include genetic influences, environment, 
physical and psycho-social stress, infection, inflammation, trauma, immunological 
response and continued nociceptive stimuli. 
Studies have shown that genetic factors may predispose people to a genetic 
susceptibility for the development of FM. Buskila and Neumann ( 1997) have found 
that blood relatives of FM patients have a higher prevalence of FM and more tender 
points than an age-matched group within the general population. 
Pillmer, Bradley, Crofford, Moldofsky and Chrousos (1997) suggest that FM 
may be a stress-related illness, because it is often associated with a stressful physical 
or psychological situation. Littlejohn (2004) notes the influence of psychosocial 
impact on patients with FM. He refers particularly to studies of the stress axis, with 
emphasis on the hypothalamic-pituitary-adrenal axis which displays abnormalities in 
many patients with FM. Littlejohn describes the pathophysiology of FM as a range of 
complex and integrated neurobiologic mechanisms which are responsive to stress 
and emotion. Wallace and Wallace (1999) note that, when FM patients are asked 
what they think caused their FM, the most common replies are trauma, infection and 
stress. 
Central Nervous System Hyperexcitability 
As a peripheral cause of pain cannot be easily identified in most FM patients, 
it has been suggested that most of the 'action' is at the level of the spinal cord and 
above (Bennett, 2002a). Researchers are therefore focusing more on the role of the 
central nervous system rather than on the musculoskeletal system in an effort to 
explain the symptoms of FM. A disorder of the central processing of sensory 
information from the nociceptor and mechanoreceptor systems can result in 
numerous neurophysiological changes that are observed in FM sufferers. Yunus and 
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Inanici (Baldry, 2001) define central sensitisation as hyperexcitability of the central 
nervous system neurones which results from peripheral noxious stimuli. This can 
lead to an exaggerated response to a normally painful stimulus known as 
hyperalgesia. Similarly, allodynia, a painful response from a normally non­
nociceptive stimulus such as touch, can occur. There is also an increased duration of 
response after a brief stimulus (Staud, 2002). 
Clauw ( 1995a) notes that once central nervous system hyperexcitability is 
apparent, then all or some of the effector arms of the central nervous system can 
become involved. He suggests that the elevated ratio of excitatory to inhibitory 
neuromodulators is responsible for the resultant spectrum of conditions, the region of 
the central nervous system being affected being reflected in the symptomatology. A 
clinical spectrum of FM encompassing neurogenic inflammation, increased 
peripheral and visceral nociception, neuroendocrine disturbances and autonomic 
nervous system dysfunction can result, with symptoms being evident in any or all of 
the effector arms of the central nervous system (Clauw, 1995a). This etiologic 
hypothesis presented by Clauw is delineated in Figure 3. 
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Figure 3: Etiological Hypothesis for Fibromyalgia. Adapted from Clauw (1995a) 
Autonomic 
dysfunction 
These four mechanisms of neurogenic inflammation, increased peripheral and 
visceral nociception, neuroendocrine disturbances and autonomic dysfunction, may 
all individually or collectively impact on bladder symptomatology and influence 
lower urinary tract function in women with FM. 
Neurogenic Inflammation 
Neurogenic inflammation is described as 'inflammation caused by an 
injurious stimulus of peripheral neurons and resulting in the release of neuropeptides 
that affect vascular permeability and help initiate pro-inflammatory and immune 
reactions at the site of injury' (Medical Dictionary Online, 2004). The concept of 
neurogenic inflammation is based on the release of Substance P and related peptides 
by an axon reflex mechanism. Investigation on peptide-induced release of 
inflammatory mediators by the urinary bladder, has shown that the peptides 
evaluated induced changes which may directly regulate the participation of these 
peptides in the pathogenesis of cystitis (Saban et al., 1997). Similarly, Callsen­
Cencic and Mense (1997) questioned whether alterations in the expression of 
neuropeptides and nitric oxide synthase in the neuronal pathways to the bladder 
might be involved in the hyperexcitability of the bladder with the development of 
cystitis. 
A theory by Cervero and Janig (1992) suggested that a large component of 
the afferent innervation of internal organs consists of afferent fibres that are usually 
unresponsive to stimuli until they are activated by inflammation. Cervero and Janig 
suggest these sensory receptors contribute to the signalling of chronic visceral pain, 
to long term alterations of spinal reflexes and to abnormal autonomic regulations of 
internal organs. 
Butrick (2004) states that IC is not an end organ disease but a visceral pain 
syndrome involving chronic neurogenic inflammation, primary afferent overactivity 
and central sensitisation which lead to the perpetuation of pain. Butrick (2004) cites 
Birder and deGroat who have shown that neuronal-like properties of urothelial cells 
enable cells to have a sensory function and interact chemically with afferent nerves. 
Brookoff ( 1997) believes the consequence of bladder inflammation in IC is 
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hypersensitivity of the chemo-sensitive afferent bladder nerves resulting in 
hyperalgesia. With increasing inflammation, mechanoreceptive nerves in the bladder 
wall can generate pain signals in response to a small increase in intravesicular 
pressure, resulting in allodynia (Brookoff, 1997). 
Elbadawi (1997) describes responses brought into play by neurogemc 
inflammation as sensory nerve excitation, the release of neuropeptides and activated 
differential secretion of potent mast cell mediators. Radziszewski and colleagues 
(2002) consider that the painful bladder may represent different expressions of 
'neurogenic inflammation of the bladder' where previously silent C-fibres may be 
activated. 
Increased Peripheral and Visceral Nociception 
The altered properties of visceral afferents that result from the instability of 
the transduction properties of these nerves are described as forms of plasticity that 
can affect the encoding and transmission of sensory information (McMahon, 2004). 
This increases chronic pain states by increasing the excitability of sensory neurones. 
Butrick (2004) showed that silent visceral afferents become activated with prolonged 
stimulation and produce tissue sensitisation and pain in the bladder. The bladder has 
the highest neural density and the greatest proportion of silent C-fibres than any other 
viscera (Cervero, 1994). 
Cervero and Laird (1999) suggest that increased awareness of visceral 
hyperactivity could come about from sensitisation of the peripheral nociceptors or of 
alterations of central processing with an increased activation of the visceral 
nociceptive pathways. Giamberardino and colleagues (2001) further showed that 
algogenic conditions of one internal organ can affect reactivity to painful stimuli of 
other visceral areas, such as in the female pelvic reproductive organs and urinary 
tract. Yoshimura and colleagues (2002) hypothesise that the hyperexcitability of the 
C-fibre afferent pathways may be the mechanism for bladder pain and urgency and 
are focusing on treatment of these symptoms by modulating the activity of bladder 
afferents pathways. 
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In a study on the relationship between FM and interstitial cystitis, Clauw and 
colleagues (1997a) showed significant overlaps in symptoms, which included 
increased peripheral nociception. They suggested that IC may be part of the disorder 
of central processing of sensory information. This theory was discussed within a 
forum at a urology symposium on management of the painful bladder syndrome 
where bladder pain in IC was described as being mediated by central pain 
mechanisms in the spinal cord (Blaivas et al., 1999). Likewise, Wesselmann (2001) 
revealed the similarities between IC and other chronic, non-malignant visceral pain 
syndromes in her conceptual common approach to treatment for both conditions. 
Other studies have implicated the urogenital system in the central nervous system 
sensitisation process. These studies, already referred to in the literature review of this 
thesis, include articles by Al-Chaer (2000), Costa, Glise and Graffer (2004), Bennett 
(2002c) and Ishigooka and colleagues (2001 ). 
Neuroendocrine Disturbances 
As well as neurotransmitter abnormalities, hormonal and biochemical 
abnormalities are detectable in patients with FM (Clauw, 1995a). The hypothalamic­
pituitary-adrenal (HP A) axis is a complex brain-to-body pathway and is central to the 
stress response. FM is characterised by an under active stress response. Clauw 
(1995a) suggests that the decreased capacity in response to stressors in both the 
neuroendocrine and autonomic nervous systems provides a pathway where stressful 
events could exacerbate symptoms associated with one or more of the effector arms 
of the nervous system. 
Jain and colleagues (2004) describe a loss of adaptability and stress tolerance 
associated with dysfunction of the HP A axis in patients with FM. In relation to the 
abnormalities apparent in the HP A axis in FM, Crofford (2002b) questions whether 
the axis abnormalities reflect pre-existing vulnerability to the FM condition or 
whether the chronic pain alters the HP A axis activity. 
Bennet ( 1993) suggests a disruption of the neuroendocrine axis that controls 
growth hormone production could be the link between disturbed sleep and muscle 
pain because this hormone is produced mainly during level IV sleep. Sleep 
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disturbance with FM is intricately linked with voiding at night. Whether nocturia is 
due to bladder sensation messages or to the 'just in case' voiding when one is already 
awake is as yet unknown. Results of a study by Lutgendorf and colleagues (2002a) 
suggest that the dysregulation of the HP A axis may be linked to interstitial cystitis 
symptomatology. 
Autonomic Nervous System Dysfunction 
The autonomic nervous system (ANS) is described as a dynamic system with 
intense and instantaneous onset of action and dissipation that works closely with the 
endocrine system, especially the HP A axis and the growth hormone axis (Martinez­
Lavin, 2002). Because the ANS regulates the function of most of the organs and 
systems of the body, it is the main homeostatic system of the body. Abnormal 
sensory symptomatology of the lower urinary tract in women with FM may be partly 
due to abnormalities of the ANS. Martinez-Lavin (2002) suggests that dysautonomia 
may play a central role in the pathogenesis of FM because autonomic nervous system 
dysfunction is frequently found in patients with FM. 
Zermann, Ishigooka, Doggweiler and Schmidt (1998) describe lower urinary 
tract function as a complex multi-level and multi-neuronal interaction, involving 
facilitation and inhibition at many levels of the CNS. They further describe the 
coordination of lower urinary tract function as being mediated by reflex pathways 
regulated in the lumbo-sacral and thoracolumbar spinal cord as well as by reflex and 
voluntary mechanisms in the brain stem and cortex (Zermann et al., 1998). These 
researchers note that, in research on the central innervation of the lower urinary tract, 
the spinal cord and pontine micturition centre have been investigated thoroughly 
while the role of the higher centres has been ignored. 
Recent experiments on the whole bladder of the guinea pig (Gillespie, 
Harvey, & Drake, 2003) show neurogenic control by two separate mechanisms, the 
parasympathetic system fundamental to micturition and a second system generating 
non-micturition activity, with the central nervous system coordinating both systems. 
The bladder is rhythmically active during the filling stage (Gillespie, 2004). Gillespie 
describes the activity generated in the bladder wall at this time as autonomous 
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activity . This activity involves contraction and localised stretches of the bladder wall, 
thought to be initiated by a network of pacemaker cells and connecting interstitial 
cells that are impacted upon by excitatory and inhibitory neural inputs. Gillespie 
(2004) suggests that escalation of autonomous activity as excessive excitatory inputs 
or failure of inhibitory inputs may contribute to uncontrolled bladder activity in the 
filling phase . 
Gillespie (2004) proposes a hypothesis that bladder overactivity is due to 
inappropriate non-micturition activity. He suggests that this autonomous bladder 
hypothesis may make it possible to control the initiation and modulating of 
pathological non-micturition activity without interfering with the micturition reflex. 
This area of etiological research into sensory bladder neurology is ongoing. 
In summary, the mechanisms of neurogenic inflammation, increased visceral 
nociception, neuroendocrine disturbances and autonomic dysfunction all have the 
capacity, individually or collectively, to influence the functioning of the lower 
urinary tract of women within this FM population. These mechanisms do not 
function in isolation. Pillemer and colleagues ( 1997) demonstrate this in their 
description of triggering events which may initiate changes in the HPA axis and the 
autonomic nervous system that can result in sensitisation of the central nervous 
system via neuropeptides with the resultant alteration of nociceptive processing. 
The Measurement Model 
There is currently no questionnaire to specifically assess urological symptoms 
or their impact on women with FM. Such a questionnaire would assist in determining 
the nature of the problem, the extent and frequency of the symptoms and the impact 
the condition has on the patient's sense of well-being and activities of daily life. Pre­
treatment and post-treatment-validated questionnaires for these specific conditions 
can clearly indicate treatment outcomes. 
It is important that current updated measurement tools are developed as our 
knowledge in the urological and FM areas increases. It is recommended that 
measurements of health-related quality of life, as well as symptom measurement, be 
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included in outcome measures for urological dysfunction (van der Vaart et al., 2003). 
The ICSI/ICPI responds to this recommendation by measuring both symptoms and 
impact of IC. This is important not only in the primary areas of urological disease, 
but also in the areas where urinary symptoms are associated symptoms of other 
conditions such as FM. 
The measurement model is based upon literature that describes sensory 
bladder symptomatology experienced by women with FM. The bladder 
symptomatology includes urinary frequency, urinary urgency, bladder 
pain/discomfort and nocturia. The measurement tool trialled for validation within the 
FM population is the ICSI/ICPI, a measurement tool already validated for measuring 
urinary symptoms and their impact for patients with IC. The ICSI/ICPI is a 
condition-specific instrument that measures the sensory urinary symptoms of 
frequency, urgency, pain and nocturia and their impact within the IC population. 
Because of the apparent, reported overlap of symptoms between IC and FM, 
especially the sensory urinary symptoms, the ICSI/ICPI was identified and tested for 
validation within the FM population of women with urinary symptoms. The 
measurement model for this validation procedure is displayed in figure 4. This 
current study has tested and modified the ICSI/ICPI for the FM population, 
producing a validated instrument for women with FM who experience bladder 
irritability. 
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CHAPTER4 
METHODOLOGY 
Introduction 
This chapter includes the methods and procedures used to conduct Phases I 
and II of this research on Fibromyalgia (FM) and bladder irritability. The first 
component of this chapter describes the methods and procedures of Phase I, while 
the second component describes the methods and procedures related to Phase II of 
the research. 
Research Plan 
This research involved a two-phase program of research to validate and test 
an existing instrument within a new population of women diagnosed with FM who 
experienced symptoms of bladder irritability. Phase I used a qualitative research 
approach. Focus groups with women who had been diagnosed with the condition of 
FM and who experienced bladder irritability symptoms were conducted. Phase II 
tested the instrument within this new population for reliability and validity. The 
findings of the focus group were incorporated into the second phase of this study. An 
example of this was the finding of the symptoms and impact ofvulvodynia in women 
from the focus groups. As a result, a vulval symptoms questionnaire was developed 
as a data collection method for this symptomatology for Phase II of the study. 
Ong (1993) suggests an approach to research that draws on a wide spectrum 
of methodologies which can be integrated as the most appropriate approach to the 
multi-dimensional and multi-disciplinary issues encountered in the health field. 
Herbert and Higgs (2004) comment that, despite the philosophical and 
methodological differences between quantitative and qualitative research paradigms, 
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research across the paradigms can provide complementary ways of learning. Herbert 
and Higgs note that this can be particularly relevant in the area of health care because 
this area is involved with both the physical and social world of people. 
Within the physiotherapy profession, Ritchie ( 1999) credits qualitative 
research as a means of' adding the humanistic mission to result in the best practice in 
physiotherapy' (p.25 1 ). This move within the physiotherapy profession embraces the 
specific needs of the patients as well as developing evidence-based practice. Ritchie 
discusses the obligation we have as physiotherapists to refine the art and science of 
good health care through systematically combining patient-focused care and 
evidence-based practice, a qualitative as well as quantitative approach to our 
research. 
The two research methodologies were combined in this study to enable 
information from the focus group discussions to be interpreted in the development of 
the data collection instrument for Phase II of the study. Barbour ( 1999) recommends 
the consideration of the contributions that a qualitative component can make to 
research that is mainly using quantitative methods grounded in the quantitative 
paradigm. In this study, it was important that the research did not progress towards 
structured questionnaires without firstly undertaking some qualitative work to 
establish relevant questions and issues. New relevant variables for the data collecting 
questionnaires were identified as a result of the qualitative methodology of the first 
phase of this study. 
Methodology Phase I 
Design 
Focus groups were the method of gathering data on the symptoms and impact 
of lower urinary tract sensory symptoms on women with FM. A descriptive design 
was used for this phase of the study. Information from relevant literature and 
qualitative methods were combined to develop the format for data collection. An 
interview guide was used to outline the relevant topics for the group discussions and 
to elicit thoughts, ideas and perceptions about the participants' symptoms (Appendix 
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C). Group participants were all women who had been diagnosed with FM by a 
rheumatologist and who had experienced sensory bladder symptoms. The conducted 
interviews and discussions were to ensure that the key indicators and the way in 
which the participants experienced bladder irritability were compatible with and 
inclusive in the ICSI/ICPI instrument to be validated in Phase II of this research. 
Why Focus Groups as the Data Collection Method? 
Relevant literature and focus groups were used as the qualitative method of 
data collection for this first phase of this research. Benoliel (Polit & Hungler, 1989) 
describes four broad areas in which unstructured qualitative approaches have merit. 
One of these areas describes a person's adaptation to critical life experiences such as 
chronic illness. Portney and Watkins ( 1993) describe qualitative research as seeking 
to describe the complex nature of human beings and how humans perceive their own 
experiences. They continue to explain the purpose of qualitative inquiry as 
examining such experiences with a holistic approach that focuses on the true nature 
of the participant's 'reality'. 
The focus group has been described as a guided interactional discussion for 
generating rich experiential information (Carey & Smith, 1994). Basch (1987) 
commented that the focus group interview is a technique of qualitative research that 
determines feelings and opinions about an identified topic. The topic to be addressed 
in this research is bladder irritability symptoms experienced by women who had been 
diagnosed with FM. 
Greenbaum (Diloroi, Hockenberry-Eaton, Maibach, & Rivero, 1994) states 
the benefits of focus group data collection as allowing for the combination of 
elements of group process theory and qualitative research methods as well as 
enabling the group facilitator to establish a permissive environment encouraging in­
depth discussion of the research topic. Krueger and Morgan (Asbury, 1995) note that, 
by design, focus groups rely more on the dynamic of the group interaction to 
stimulate thought processes, with resultant verbal contributions of the participants, 
thereby providing the researcher with a richer and more detailed perspective. 
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Based on the above rationale, and in considering the various approaches 
available for qualitative data collection, the focus group was deemed to be the most 
appropriate for this research project. Because of the intimacy of this research topic 
on bladder function and dysfunction, individual interviews as a method of data 
collection for this project were considered. However, the interactive components of a 
focus group were considered and focus groups were selected as the means of data 
collection because it would provide more detailed and complete information on 
symptoms and impact. 
Diiorio, Hockenberry-Eaton, Maibach, and Rivero ( 1994) suggest that 
information from focus groups can provide an excellent basis for the development of 
research instruments. The person who has the symptom can most correctly supply the 
symptom and impact scale related to their condition. Basch ( 1987) describes the 
benefit of focus groups in the development of quantitative instruments because the 
group interaction reveals appropriate response categories, language usage, 
vocabulary and vernacular used by the research participants. For this FM research, 
the women in the focus groups were able to elicit thoughts, ideas and perceptions 
about their bladder symptoms. They were able to describe the increased impact on 
their lives that resulted from the involvement of their bladder in their overall FM 
symptomatology. 
Population and Sample 
Participants for the focus groups in this first phase of the study were women 
from Perth, Western Australia who had been diagnosed with FM by a rheumatologist 
and who experienced lower urinary tract sensory symptoms. 
Recruitment 
Recruitment for this stage of the research was via a rheumatologist. 
Following a meeting with the rheumatologist, where I explained the research and its 
methodology, he was provided with copies of the Phase I information sheet for 
participants (Appendix D). The rheumatologist organised for these information 
sheets to be attached to a letter to FM patients from his medical practice database 
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asking for expressions of interest in the FM study, or mentioned the study to 
potential participants at the time of consultation (Appendix E). This method of 
recruitment therefore ensured that all participants had been diagnosed with FM by a 
rheumatologist. Participants were asked to telephone the researcher directly if they 
were interested in the research. Through this method of recruitment, the privacy of 
the patients was protected. 
Potential participants were screened over the telephone. The first twenty 
women who called, who expressed an interest in the phase of the study and who met 
the inclusion criteria, were invited to join the focus groups. All participants 
experienced at least two of the sensory urinary symptoms associated with FM. These 
sensory symptoms included urinary frequency, urinary urgency, nocturia and a 
constant awareness of the bladder, or discomfort, or, pain in the bladder. 
The Focus Groups 
The three focus groups were all conducted on university premises, which 
were readily accessible for the majority of participants. Car parking on the premises 
was arranged free of charge. Care was taken to ensure that the meeting room was 
friendly and had an appropriate temperature. Seating was arranged around a 
rectangular table setting to encourage interaction, with the moderator placed adjacent 
to the participants and not at the end of the table as a leader figure. Because of the 
impact of the participants' urinary symptoms, close proximity to toilets was 
considered. Participants were given name badges for first names only and 
introductions were given. The total number of women in the focus groups was 10. 
There were four women in the first group, four women in the second group and two 
women in the third group. 
A co-facilitator, another women's health physiotherapist, was present and 
talked to the participants prior to the commencement of the session regarding issues 
of confidentiality, consent forms and the recording of, and format of, the session. 
Information was also given about the purpose of the study and benefits of the 
research. Prior to the commencement of the session, all participants signed consent 
forms for participation in the study (Appendix F). The co-facilitator's role included 
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minimising interruptions, recording the session, providing refreshments and acting as 
an observer of non-verbal behaviour or other non-recordable dynamics within the 
group. These observations were imparted to the researcher/facilitator at the 
debriefing session between the facilitator and co-facilitator following the focus 
groups. 
The three focus groups, with the total number of ten participants, resulted in a 
sense of completeness of information and experience on the research topic. The 
discussions from these three focus groups provided multiple aspects of living with 
FM and its associated bladder symptoms. After the third focus group, most of the 
information given became repetitive, suggesting that most 'new' information had 
been obtained. Information redundancy was achieved. 
Data Collection and Protocol 
All three focus group sessions were audiotaped to enable accurate retrieval of 
data. The semi-structured interview, based on the relevant literature and validated 
questionnaires planned for use in the second phase of this research, was used to elicit 
information about the participants' bladder and non-bladder FM symptomatology. 
The interview guide used for the focus groups was partly derived from the Interstitial 
Cystitis Symptom Index and Problem Index, the voiding and pain indices being 
validated for use within the FM population. This was to ensure that the key 
symptoms and the impact on these women were compatible with, and inclusive in, 
the ICSI/ICPI instrument. 
Questions from the Fibromyalgia Impact Questionnaire, the Kings Health 
Questionnaire and the SF-36 Health Questionnaire were also used during the focus 
groups. These questionnaires formed part of the main data collection instrument for 
Phase II of this research. The rationale for adding relevant sections of these 
questionnaires to the interview guide was to expand the collected data to include 
issues concerning the effect of bladder problems on physical as well as psycho-social 
aspects of women's lives. Demographic information questions were also included in 
the interview guide. 
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Questions from the interview guide were discussed at length to ensure 
participants' understanding of symptom descriptions, symptom comprehension, word 
comprehension, and the arrangement of numerical values in relation to symptoms 
and impact. All relevant information from the focus group participants was 
considered in refining the instrument for data collection for Phase II of this research. 
Some minor changes were made in the demographic questionnaire as a result of the 
focus group discussion re the comprehensibility of the questionnaire. The 
interview/discussion format of the focus groups successfully encouraged participants 
to become involved with the answering of questions, often followed by a discussion 
of their personal experience of the specific topic. 
Data Analysis 
Ingleton and Seymour (2001) refer to the various mechanical and creative 
processes interwoven into the production and analysis of data. The analytical process 
of this qualitative study reflects this intertwining of personal knowledge and 
experience of the researcher as a physiotherapist continence adviser, the study 
participants' comments, conversations, accounts and experience of their personal 
experience with FM and the information, and interpretation from the relevant 
literature. 
Goldman and McDonald (Henderson, 1995) comment that qualitative 
analysis begins during the group session itself. They recommend that the group 
moderator be continually alert to analytical implications during the process of the 
focus groups. This was certainly the case in the collection of the data from this focus 
group of women with FM and bladder irritability. As the semi-structured interview 
was based on validated FM and urinary symptom and problem indexes, the questions 
were directed to the participants' symptom range and the impact of the symptoms on 
their lives. The shared symptom and impact experience of these women seemed to 
give them not only permission to talk about an intimate and often taboo subject, but 
also to share their stories, which they did, almost with a sense of urgency. Henderson 
(1995) acknowledges that the perceptions, beliefs, opinions and attitudes that result 
from data collection in focus groups are subjective. Henderson also comments that 
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the different backgrounds of qualitative practitioners provide a conversion 
mechanism giving interpretation to what respondents say. 
Portney and Watkins ( 1993) describe qualitative data analysis as primarily an 
inductive process reflecting a constant interplay between the observed reality and 
theoretical conceptualisation of that reality. Because of the narratives involved in 
interview response, qualitative data have to be reduced to derive meaning from them 
for summary and presentation (L. G. Portney & Watkins, 1993). A process of coding 
and content analysis can achieve this process. 
Coffey and Atkinson ( 1996) refer to coding as condensing the bulk of the 
data set into units for analysis by creating categories and generating concepts from 
within our data. Essentially coding is a method of organising qualitative data. 
However, Coffey and Atkinson ( 1996) suggest that coding data can be part of the 
analytical process as giving codes to data and generating concepts enable us to 
rigorously review what our data are saying. The authors continue by acknowledging 
that, as coding links different segments of the data together, it creates categories of 
data defined as being about a particular theme or concept. Coffey and Atkinson 
( 1996) recognise therefore that codes, data categories and concepts are related to one 
another. 
Computer software packages such as NUD.IST are used for the coding of the 
qualitative data. Coffey and Atkinson (1996) refer to this computer software use as 
'the code-and-retrieve program'. These programs allow the researcher to identify 
segments of data by attaching code words to them. The data are then explored for 
segments that can be identified by the same code. Coffey and Atkinson discuss the 
move from coding to interpretation in various stages. The first stage is the retrieval 
and categorisation of the data. The second stage is the playing with, exploring, 
splicing and linking the created codes and categories. The next stage is the 
interpretation, described by the authors as the transformation of the coded data into 
meaningful data. 
This was the process used for the data analysis from the transcripts of the 
three focus groups for this research. With the assistance of NUD.IST software, data 
were identified, coded, retrieved and all segments identified by the same code were 
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collected together for further analysis. This involved the identifying of themes, 
patterns and responses and finally led to the interpretation. 
The interpretation and testing of emergent ideas in qualitative analysis are 
described by Ingleton and Seymour (2001) as the researchers demonstrating that 
'they have opened up their minds to a range of possible interpretations of qualitative 
data, and therefore have captured, as far as possible, the essence of the everyday 
world under study' (p. 23 1 ). This 'capturing' of the essence of the world of 
symptoms and impact of urinary irritability on women with FM began. 
The 80 pages of transcripts for this research were transcribed, read and re­
read by me as the primary investigator to ensure absolute immersion into the data. 
Through the reading and the re-reading of the transcripts, thoughts and recollections 
of the group dynamic and expression were noted. Fallowing detailed analysis of the 
transcripts, primary codes were identified. As recommended by Miles and Huberman 
( 1984) the codes were first developed as chunks of words that go together and 
reconfigured as the data expanded. These primary codes were then superimposed on 
to the transcripts to verify their placement. My academic supervisor (LK) and a 
second research investigator (AP) verified these codes as being representative of the 
data, following numerous meetings where the coding was revisited. 
Emerging themes from the coded data were recurrent. My academic 
supervisor and a third individual with qualitative research experience (JW) reviewed 
thematic configuration and participated in discussions of the interpretation of these 
emerging themes. The development of an audit trail and the use of second and third 
researchers to verify coding of the data established the rigour of the data analysis. An 
audit trail is the researcher's progressive documentation of the data collection, the 
categorising and organising of the data and the data analysis (Macnee, 2003 ). 
Lincoln and Guba (1985) describe the audit trail as a method of confirmability, the 
consistency and repeatability of the decisions taken during the process of data 
collection and analysis. Some of the findings from Phase I were instrumental in some 
changes to the data collection instrument used in Phase IL 
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Methodology Phase II 
Design 
This phase of the research involved the testing of the Interstitial Cystitis 
Symptom and Problem Index (ICSI/ICPI) within the FM population for reliability 
and validity. A cross-sectional study design of a group of women with FM and 
bladder irritability was used to test the ICSI/ICPI instrument for reliability and 
validity for use within the FM population. The instrument for data collection was a 
self-administered questionnaire. This questionnaire included a demographic 
questionnaire (Appendix G), the ICSI/ICPI (O'Leary et al., 1997) (Appendix A), the 
Fibromyalgia Impact Questionnaire (Burckhardt, Clark, & Bennett, 199 1) (Appendix 
H), the Kings Health Questionnaire (Kelleher, Cardozo, Khullar, & Salatore, 1997) 
(Appendix I}, the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-
36) (Ware & Sherboume, 1992) (Appendix J) and the Vulval Symptoms Assessment 
Scale (Appendix K). The vulval symptom assessment scale was developed as a result 
of the findings from the focus group of Phase I of this research to gauge the extent of 
vulval symptoms and their impact in this study population. 
The rationale for including the Fibromyalgia Impact Questionnaire, the Kings 
Health Questionnaire and the SF-36 questionnaires was to expand the collected data 
to include issues concerning the effect of bladder problems on physical as well as 
psycho-social aspects of women's lives, the impact of the condition of FM on these 
women and their general health. The demographic questionnaire outlined socio­
demographic information and illness and disease specific factors. As there is no gold 
standard for assessing lower urinary tract sensory symptoms of women with FM, 
validity was assessed by comparing the ICSI/ICPI with the score that patients 
obtained from similar reliable measures such as the Kings Health Questionnaire 
(Kelleher et al., 1997), the Fibromyalgia Questionnaire (Burckhardt et al., 199 1) and 
the SF-36 Questionnaire (Ware & Sherboume, 1992). It was anticipated that women 
with more FM and bladder symptoms would score higher in the ICSI/ICPI. 
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Population and Sample I Inclusion and Exclusion Criteria 
Data were collected via the self-administered questionnaire administered to 
90 women who met the inclusion criteria. Women were recruited from two 
Australian state capital cities, Melbourne and Perth. 
Inclusion Criteria 
• All subjects were female and between the ages of eighteen years and sixty-
five years inclusively 
• All subjects experienced at least two sensory bladder symptoms. 
• Rheumatologists have diagnosed all subjects in the study with fibromyalgia. 
• All subjects in the study have undergone a non-invasive urological screening 
by a urologist or urogynaecologist to eliminate conditions with abnormal 
pathology. 
• All subjects understand spoken and written English. 
Exclusion Criteria 
Subjects were excluded from the study if any of the following criteria applied: 
• Under the age of eighteen years or over the age of sixty-five years. The 
increase in urinary symptoms in the aged is well documented. Therefore the 
inclusion of women over sixty-five years of age in this study could create a 
significant confounding factor. 
• Pregnancy 
• Current urinary tract infection 
• Recurrent urinary tract infection 
• A diagnosis of bladder conditions with abnormal pathology resulting from the 
urological screening. 
• Neurological disorders (apart from that due to FM) 
• Presence of a urinary catheter 
• Drugs that can cause irritative symptoms eg. cyclophosphomide or 
tioprofenic acid 
• Carcinoma of the bladder 
• Inability to understand spoken and written English. 
- 136 -
Recruitment 
A number of different methods of recruitment were employed. In Perth, 
women were recruited through referral by rheumatologists. This study' s research 
proposal was presented to Perth rheumatologists at their monthly research meeting, 
explaining the need for participants in the study who had been diagnosed with FM by 
rheumatologists. Research information letters (Appendix L) were sent to 12 
rheumatologists with follow-up visits to eight of the practitioners. 
A number of rheumatologists assisted the recruitment process by sending 
letters to their FM patients asking if they were interested in finding out more about 
the study and, if so, to contact the researcher directly. Some rheumatologists 
mentioned the study to patients during consultation if the patient met the 
rheumatological inclusion criteria of the study. General information sheets for 
surgeries, as well as notices on rheumatology clinic waiting room notice boards, 
were made available to the participating medical practices (Appendix M). 
Two media releases from the Edith Cowan University public relations 
department were distributed during the recruiting period to local newspapers and 
media outlets (Appendix N). This resulted in excellent coverage by a number of the 
local newspapers. Recruitment advertisements continued in the community sections 
of some of the community newspapers during the recruitment period. Similar 
advertisements were also placed in: the "Arthritis Today" newsletter of the Arthritis 
Foundation of Western Australia; "Pipeline", the newsletter of the Continence 
Foundation of Australia (WA); the Australian Physiotherapy Association newsletter; 
and the Women's Health and Continence Physiotherapists national group newsletter. 
Information on the study and recruiting information was published in the Gazette of 
Edith Cowan University and on the post graduate discussion board of the University. 
Details of the research project, together with requests for recruitment assistance, 
were emailed to eleven of the Western Australian Divisions of General Practice of 
Medicine. The Women's Information Service from the State Government's Office 
for Women's Policy also publicised the research through their monthly newsletter. 
Recruitment in Melbourne, Victoria was very successful following a short 
presentation at a Fibromyalgia one-day meeting in Melbourne organised by Arthritis 
- 137 -
Victoria. Approximately 500 people attended the meeting. Information sheets, with a 
tear off 'expression-of-interest' section, were available at the meeting. The research 
information was also emailed to all members of the Victorian Rheumatology 
Association via the association's office in Melbourne. 
Approximately 500 women expressed an interest in the study during the 
recruiting period of 18 months. An initial telephone interview with all of these 
women confirmed their continued interest in the study and ensured they met the 
preliminary inclusion criteria. Many women did not meet the inclusion criteria for 
the study, but wanted to talk with someone about their condition and management of 
FM. These women were offered information about services such as the FM support 
groups and/or the Continence Advisory Service. A total of 120 women was recruited 
for the study. Of this number, 90 women completed both steps of Phase II of the 
study, 70 women from Perth and 20 women from Melbourne. 
Data Collection and Protocol 
All participating women were mailed information packs pnor to their 
screening appointment. Included in the pack were information sheets on this phase of 
the study (Appendix 0), a consent form (Appendix P), a three-day bladder diary with 
instructions on use (Appendix Q), details of their appointment and a thank you 
message for their participation. Melbourne participants were also sent the data­
collecting questionnaire and asked to complete it after their screening. 
Participation in the study was described as two steps: firstly, a non-invasive 
urological screening and secondly, a questionnaire completion. All of the women 
understood that, if there were any abnormalities in the findings from the screening, 
they would be referred to their general medical practitioner for investigation and 
would be unable to participate in the study. Perth participants were screened at a 
metropolitan urology clinic under the direction of a urologist and urology nurse. A 
urogynaecologist screened Melbourne participants at a Melbourne continence clinic. 
The urological screening (Appendix R) involved a subjective assessment, the 
interpretation of the three-day bladder diary, a mid-stream urine sample, urinary flow 
rate reading and a bladder scan. In the absence of other bladder pathology, and 
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following the assessment by the urologist, urogynaecologist or continence nurse, 
these women were recruited into the study. 
The subjective assessment involved taking a detailed medical history with 
particular emphasis on current bladder and FM symptoms and medications. This 
assessment was conducted by either the urologist, urogynaecologist or continence 
nurse following the urine sampling and flowmetry. The three-day bladder diary, 
completed by all participants prior to their appointment, provided semi-quantitative 
data on micturition patterns including fluid intake and urinary output. Frazer (2003) 
describes the frequency/volume charts as an excellent and simple method of 
displaying symptoms, while Abrams and Klevmark ( 1996) describe the 
frequency/volume charts or urinary diaries as the most important tool in the 
investigation of lower urinary tract symptoms. 
Although it required commitment and time by participants to complete a 
three-day bladder chart prior to their urological assessment, it was necessary because 
previous results have shown poor agreement between subjectively estimated 
frequency and chart-determined frequency (McCormack, Infante-Rivard, & Schick, 
1992). A recent study by Ku, Jeong, Lim, Byun, Paick and Oh (2004) has shown that 
seven days, the most commonly recommended diary duration, does not affect patient 
compliance, but rather this extended seven-day diary is associated with patient 
burden. Nygaard and Holcomb (2000) have shown that the results of the first three 
days of the bladder diary correlate with those of the last four days indicating that this 
three-day diary is an appropriate outcome measure for lower urinary tract symptoms. 
The increased patient burden on the FM study participants in this study was therefore 
not necessary and a three-day bladder diary was deemed sufficient. 
Free flowmetry provided a measure of the speed of the bladder emptying. The 
urinary flow rate is a composite measure of the interaction of the detrusor pressure 
and the urethral resistance. As urine flow rates are dependent on voided volume, with 
the larger the voided volume resulting in the greater flow rate in millilitres per 
second, all participants were asked to refrain from voiding for at least an hour prior 
to testing. The free flowmetry was combined with the measurement of residual urine 
by ultra sound bladder scanning to give evidence of voiding efficiency. The urologist 
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cited various reasons for non inclusion in the study for twelve of the women. These 
included patient histories of autoimmune disease, Bornholm disease, Behcet' s 
syndrome, coccygectomy, other neurological symptomatology, recurrent urinary 
tract infections and minimal urinary symptoms 
Following the urological screening, recruited participants were asked to 
complete the self-administered questionnaire. Some questionnaires were completed 
immediately after the screening, while others were posted back to the researcher in 
the provided addressed, stamped envelope. To ensure data for the test-retest of the 
ICSI/ICPI, a repeat ICSI/ICPI questionnaire was sent to the participants as soon as 
the first questionnaire was returned to the researcher. Participants were asked to 
complete this second ICSVICPI questionnaire and return it to the researcher as soon 
as possible. The average time from the mailing out of and receiving the second 
ICSI/ICPI questionnaire back was ten days. A number of participants did not return 
the retest questionnaire before 30 days and a few were not returned. Because of the 
possibility of changing symptoms within the month in this FM population, any retest 
ICSVICPI questionnaires returned after four weeks were not included in the 
test/retest analysis. Eighty-three of the 90 (92%) study participants participated in the 
retest sample. 
Data Analysis 
Assessment was made for internal consistency reliability, test-retest reliability 
and concurrent validity of the ICSI/ICPI instrument. Reliability indicates the 
reproducibility of a scale, indicating what proportion of a patient's test score results 
are true and what proportion is caused by individual variation (Penson & Litwin, 
1997). Internal consistency reliability is a measure of the similarities of a person's 
response across several items and indicates the homogeneity of the scale while test­
retest reliability measures the question response stability over time (Penson & 
Litwin, 1997). Validity refers to the degree to which the scale measures what it is 
supposed to measure. Concurrent validity is described by Penson and Litwin as a 
more quantitative approach to assessing the performance of instruments and involves 
correlation of scale scores with results from other established tests. 
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Cronbach 's alpha coefficient was used to assess internal consistency 
reliability. A criterion of at least 0.70 was pre-set as the acceptable level for internal 
consistently reliability (Nunnally & Bernstein, 1994). Internal consistency reliability 
also involved assessment of inter-item correlation with an expected value of between 
0.30 and 0. 70 (Carmines & Zeller, 1979). Item-to-total correlations were examined to 
determine whether 50% of these values achieved a correlation of between 0.40 and 
0.70 (Carmines & Zeller, 1979). Stability over time was assessed using the test-retest 
procedure as estimated by the intra-class correlation (ICC). Examining the simple 
correlations between the ICSI/ICPI and other similar instruments provided evidence 
for concurrent validity assessment. 
Factor analysis was undertaken to assess the internal structure of the scale 
and to identify relevant subscales for use in the FM population. Multiple regression 
analysis was also used to identify factors associated with bladder symptoms. 
Ethical Considerations (Phase I and Phase II) 
Ethics approval for this research was obtained from the Edith Cowan 
University Committee for the Conduct of Ethical Research. All participants in both 
phases of this study were fully informed of the purpose of the study and were 
provided with an information sheet describing the process of their involvement. 
Informed consent forms were signed and dated by all participants and the researcher. 
The consent form indicated that the subject was free to discontinue participation at 
any time during the study without prejudice. 
Taped interviews from Phase I were transcribed by the researcher. The tape 
recordings were then erased. There were no names or identifying information on the 
questionnaires in this study. Medical assessment forms from the urological screening 
for Phase II of this study were secured in a locked filing cabinet in the researcher's 
office. All hard copy raw data and signed consent forms were secured in locked 
filing cabinets. Consent forms and data files were stored separately. Only the 
researcher and principal supervisor had access to these records. Code numbers were 
used on all documents and computer data entries to ensure participants' privacy. 
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Only the researcher and primary supervisor had password access to the computer 
data. 
The researcher acknowledged the sensitivity and personal nature of this area 
of research and at all times acted in a professionally appropriate manner. The 
researcher has worked clinically in the urology area as a physiotherapist continence 
adviser, assessing and treating pelvic floor dysfunction for the past fifteen years. 
Continence Foundation brochures were made available to all women who requested 
information on bladder symptoms and/or good bladder habits. Information on FM 
support groups was made available to women who requested information on group 
support. 
Following the analysis of Phase II data, the findings of both phases of the 
study were reviewed, recorded and form the essence of the following chapters on 
findings and discussion of this study on FM and bladder irritability. 
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CHAPTERS 
RESULTS AND DISCUSSION: PHASE I 
Introduction 
This chapter documents the findings from the qualitative analysis of Phase I 
of the research. It also describes the participants in terms of their demographic 
characteristics, the preparation of the data for analysis, the analysis steps and the 
results. The results are interpreted in relation to existing literature. 
Who Participated? 
Sixteen women were recruited for the focus groups. To accommodate 
personal commitments and preferences, the focus groups were offered at different 
times during the day. Some women were unable to keep their appointments to 
participate in the groups. The final numbers in the three focus groups were four, four 
and two, totalling ten participants (n = 10). Each focus group was of two hours 
duration 
Demographic Characteristics of the Focus Group Participants 
The majority of the women were Australian born (seven of ten). The 
women's ages ranged from 25 to 58 years with an average age of 47 years. The 
number of biological children per woman ranged from zero to three, with an average 
number of two children per woman. Most of the women had tertiary qualifications 
(seven of ten). Occupations included professional positions (four), homemaker 
(three), clerical (one), retired (one), and one was receiving a disability pension. All 
participants reported being treated for FM by a rheumatologist between 1993 and 
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200 1. However, all women had experienced pain and disruption for years before the 
diagnosis was given. Main health concerns apart from FM were listed as osteoporosis 
(three), headaches (two), gastric reflux (two), osteoarthritis (two) and tinnitus (two). 
Prescription drugs included antidepressants for sleep enhancement and reduction of 
pain (four), hormone replacement therapy (three), anti-inflammatory medication 
(two), thyroxine (two), aldactone (two), ditropan (one) and cholesterol medication 
(one). Five women were postmenopausal, one was perimenopausal and four were 
premenopausal. 
Non-Bladder Symptoms 
The findings from this study confirmed those found in other qualitative 
studies on the experience of people diagnosed with FM. Raymond and Brown (2000) 
depicted the patient's journey as a continuum that included the onset of symptoms, a 
search for a diagnosis, and a phase of coping with the illness. Asbring (200 1) 
described FM as a chronic disease that can result in a radical disruption in a woman's 
biography that can have profound consequences for her identify. Both the FM 
journey and the resultant adaptive changes were evident in these Australian women 
who participated in these focus groups. 
The findings from this study reveal the enormity of the impact that FM has on 
the lives of women. The unpredictability of the symptoms and the resultant 
constantly changing management strategies undertaken by these women demonstrate 
the notable impact of FM on their lives. So challenging and unpredictable is it that it 
becomes difficult for women to predict symptomatology and therefore plan their 
lives. FM seemed to encroach from all corners of their living space, impinging on 
their every experience and tethering them within restricted physical, emotional, 
social and psychological boundaries. The impact of these four components is 
depicted in Figure 5 below as a puzzle image. 
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Figure 5: The Tethering Effect of Non-Bladder Symptoms on Women with Fibromyalgia 
Although tethered and contained by these restrictions, the women still 
enjoyed a certain freedom of movement, expression and experience within limited 
boundaries. The women described the impact of this symptomatic tethering even 
before the discussion included their bladder symptoms. They lived within the 
confines that FM and its bladder effects dictated to them. This is their story. 
Emerging Themes 
The Physical Impact of Fibromyalgia 
Pain was the dominant FM feature experienced by the women in the focus 
groups. Their pain was evident in the way they sat, the way they moved and 
emotionally in the description of their pain. The pain from the pelvis, from the back, 
from the neck, the feet, the ribs, the pain that caused these women to drag themselves 
through most days, was all consuming. The women described their pain as 
interfering and impacting in all aspects of their lives. 
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When you get the real FM pain, you get it everywhere, your hands hurt, 
your feet hurt, your head, your back, your vulva, your legs, your internal 
organs hurt, your cheeks hurt. It is all part of the syndrome isn't it? Like 
the whole body. (Focus group 1 E) 
From migraines to trying to walk down the stairs, from early morning 
stiffness heralding the start of their day, the women were exhausted. Within the 
groups, the collective impact on each other validated the expression and experience 
of their pain. Early in the discussion, there was a sense of awareness and relief that 
there were other women who lived similar lives affected by FM. The head nodding in 
affirmation when one woman talked of not knowing what it was like to live without 
pain reflected the ongoing non-verbal agreement between these women. 
I was going to the doctor because the pain was so intense ... and I was 
doing my exercises in the morning because after midday I am of no use to 
anybody. I had to talk to myself with positive thoughts in my mind ... ! 
don't know what it is to live without pain. (Focus group 1 F) 
Their descriptions of the relentlessness of their pain was consistent with the 
statement by Hathaway (2004) in his article on 'Chronic Pain and Fibromyalgia: 
trapped in a World of Hurt' where he described pain as 'a relentless taskmaster that 
demands constant consultation before even the most mundane activities are 
attempted' (p. l ). 
For the majority of women in the group, sleep was a luxury. Unanimously the 
women agreed that when they were able to obtain more sleep they felt better "all 
around". Four to six hours sleep each 24 hours allowed them to function "to a certain 
extent during the day". Most of the women knew that if they did not get sufficient 
sleep their pain could be worse. This pain contributed to less sleep and finally total 
exhaustion. This was reflected by reports of 'dragging one's self through each day'. 
There was an initial resistance to the use of medication to improve sleeping patterns. 
However, the women eventually had to accept the use of medications in order to 
sleep. Four of the ten participants were on antidepressant medication to improve the 
quality of their sleep. 
I have been much better since I have been on doxipine this year. I am 
really anti medication. I have to be honest about that. But this year I 
really gave in and it just got so bad, !just wasn't coping ... Jjust got to the 
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point where I was so tired and run down that I went on to doxipine. 
(Focus group 2, All) 
The need to be self-sufficient and non-reliant on drugs prompted the women 
to seek alternative treatments or to just charge ahead with their lives and suffer the 
consequences. Four of the women in the groups had tried non-prescription 
medication to try to find relief from their symptoms. Physiotherapy treatment was 
popular with some of the women, providing them with short term relief. 
The primary approach for treatment of FM is a change of lifestyle to ease 
demands on the body and medication for pain and sleep management. The majority 
of women in the groups were very self-sufficient, goal setters and self-driven. It was 
of interest to note that, of the ten women in the focus group, seven had completed a 
tertiary education. 
The pain and fatigue of FM resulted in significant muscle deconditioning and 
poor aerobic fitness levels for most of the participants. They spoke of their inability 
to be involved in family physical activities and were aware that their partners' lives 
were also affected by their illness. 
The Emotional Impact of Fibromyalgia 
The diagnosis of FM usually follows years of looking for answers and 
solutions to a pot-pourri of symptoms. Although FM research has discovered some of 
the biological markers of FM, some are illusive and some techniques necessary for 
locating the diagnostic markers are too invasive. As a consequence, people with FM 
are often classified as experiencing psychosomatic symptoms or possessing poor 
coping skills to deal with life issues. This was the experience of some of the women 
in the focus groups. 
I went and asked my GP if he would take my FM seriously. I asked him if 
he had heard of FM and did he believe in it. And I sat down and he said 
that he didn 't know enough, "but this is what I know and yes I believe in 
it " ... I just think it would be fantastic to wake up one morning and know 
that /felt alive, awake and well. It would be fantastic! (Focus group 3, S) 
For all women, the diagnosis of FM was a validation of their symptoms and 
distress, accompanied by a feeling of relief because a diagnosis had finally been 
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obtained. However, their diagnosis also triggered a sense of foreboding about their 
health future. At the time of diagnosis, most women were given pamphlets about 
their condition, a prescription for medication and advice to increase their exercise 
and change their lifestyle. Some were given the diagnosis and told that there was no 
treatment for the condition and they would have to make changes in their lives to 
accommodate FM. Five of the ten women had not met or heard of anyone else 
having this diagnosis. The feeling of isolation and sense of 'where to from here' was 
overwhelming for them. This sense of aloneness was compounded by a lack of FM 
knowledge, support and understanding from their general medical practitioners. 
The women in the focus groups were driven in their search for answers to 
improve their health and to improve the quality of their lives. Through their pain and 
disability they maintained seeking, hopeful and generous personalities. 
I feel more inspired by talking about what research is out there to 
actually help the problem. And that is what I like about Dr _ 's group that 
we talk about things that actually help. E talks about DHEA and we talk 
about other things. There is urgency for us to get on and try and make do 
and get on with life. (Focus group 1 V) 
I just think it would be fantastic to wake up one morning and think, 'I feel 
alive and well '! It would be fantastic. I hobble into the shower and I 
hobble out of my car at work. (Focus group 2 All) 
The emotional impact of FM on the women was more than adapting to the 
physical distress they endured. It was coping with a disability that affected all 
sections of their lives. For one young woman, FM even impacted on her future plans 
of becoming a mother. 
It is funny because I now have concerns because I am thinking of starting 
a family in the next couple of years. I have concerns about do I want a 
female child because I am frightened of passing on these things that I 
have lived with. I would prefer not to and would it be different if I had a 
son. Can I still pass that sort of thing on to a male child? (Focus group 2 
J) 
This grieving for future loss and constant adaptation was intertwined with 
grieving for the loss of lifestyles they enjoyed prior to the onset of FM. The grieving 
in some was hidden behind well-developed coping facades. The common experience 
of FM shared by the women in the focus groups was very disarming for some, 
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resulting in tears of frustration and pain. The unspoken permission to just 'be 
herself, the anger tethered and controlled for so long and the anguish of living with 
constant pain were quietly evident during the discussions and at times erupted into 
hostility demanding of answers. 
The women's frequent use of humour lightened many of the more difficult 
moments. Comments such as 'I stopped trampolining sometime ago' or 'Mum and I 
find retail therapy is a great help' created relief through laughter and light-hearted 
response. 
The Social Impact of Fibromyalgia 
Kitzinger ( 1994) wrote that group participants of a focus group provided an 
audience for each other that greatly enhanced communication and enriched data 
collection. She concentrates on the interaction amongst research participants and 
describes this interaction as the participants becoming co-researchers, taking the 
research topics into new and unexpected directions. 
This interaction was apparent in the focus groups. Because the women shared 
a common diagnosis, they shared an understanding of each other's challenges. They 
communicated, they agreed, they disagreed, they questioned and demanded answers. 
There was a collective response as well as individual responses from the women, 
especially in this area of the social impact of FM. 
Your comment earlier about having your FM in perspective . .. that is fine 
until someone asks you how you are. They want you to say fine. Don 't 
they! I mean they don 't want to hear you say, 'I am bloody awful again 
today '. Do you know what I mean? You actually have to learn to mask it 
and get on with it. Otherwise people would think you are a 
hypochondriac. (Focus group 2, All) 
FM is often described as an invisible illness as the majority of women with 
this condition appear physically normal. For the majority of women with FM there is 
no obvious disability. Sveilich (2005) reveals that people who live with unseen 
illnesses and chronic conditions 'often conceal their physical challenges and project 
themselves to the world in a particular manner that is contrary to the way they feel. 
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These individuals choose to wear the mask of normalcy and often appear just fine, 
despite having to contend with a host of invisible and difficult challenges' (p. 20). In 
Soderberg and Lundman's study (200 1), women described other people viewing 
them as healthy beings. 
Most of the women in the focus groups fought to maintain this illusion of 
wellness within their family, work and community groups. Therefore, normal 
expectations were placed upon them. These women fought to maintain a normal day­
to-day existence with their family and work environments. For a few of the women 
these expectations were insurmountable, but for others there was no option but to 
'get on with it'. 
Do you want it to control me or for me to control it? That was the 
mindset I took. I think when you first find out what is going on you get 
very keen and read everything and say, 'Yes, I have got that and I have 
got that so poor me '. But then really on a relative scale you sort of think, 
well I want to enjoy life, so let 's get on with it. (Focus group 2 All) 
Patients with FM frequently report a decline in cognitive functioning, 
memory and mental alertness. The women referred to this mental confusion and 
forgetfulness as 'fibro-fog'. They described their episodes of cognitive dysfunction 
as mental blackouts that increased when their FM was flared. They described the 
effects this had on their ability to function effectively at home and in the work place. 
The effects varied from emotional despair to absolute acceptance. Above all, their 
resilience and determination to move on with their lives was inspiring. 
The Psychological Impact of Fibromyalgia 
The women in the focus groups described the psychological impact of FM in 
many ways. They spoke at length of the avoidance of stress in their daily lives. Stress 
can exacerbate the symptoms of FM (Davis, Zautra, & Reich, 200 1 ). The women in 
the group attempted every day to avoid unnecessary stress, to live within their energy 
restraints, tethered by the impact of their symptoms. However, for all of the women, 
this loss of freedom, the fatigue and the pain increased their stress, their sense of 
frustration and their anger. Most of the women were attempting to bridle this impact 
with a quiet determination to move on with their lives. 
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One day I am ok and the next I am not. When I am not I do my best and 
when I am well I do my best as well. I take it as it comes. I can 't handle 
stress any more. So I try to make my life as less stressful by not worrying 
so much and just take one day at a time. (Focus group 2 An) 
The symptoms of FM can affect all organ systems of the body. The 
symptoms are unpredictable and variable. As a result, these symptoms of FM layer 
themselves on to their sufferers without finite definition, resulting in overall body 
pain and fatigue. This psychological impact of their disability extends into their 
families and work environments. The grief experienced by the women regarding the 
loss of the lives they enjoyed before FM, such as camping with the children and 
working in full time professional positions, was vocalised and discussed. 
I used to run 5 kilometres a day. I had the muscle tone of an athlete. I 
now couldn 't run to save my life. I have been on a downhill slide for the 
past three or four years. It is so frustrating. I am only 25 years old and I 
feel like a grandma ... / get really upset because my husband met me when 
I was still doing a little bit of modelling and I was a size 10 and I was 
this beautiful skinny little blond and that. Now I am so self-conscious 
because I have put weight on and I don 't want to do those sorts of things 
and sometimes I don 't even want to be undressed in front of him and it 
gives you all those sorts of feelings that I never had before. And I am so 
young. That is sad. Jjustfind that so sad. (Focus group 2 J) 
They talked of trying to lead normal lives, but found that sometimes it was 
easier to retreat. Their anger at their loss of life style and the frustration of continuing 
symptomatology were evident in all of the women in the groups. The blending of the 
tolerance of their symptoms, hopes, optimism, frustration and a knowing of 
ineffective medical knowledge and management of FM created interesting 
interactions and comments within the groups. 
Do you get angry that your children have really lost their Mum? I get 
angry because my daughter was eight when I started with the symptoms 
and she has lost her Mum because there was a lot I couldn 't do with 
her ... You do, you do struggle on. But there are some things you would 
like to do like go and run and dance around the park. But you can 't, can 
you! (Focus group 2, Ja) 
The physical, emotional, social and psychological impact of FM on the lives 
of these women was very evident. For most of the women, the impact of FM 
decreased their range of movement and choices in life, but not their resilience. They 
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had learned to move effectively, to live and to enjoy their lives within the boundaries 
that FM had set. 
Morse ( 1997) has developed a model, 'Responding to Threats to Integrity of 
Self, a five-stage model of recovery and rehabilitation. This theory was developed 
for use in the understanding and supporting of patient responses to either acute or 
chronic illness. The theory concentrates on the individual and how he/she seeks self­
comforting strategies to manage his/her experience. The five stages of the model 
include : Vigilance; Disruption, enduring to survive; Enduring to live, striving to 
regain self; Suffering, striving to restore self; Leaming to live with the altered self 
(Morse, 1997). Morse describes stage five as the major task, that of learning to live 
with the altered self, learning to accept the consequences of their experience and 
accepting that life will not be the same again. She describes the experience of 
learning to revalue life, to appreciate different things, to establish different goals and 
to reprioritise aspects of life. 
This fifth stage described by Morse encapsulates the expenence of the 
women with FM who participated in the focus groups. They were learning to live 
with the altered self. 
Bladder Symptoms 
Previous studies by Clauw and colleagues ( 1997a), White and colleagues 
( 1999a) and Pairi ( 1994) have shown the prevalence of genitourinary symptoms in 
patients with FM. This current study is the first research on bladder irritability 
symptomatology in Australian women with FM. The effects of the bladder symptoms 
were very significant for the women participating in the focus groups. FM impinged 
on every aspect of these women's lives . The further impact of the urogenital 
symptoms of FM on their lives was enormous, further restricting their freedom of 
movement and available choices. The dual impact of non-bladder and bladder 
symptoms combined to increase the challenges for these women to find the most 
manageable way through each day. 
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All of the women in the focus groups experienced a range of sensory urinary 
symptoms. Following the interview guide items of the I CS I/I CPI index, the women 
were asked about the urinary symptoms of urgency, frequency, nocturia and pain or 
burning in the bladder and how problematic these symptoms were. Further 
discussion was elicited by following the questions of the Kings Health 
Questionnaire. This questionnaire allowed the women to expand on to the effect that 
their bladder dysfunction had on their daily roles, physical activities, social lives, 
personal relationships, emotional health, and sleep and energy capacity. Their 
accounts are described below. 
The Impact of Urinary Frequency 
Some of the women from the focus groups were not aware that their urinary 
symptoms could be part of the condition of FM. Day time urinary frequency is 
described as the complaint by the patient who considers that she voids too often 
during the day (Abrams et al., 2002a). Urinary frequency was a significant symptom 
for the women in the focus groups. Urinary frequency ranged from 'less than one in 
five times' to 'almost always'. The impact of their urinary frequency ranged from 'a 
very small problem ' to 'a big problem'. Some of the women were very conservative 
in their description of how problematic urinary frequency was for them. One woman 
voided from 15 to 25 times a day and described it as a nuisance. Another described 
her frequency as part of her life and she dealt with it. She visited the toilet so often 
during the day that it had 'become her day'. She chose to forget about it and to 'get 
on with her life'. 
Well, I mean you have really got to time your outings and if I do go out it 
is only for a short time. Just before I came here I had to go and pick up 
some macca and I had to go to the toilet. I left, and it was only a five­
minute drive but as soon as I got there I had to go again and when I 
finished and got my things I had to go again and now I am here. I haven 't 
been yet but I have crossed my legs at the moment (Focus group 1, T) 
Unknowingly some of the women were increasing the irritability of their 
bladders by decreasing their fluid intake, feeling that if they drank less they would 
void less often. For some women this was a way of saving time. One of the 
participants drank a maximum of 400mls per day. All the women knew where the 
nearest toilet was situated. They spoke of knowing 'all the toilets in the city'. The 
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women spoke of their fear of aggravating their bladder problems and their anxiety at 
managing everyday and family activities in relation to their bladders. 
It is difficult because if you can 't find a toilet if you are out . . .  Jf it is a 
problem finding the toilet when you are out then it is a matter of how 
often you are out. If you are out all day and every day, then it is a major 
problem. Or someone else who is at home all day with access to the 
toilet, it is not a problem. (Focus group 2, A) 
Existing urinary frequency can be aggravated by a 'just-in-case' behaviour 
where women will void just in case they may not be able to find a toilet when they 
next need to void. This self-induced frequency compounds and aggravates the 
existing problem. Textbook descriptions of this self-induced frequency were given 
by most of the women. One woman described how she voided before leaving home 
to do the shopping at a centre ten minutes from her home. On arriving at the 
shopping centre, her first stop was the toilet . Another spoke of her pre-bedtime 
voiding pattern. Every night she voided four times within the 20 minutes before 
getting into bed, then another three voids while reading in bed for an hour and then 
waking every two hours to void during the night. 
But when I am awake that feeling is there I 00% of the time. I also have 
found that I go to the toilet more than I ever have before. And I am 
already thinking ahead, before I leave home I will go. When I left home 
tonight I went, and I arrived in the building and I went because I just 
know that if I don 't go at regular intervals I am going to need to excuse 
myself (Focus group 2, Al) 
The urinary frequency impacted on the women's ability to travel short and 
long distances by car or by plane. Some of the women would rather stay at home 
than cope with the inconvenience and embarrassment resulting from their urinary 
frequency and urgency. 
The same with travel . .. ! have a daughter living in a remote area. We go 
about one and a half hours inland and it always has to be that I am 
always saying to my husband, 'How many kilometres to the next stop ' 
and saying all the time that we are going to have to stop. If I can 't make 
it !just have to stop and open the car door and go by the side of the road. 
I ask him to tell me if a car is coming because I can 't see and quickly pull 
my pants down and go to the toilet and pull up. !find it quite upsetting ... ! 
didn 't go up there the last time she asked me. (Focus group 1, E) 
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Urinary frequency for the majority of women caused a disruption in their 
lives. It impacted on their family lives, their working lives and their social lives. One 
woman spoke of having to resign from her professional position as a counsellor 
because she was unable to spend an uninterrupted hour with her clients because of 
her urinary frequency. Another spoke of her love of the theatre, but the demands of 
her bladder dictated where she sat in the theatre and dictated its own interval. The 
activity created by the women regularly going to and from the toilet during the two­
hour focus group was evidence of the demands made on them by their bladders. The 
frustration of the bladder dictating to these women what they did and where they 
went was summed up by (T) in her comment 'We never go anywhere'. However, the 
resilience and humour of these women, despite their disability, were notable. 
People do comment though. People say to me, 'But you have just been, 
why do you want to go to the toilet again when you have just been? ' /just 
say, 'Well I have got to go! What do you want? Do you want me to wee 
on the carpet or are you going to let me go? ' I mean /just make a joke of 
it. There is no other answer because when you have got to go, you have 
got to go, but it can be off putting to people you don 't know because you 
have gone to seek the toilet again. But that has been the way it has 
been .. . and then you get someone who stops you on the way to the toilet. I 
just have to say that I will come back to you, just give me a moment. 
(Focus group 3, A) 
Using the ICSI/ICPI questionnaire, the women in the focus groups were 
asked how many times during the last month had they had to urinate less than two 
hours after they had finished urinating. Figure 6 displays the proportion of women 
with varying urinary frequencies. They were also asked how much of a problem 
frequent urination was for them during the past month. Figure 7 displays this impact 
of urinary frequency on the women in the focus groups. 
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Figure 6: Proportion of Women in the Focus Groups with Varying Urinary Frequency 
Big problem 
1 .00 
Medium problem 
4.00 
ICP I  Urinary Frequency 
n = 1 0  
No problem 
1 .00 
Very small problem 
1 .00 
Small problem 
3.00 
Figure 7: Impact of Urinary Frequency on Women in the Focus Groups 
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The Impact of Urinary Urgency 
Urinary urgency is described as the complaint of a sudden compelling desire 
to pass urine that is difficult to defer (Abrams et al., 2002a). This was a significant 
symptom experienced by women in the focus groups. The unpredictability of the 
urge to urinate was a fear that encouraged self-induced frequency, an increase in 
urinary frequency because of 'voiding-just-in-case' behaviour. The majority of 
women in the group experienced this urgency/frequency combination. Just listening 
to the pouring of the drinking water from the jug to the glass during the group 
discussion was enough to prompt the desire to void in some women. 
The women expressed fear of being 'caught out' in many situations. They 
described embarrassing episodes of urgency in the gym, at the office river cruise 
Christmas party, travelling on aeroplanes, during their daily walking regime, and the 
urgency of the 'key-in-the-door' situation when arriving at home. One woman had 
her personal key to the staff toilets to enable her to 'make it'. As with urinary 
frequency, some kept their fluids restricted because of the unpredictability of, and the 
anxiety associated with, the urinary urgency. 
It is just the urgency. It just catches me out. At work some of the people 
must think I am nuts because suddenly I will get up and go to the loo. You 
are going to the bathroom and that is it. You can't concentrate on 
anything else suddenly, just suddenly. They must think I am odd! (Focus 
group 3, S) 
Some of the women experienced a constant sensation of needing to void. 
Some described this as a burning sensation even when on voiding they only 'passed a 
few drops'. One woman described this urgency as being more apparent and difficult 
to control when her other FM symptoms were heightened. 
This urinary urgency placed another demand on these women whose capacity 
to manage yet another symptom was already extended beyond normal limits. The 
fear of their urinary urgency extending to urge incontinence increased the stress on 
the women. 
When I have the urge to go, I get really stressed. When I am out and I am 
in the car and I have to go home, it is like you just want to put the 
accelerator right down and go through all the traf ic lights because it is 
really painful. I find that when you hold on, I find you are using all the 
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muscles in your legs and your back. You are doing everything to hold on 
and it is very painful. I don 't leak, but I find that I use every muscle in my 
body and once I have gone, I am pretty wiped out. (Focus group 1 ,V) 
One of the important treatment regimes for people with FM is to maintain 
some form of exercise to increase endorphin levels, to maintain levels of aerobic 
fitness and to maintain muscle integrity. This was hampered for some by their 
urinary urgency. Walking was often restricted to parks and areas where public toilets 
were available. Some experienced the need to stop and stand still and wait during 
their walk to manage the urgency. Swimming is encouraged as an appropriate form 
of exercise for people with FM because of the minimal weight-bearing impact when 
exercising in water. For some of the women, their urgency was aggravated in these 
situations because they experienced the need to void as soon as they entered the 
water. 
The frustration of repeat visits to their general medical practitioners for urine 
cultures to check for urinary tract infections added to their list of medical 
maintenance. The women felt that, because they were experiencing acute symptoms 
of urinary urgency, frequency and discomfort, they therefore must have a urinary 
tract infection. 
I thought I must have had a bladder infection so I will go to my doctor. 
He did two or three urine samples and came back with nothing, 
completely clear. The problem just seemed to be getting worse and worse 
and worse. I just felt I needed to go 100% of the time, all the time, 
continuous. I could go to the toilet, go and sit in my seat and then feel as 
though I needed to go straight back again. (Focus group 2, J) 
The women were asked to respond to the ICSI/ICPI question on urinary 
urgency: How often during the last month had they felt the strong urge to urinate 
with little or no warning? Figure 8 displays the proportion of women with varying 
urinary urgency. They were also asked how much needing to urinate without warning 
over the past month had been a problem for them. Figure 9 depicts the response to 
this question. 
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Figure 8: Proportion of Women in the Focus Groups with Varying Urinary Urgency 
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Figure 9: Impact of Urinary Urgency on Women in the Focus Groups 
The Impact of Nocturia 
Nocturia refers to a person's need to wake at night one or more times to void 
(Abrams et al., 2002a). Hetta (1999) comments that the importance of sleep can be 
gauged by considering the consequences of insufficient sleep. Sleep deprivation has 
a deleterious effect on frontal lobe functioning, impacting on concentration and 
intellectual skills (Hetta, 1999). Hetta lists the effects of sleep deprivation as fatigue 
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and sleepiness, reduced concentration and co-ordination, problem-solving 
difficulties, reduction in creativity, mood alterations, muscle stiffness and an 
increased risk of infections. Nocturia has a profound effect on a person's mental and 
physical health. Jennum (2002) describes nocturia as an annoying and potentially 
damaging symptom because it fragments sleep and may therefore result in adverse 
consequences. 
For women with FM, nocturia 1s more difficult to define. Coyne and 
colleagues (2003) state that nocturia is not a benign symptom. This was certainly 
evident from the participants in the focus groups. What factors cause these women to 
get up at night to void more than the acceptable once per night after they have gone 
to sleep? Is it the insomnia that is such a significant feature of FM that causes the 
women to void many times during the night because they are awake for long 
periods? Is it the musculoskeletal pain that wakes these women from sleep and, when 
awake, they feel the need to go to the toilet? Is it the irritability of the bladder that 
wakes women from sleep and results in nocturia? Or is it the anxiety about the 
possibility that they may not sleep again that night that impacts on bladder 
behaviour? The women in the focus groups who voided more than once during the 
night were unsure of the reason they were up going to the toilet at night. Excerpts 
from the focus groups demonstrate these issues. 
But the worse thing is having the burning sensation and getting up so 
many times at night. I feel as though I have got to go and when I go at 
night time I get up many many times. (Focus group 1, F) 
In winter, if the pain wakes me up I can 't sleep because of the pain and 
the combination of going to the toilet and the winter, I wake up more. 
The pain is all over muscle pain ... / am just a wreck. In summer the pain 
is not as bad. In summer it is the urge to go to the toilet that wakens me. 
(Focus group 3, A) 
If my sleep is not deep then it just niggles and niggles and niggles. You 
have just got to get up and go or else you won't go back to sleep. But I 
think it might be the sleep in the first place. I don't know. (Focus group 3, 
S) 
Whatever the reason, the end result was disturbed sleep with increased 
fatigue and increased pain the following day. Some of the women felt their nocturia 
was a small problem because, although it was annoying, they could 'handle' it. For 
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one woman, it was a small problem because she did not know what sleep meant. She 
was grateful if she had three hours maximum sleep during a night. Others felt that 
their bladder disturbed them because they were light sleepers. This deprivation of 
restorative sleep in FM patients has a major impact on their sense of well being and 
management of their symptoms. 
I wake up every two hours. If I have four hours of continuous sleep, I am 
happy ... Do !feel worn out and tired? Fancy asking me this? I couldn 't 
say anything about if my bladder affects my sleep because I am awake 
anyway. I definitely feel worn out and tired all the time. (Focus group 1, 
T) 
Tricyclic medications in doses lower than those used to treat depression are 
often prescribed for women with FM to provide the benefits of reducing 
sleeplessness and for pain management. The tricyclic medication can increase the 
amount of delta wave sleep, improve the availability of serotonin to nerve cells and 
enhance the effects of endorphins that can decrease pain (Wallace & Wallace, 1999). 
The anticholinergic effects of the tricyclics also result in relaxation of the bladder, 
decreasing the intensity of bladder contractions and deceasing frequency by delaying 
the desire to urinate (Hanno, 1994a) 
Four of the ten women in the focus groups were taking tricyclic medication 
primarily for the relief of FM symptoms rather than for the bladder effects. 
Medications for the treatment of the variety of symptoms of FM can impact 
positively on the quality and amount of sleep with a resultant positive impact on the 
bladder. These medications would probably be impacting positively on their bladder 
irritability without the women necessarily being aware of this secondary effect. One 
woman was medicated with ditropan, an anti-cholinergic drug used for urinary 
frequency, urgency and incontinence. 
I went to see my doctor about my sleep to get some tablets because I used 
to be exactly like that until I found a GP who had chronic fatigue. That 
was the first thing he said to me, 'We will get your sleep sorted out first 
and then we will worry about everything afterwards '. It made such a 
difference to my life, a huge difference. That was the big turning point for 
me. (Focus group 3, A) 
The women were asked to respond to the ICSI/ICPI question on nocturia : 
How often during the last month had they most typically got up at night to urinate? 
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Figure 10 displays the proportion of women with varying nocturia episodes. They 
were also asked how much had getting up at night to urinate over the past month 
been a problem for them. Figure 11 shows this impact of nocturia on the women in 
the focus groups. 
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Figure 10: Proportion of Women in the Focus Groups with Nocturia 
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Figure 11: The Impact of Nocturia on Women in the Focus Groups 
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The Impact of Bladder Pain, Burning, Discomfort or Pressure 
For the women in the focus groups, pain and discomfort in the bladder often 
accompanied urinary urgency. This was described as a sharp pain or the burning 
sensation 'that is always there'. For some women the bladder discomfort was worse 
when their FM was ' flaring'. Pain from their musculoskeletal system seemed to be 
reflected in their bladder symptoms. Some of the women described their bladder pain 
as a cramping in the bladder itself. 
All the gynaecologists kept telling me was to do more pelvic floor 
exercises. They said I was very weak in the area. The more pelvic floor 
exercises I did, the more I got bladder cramps. The bladder cramps 
became worse and I got chronic pain in that bladder area. It felt like a 
ball moving inside me. The urges became greater to go to the toilet and 
so forth. And they kept saying do more pelvic floor exercises, just keep 
going, keep going and I just became so debilitated. It was like giving 
childbirth again. The pain was so chronic in that area. (Focus group l ,V) 
Pain was sometimes evident when the bladder was emptying or at the end of 
a void. It was described as 'a pain that shoots up the bladder'. Some of the 
participants described their bladder symptoms as a discomfort or pressure rather than 
pain or burning. Some commented that their abdomens felt swollen. 
For me the problem is not so much the burning or pain, but the 
discomfort and the pressure. (Focus group 1 ,  F) 
For others it was the burning sensation that accompanied urinary urgency. 
The women were often checked and rechecked for urinary tract infection for the 
burning symptoms, but no abnormalities were detected. Not only did the descriptions 
of the type of pain vary, but also the intensity of the bladder/pelvic pain differed with 
each participant. 
With pain, I suppose it depends on your personality. I mean it is quite 
significant, but to me, it is a small problem because on the scale of things 
(Focus group 2, All) 
Yes, in the lower part of the abdomen just above this bone. Yes, it is a 
feeling of um ... at the beginning I thought it was inflammation so I got 
checked and there was no infl.ammation, especially not being active 
sexually. I have been checked through and through and there was no 
inflammation. And it is getting worse. (Focus group 2, An) 
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For some women, the bladder pain was just part of the whole spectrum of 
body pain, just another sore part of the body. It was part of the larger problem and 
was not singled out from the rest of the body pain. 
The women were asked to respond to t he ICSI/ICPI quest ion on bladder pain, 
if, during the past month, t hey had experienced pain or burning in the bladder. Figure  
12 depicts the proport ion of women with varying bladder pain experiences. They 
were also asked how much had burning, pain, discomfort or pressure in their bladder 
been a problem for them over the past month. Figure 13  shows this impact of bladder 
pain on the women in the focus groups. 
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Figure 12:  Proportion of Women in the Focus Groups with Bladder 
Pain/Burning/Pressure/Discomfort 
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Figure 13:  Impact of Bladder Pain/Burning/Pressure/Discomfort on Women in the Focus 
Groups 
Stress Urinary Incontinence and Urge Urinary Incontinence 
Stress urinary incontinence is the complaint of involuntary leakage on effort 
or exertion or on sneezing or coughing (Abrams et a l. ,  2002a). Urge unnary 
incontinence is the complaint of involuntary leakage accompanied by, or 
immediately preceded by, urgency (Abrams et al., 2002a). Although the literature 
shows that urinary incontinence is not a major symptom for women diagnosed with 
FM who experience bladder irritabi lity, it is of interest to note the incidence of 
incontinence within the focus groups. 
Four of the ten women did not experience any stress urinary incontinence. 
Three women experienced a little, two women experienced it moderately and one 
woman experienced a lot. Three of the ten women did not experience any urge 
urinary incontinence. Three women experienced it a litt le and four women 
experienced it moderately. Data on the incidence of both stress and urge urinary 
incontinence will be recorded from Phase I I  of this study. 
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Vulvodynia 
An unexpected cause of pain for the women in the focus group was the pain 
associated with vulvodynia-like symptoms. The International Society for the Study 
of Vulvovaginal Disease (National Vulvodynia Association, 2002b) defines 
vulvodynia as chronic vulvar discomfort or pain, especially that characterised by 
complaints of burning, stinging irritation or rawness of the female genitalia. 
Julian (1997) recommends that vulvodynia needs to be managed as a pain 
syndrome rather than as a pain secondary to an underlying disease or as a problem 
with an obvious cure. Silver and Wallace (2002) describe vulvodynia as an 
associated symptom of FM. Reed, Haefner, Punch, Roth Gorenflo and Gillespie 
(2000) comment on the controversy in regard to the nature and etiology of 
vulvodynia. They note the absence of abnormal dermatological physical findings, the 
lack of infectious and allergy or oncologic aetiology in the genital region. Their 
research findings determined that a primary psychological cause of vulvodynia was 
not supported. 
Within the focus groups, four of the ten participants experienced significant 
vulvodynia symptoms. 
My problems came more from the vulvodynia than the bladder. Real 
burning pain of the vulva and I went from gynaecologist to gynaecologist 
trying to find out what the problem was and they did swab upon swab 
upon swab and found nothing ... They did biopsies of different areas. They 
did it from the vulva, right up in the cervix and they always found chronic 
inflammation, but no pathogens present. (Focus group 1, V) 
The symptoms described included dyspareunia, burning pain of the vulva, 
skin soreness, chaffing and irritation of the skin in the vulva! area. There were few 
interventions offered that gave symptom relief. 
Well, when I have intercourse is my main issue. It hurts during 
intercourse and after intercourse although I am not so bad now, but I 
used to puff up like a balloon and have to go and get iceblocks and pat 
myself. (Focus groupl, E) 
The women spoke of changes of sexual behaviour because of their pain and a 
fear of increasing their pain. The dyspareunia combined with the urinary urgency that 
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some of the women experienced with sexual intercourse affected their sexual 
activity. One women described having sexual intercourse as 'something you paid for' 
with pain over the next two or three days together with the added concern of 
infections. Some chose to not be sexually active because 'between that and being 
squeezed and touched being so painful I thought I don 't need this, leave me alone' 
(Focus group 2, An). Another young woman spoke of her avoidance of a physical 
relationship when she had other FM symptoms as well as vulvodynia symptoms. She 
commented that because she knows what it would feel like, it is not something she 
would like to feel. 
What happens with us is that I have only been remarried for three years 
and my husband felt he was the cause of it so he was sort of reluctant to 
initiate and then I would think 'what is wrong with me ' so we had some 
trouble initially. We went and had a bit of a talk with the doctor and she 
said, 'It is not you, it is her make up ' and that was embarrassing and 
having to go to the toilet often (Focus group 1, E) 
For the women who lived with partners, the centrality of their relationship 
was very important. They were very aware of the need to consciously include their 
husbands in aspects of their lives where and when energy allowed. 
The vulvodynia symptoms hampered their FM walking regime because of the 
severe chaffing of the skin of the vulva and on the inside of their thighs. They wore 
loose-fitting under garments or 'boxer ' shorts to minimise the friction on the 
perineum. 
When it is really bad when I used to get that burning, even the edges of 
my underwear would drive me crazy. I would want to pull at my pants 
and relieve it. So that was really bad. (Focus group 1,E) 
Vulvodynia symptoms increased the demand on these women, not only by 
having to endure more symptoms, but also having to seek out relief and treatment 
strategies. This extra symptomatology increased the demand on their time and 
energies. Some of the women consulted with different health professionals in their 
attempt to find answers for and relief from the vulvodynia type symptoms. A sexual 
health practitioner who suggested that their symptoms might be part of a more 
enveloping syndrome first suggested a diagnosis of FM to two of the women. The 
women had not connected their musculoskeletal symptomatology with the 
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vulvodynia symptoms. Further consultations with rheumatologists confirmed a 
diagnosis of FM. Women did not think of their symptoms as being potentially 
related. As well, some self-consciousness about their vulvodynia symptoms may 
have limited their disclosure of the problem, as was expressed by the following 
participant. 
To me it stopped me going back to work so it has had a real impact for 
me. I find it hard to talk about. Even in this group it has been difficult. It 
is not easy. (Focus group 1, V) 
Because of the vulvodynia-like symptoms experienced by the women with 
FM in these focus groups, the Vulval Symptom Assessment (VSAS) (Appendix K) 
was developed to collect data about this symptom in Phase II of this study. The 
VSAS was developed as a two-part questionnaire to assess the incidence of 
vulvodynia symptoms and the impact of these symptoms on women with FM. 
The Impact of Urogenital Symptoms 
The responses of the women in relation to their urogenital symptoms 
reflected anguish, humour, frustration, embarrassment, resignation, determination 
and acceptance. The impact of FM (Figure 5) was dramatically increased when 
urogenital symptoms were present (Figure 14). These urogenital symptoms 
encroached on the already restricted dimensions of their lives. One would expect 
that, for many, this increased burden of sensitisation of the urogenital system would 
be the final insult and result in self-absorption and self-pity. 
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Figure 14: The Increased Tethering Effect and Impact of Non-Bladder and Urogenital 
Symptoms on Women with FM, Depicting Illness in the Foreground 
The urogenital symptoms encroached on an already restricted space in the 
women's lives, increasing the demands on their patience, their capacity to experience 
life and their significant relationships. This increased burden of sensitisation of the 
urogenital system stretched the capacity of these women to re-evaluate their life 
styles, to appreciate different things, to establish different goals and to reprioritise 
aspects oflife as described by Morse (1997) in learning to live with their altered self. 
The unpredictability of bladder symptoms, combined with the randomness of 
other FM symptoms, challenged the women daily in most of their roles. Their daily 
roles had to be constantly reassessed and adapted to accommodate their bladder 
symptomatology. One woman adapted to her severe urinary urgency and frequency 
by 'working around the toilet' and, because there were two toilets in her house, she 
could work at either end of the house! Another spoke of her learning to adapt to and 
cope with her bladder symptoms and only then would she feel confident enough to 
seek work outside of the home again. Others spoke of their symptoms with 
acceptance and humour. One woman spoke of being able to turn on the lights of the 
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city with the pressure that came from her bladder and, because of her 
frequency/urgency, she was able to find a toilet by smell. Overall, the frustration of 
always having to make allowances for their urogenital symptoms accentuated the 
tethering effect of the already existing physical, emotional, social and psychological 
impact of FM on their lives. The increased impingement on the self by the urogenital 
symptomatology is diagrammatically represented in Figure 14. 
Chronicity of Symptoms of FM 
FM is not a life-threatening disease, but it is a quality of life threatening 
disease. Data obtained from the three focus groups revealed the impact of the 
chronicity of the symptoms and its impact on their quality of life. The 
unpredictability and chronicity of the multitude of symptoms from FM constantly 
challenged these women and their families. These women's experiences of living 
with the chronicity of FM were multifaceted and enduring. 
Paterson (2001) presents a shifting model of chronic illness, The Shifting 
Perspectives Model of Chronic Illness. This model was derived from a metasynthesis 
of qualitative research reported from the experiences of people with chronic illness. 
The model suggests that living with a chronic illness is an ongoing and continually 
shifting process where an illness-in-the-foreground or a wellness-in-the-foreground 
perspective has specific functions in a person's world. Paterson (2001) describes the 
illness-in-the-foreground perspective as a focus on the sickness, suffering, loss or 
burden associated with living with chronic illness. She describes the wellness-in-the­
foreground perspective as viewing the chronic illness as an opportunity for 
meaningful change in relationships, a re-visioning of what is possible and normal. 
These perspectives of chronic illness are not static. 
This model of chronic illness framed many of the dynamics experienced by 
the ten women in the focus groups. The women reflected this shifting perspectives 
model of chronic illness. The pre-diagnostic phase and the immediate post-diagnostic 
phase could be described as the illness-in-the-foreground perspective. Pre-diagnosis 
the women knew they had a health problem, they sought numerous medical opinions, 
but remained frustrated and in pain during this long phase without any diagnosis or 
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resolution. On diagnosis, one woman spoke of being overwhelmed ' knowing there 
was something new wrong with you' . Another woman spoke of being wary and upset 
when diagnosed. For some of the women, the diagnosis of FM was a relief, a 
validation of their experiences of a multitude of symptoms experienced over many 
years. One woman developed an instant wellness-in-the-foreground perspective, 
seeking management strategies for her FM on the day of diagnosis. 
I know that when I was diagnosed, on the way home my husband said to 
me, 'The specialist said you should not work. So it would be better if you 
didn't '. And I said, 'Heyl Do you want it to control me or for me to 
control it ' and that was the mind set that I took. I think the diagnosis was 
such a huge relief It put it into some sort of perspective. But if you said 
to me on any given day, 'Are you without pain? ' Well the answer is no, 
never but some days it is not even a conscious thought and then you have 
other days where you just drag yourself through the day. So I think, I 
really think that your mental attitude to it (Focus group 2, All) 
A few women in the focus groups had stayed within the illness-in-the­
foreground perspective where they focused on the illness, the pain, the loss and the 
strain of living with a chronic illness. The diagnosis of FM for them was a negative 
and destructive event resulting in absorption with their disabilities. This illness-in­
the-foreground perspective (presented in Figure 14) shows the impact of FM 
nonbladder, bladder and urogenital symptoms. 
However, the majority of women in the focus groups were challenged by 
their diagnosis and embraced a more wellness-in-the-foreground perspective in 
coping with FM (Figure 15) .  Paterson (2001) describes this appraisal of their chronic 
illness as an opportunity for change and for the woman to develop harmony between 
her self-identity and the identity shaped by the illness. The majority of the women in 
the focus groups portrayed this in a seeking, self-educating and inquiring mode. 
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Figure 15: The Increased Tethering Effect and Impact of Non-Bladder and Urogenital 
Symptoms in FM, Depicting Wellness in the Foreground 
The emphasis on FM in the group discussions did frame and highlight the 
reality of their condition at that time. For some, the emotions of maintaining such an 
organised regime to maintain a 'normal' life surfaced via anger, fear, tears and 
absolute fatigue. Paterson (2001 ) recognises this as a major paradox of living in the 
wellness-in-the-foreground perspective. She reminds us that, through this wellness­
in-the-foreground perspective, chronic illness is in the background but the 
management of the illness is always in the foreground. The focus group discussions 
and sharing of FM experiences and information brought the reality of living with FM 
and its chronicity momentarily to the foreground for all of the participants. 
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Conclusion 
The findings from the focus groups of Phase I of this study have confirmed 
that the key urinary symptoms and their impact for women diagnosed with FM who 
experience bladder irritability are compatible with, and inclusive in, the ICSVICPI. 
These sensory symptoms included urinary frequency, urinary urgency, nocturia and 
bladder pain, burning, discomfort or pressure. This qualitative study has been 
valuable in confirming these sensory symptoms of FM and directing the choice and 
formation of questionnaires for data collection for Phase II of this research on FM 
and bladder irritability. New relevant variables for the data collecting questionnaires 
were identified as a result of the qualitative methodology of this first phase. 
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'estimates of reliability based on the average correlation among items within a test' 
(p. 251). A criterion of at least 0.70 was pre-set as the acceptable level for internal 
consistency reliability (Nunnally & Bernstein, 1994). Internal consistency reliability 
also involved assessment of item-to-total correlations with an expected value of 
between 0.40 and 0. 70 (Carmines & Zeller, 1979). 
The Symptom Index 
The Symptom Index (ICSI) achieved an internal consistency estimate, as 
measured by Cronbach' s alpha coefficient, of 0.60. Item means ranged from 1.26 
(s.d. = 1.1) to 3.26 (s.d. = 1.3). The possible range of scores was O to 5. The item 
means, standard deviations and possible item scores for each item are shown in Table 
3 (n = 90). 
Table 3: The Symptom Index: Item Mean, Standard Deviation and Possible Score Ranges 
Item Item Mean s.d.
Possible Score 
Ranges 
1. Urinary Urgency 2.59 1.44 0-5
2. Urinary Frequency 3.26 1.34 0 - 5
3. Nocturia 2.58 1.32 0-5
4. Bladder Pain 1.26 1.10 0 - 4
The overall mean score for the Symptom Index was 9.68 (s.d. = 3.52). The 
possible range was O to 19. Item-to-total correlations ranged from 0.26 to 0.54. The 
two items referring to nocturia and pain achieved lower item-to-total correlations, 
contributing to the slightly lower Cronbach's alpha coefficient for this symptom 
index. 
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impact scores of urgency, frequency, nocturia and bladder pain. The overall mean 
score for the combined Symptom and Problem Index was 19.01 (s.d. = 6.40). The 
possible range was Oto 35. Item-to-total correlations ranged from 0.37 to 0.66. This 
is within the acceptable range of 0.30 to 0.70 as specified by Carmines and Zeller 
(1979). 
Factor Analysis 
For further validation of the ICSI/ICPI instrument within this FM population, 
a factor analysis was undertaken to assess the internal structure of the scale. The 
structure of the eight-item ICSI/ICPI scale was examined using Principal Component 
Factor Analysis with Varimax Rotation. Pallant (2001) suggests that the larger the 
sample size for factor analysis, the better. Nunnally and Bernstein (1994) recommend 
ten cases for each item. Therefore, 90 cases were sufficient to assess the eight-item 
scale. Pallant (2001) also recommends that, for a factor analysis, at least 50% of the 
inter-item correlations should be greater than 0.30. The data met these criteria with 
20 of the 28 inter-item correlations being above 0.30. Results of the Principal 
Component Analysis revealed two components with eigenvalues greater than 1.00 
(3.520 and 1.505). These two components explained a total of 62.82% of the 
variance. The screeplot showed a distinct curve drop after the second component. 
These two components were retained for further analysis. 
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Table 5: Item and Factor Loadings> 0.40 and Explained Variance for Two Components Based 
upon PCA Varimax Rotation. 
Items 
ICPI Bladder burning, pain, 
discomfort or pressure 
ICSI Bladder pain or burning 
ICSI Urinary urgency 
ICPI Urinary urgency 
ICPI Urinary frequency 
ICSI Nocturia 
ICPI Nocturia 
ICSI Urinary frequency 
% of Variance explained 
Factor Loading 
Component 1 
.803 
.782 
.685 
.684 
.599 
.417 
34.32% 
Factor Loading 
Component2 
.507 
.865 
.802 
.648 
28.5% 
The rotated solution revealed a pattern of interpretable loadings. According to 
Kim and Mueller (1978), a factor loading should be greater than 0.40, and the 
differences between factor loadings should be greater than 0.15 to be interpretable. 
The symptoms of, and problems associated with, bladder pain, burning and 
urinary urgency loaded on Component 1. The symptoms and problems of nocturia all 
loaded on to Component 2. The symptom of urinary frequency also loaded on to 
Component 2. The problem of urinary frequency loaded on both components with 
the difference between the factor loadings being less than 0.15. This item was judged 
to be more interpretable as a Component 2 item. 
This pattern of loading of urinary symptoms and impact within the FM 
population clearly displays two separate components of symptom and problem 
combinations as distinct from the original ICSI/ICPI developed for the interstitial 
cystitis population. These two components form the two subscales of the resultant 
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study was to validate the ICSI/ICPI within the FM population, data was collected 
using this Interstitial Cystitis instrument. The data collected was in response to these 
ICSI/ICPI questions. The analysis of the data has produced a more specific 
configuration of the eight questions of the original ICSI/ICPI index for the FM 
population. Although the sensory urinary symptoms and impact are similar for both 
the interstitial cystitis and FM populations, the ICSI/ICPI and the Fibromyalgia 
Bladder Index represent each population more specifically. 
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refers to the direction of the relationship and not the strength. Pallant (2001) cites 
Cohen in suggesting the following guidelines in interpreting values of the strength of 
the correlation between O and 1: r = 0.10 to 0.29 small; r = 0.30 to 0.49 medium; r = 
0.50 to 0.10 large. 
As shown in Table 10, there was a significant positive correlation between 
the total Fibromyalgia Bladder Index with the total Kings Health Questionnaire. 
Individual correlations between the Fibromyalgia Index and the individual Kings 
Health Questionnaire's domains ranged from 0.351 to 0.615. There was a significant 
positive correlation between both of the individual subscales of the Fibromyalgia 
Bladder Index with the Kings Health Questionnaire and the Fibromyalgia Impact 
Questionnaire. The correlation between the Urgency and Pain Subscale and the 
Kings Health Questionnaire was not as high because the latter is designed more 
specifically for incontinence rather than for the sensory bladder symptoms of pain 
and urinary urgency. Individual correlations ranged from 0.136 (Kings Health 
Questionnaire sleep and energy domain with the Urgency and Pain Subscale) to 
0.663 (Kings Health Questionnaire bladder effects on life with the Frequency and 
Nocturia Subscale). 
Significant positive correlations were also evident between the Fibromyalgia 
Bladder Index and the Fibromyalgia Impact Questionnaire (Table 10). There was 
also a significant correlation between both of the individual subscales of the 
Fibromyalgia Bladder Index and the Fibromyalgia Impact Questionnaire. Individual 
correlations ranged from 0.198 (Fibromyalgia Impact Questionnaire question asking, 
In the past week, how tense, nervous or anxious have you been? with the Frequency 
and Nocturia Subscale) to 0.433 (Fibromyalgia Impact Questionnaire total score with 
the total Fibromyalgia Index). Significant correlations were evident between the 
Fibromyalgia Impact Questionnaire and all nine domains of the Kings Health 
Questionnaire (r=0.352 to 0.589, p=0.002 to 0.000). These findings provide evidence 
for the concurrent validity of the new instrument, the Fibromyalgia Bladder Index, 
and confirm that it is not redundant in relation to the Kings Health Questionnaire. 
In summary, this assessment has provided evidence that the Bladder Urgency 
and Pain and the Bladder Frequency and Nocturia subscales yield reliable and valid 
estimates for assessing the symptoms and impact of bladder symptoms for women 
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with FM. The index, consisting of two subscales, has demonstrated internal 
consistency reliability, acceptable test-retest reliability and evidence of concurrent 
validity. 
Descriptive Statistics of the Sample Population 
The following tables summarise the level of distress exhibited by this sample 
population as measured by the new Fibromyalgia Bladder Index, the Kings Health 
Questionnaire, the Fibromyalgia Impact Questionnaire, the SF-36 and the Vulval 
Symptoms Assessment Scale. 
Fibromyalgia Bladder Index 
The Fibromyalgia Bladder Index comprises the Bladder Urgency and Pain 
Subscale and the Bladder Frequency and Nocturia Subscale. In order to develop 
meaningful total scores for these subscales, the items in the Fibromyalgia Bladder 
Index were weighted because some of the items of the questionnaire were scored out 
of four while others were scored out of five. Weighting was undertaken by 
multiplying the five-answer questions by four, and the four-answer questions by five 
to give an equal score out of 20 for each question. With four questions on each of the 
two subscales, the highest possible score on each subscale is 80 ( 4 x 20) and 160 (8 x 
20) on the combination of both subscales. Table 11 shows the frequencies of the two 
individual and combined subscales of the Fibromyalgia Bladder Index. 
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including FM. Table 17 compares the descriptive statistics for each SF-36 scale for 
the following four studies: this current Australian FM study; Schlenk and colleagues' 
( 1998) FM participants in the chronic disorder population study (USA); the female 
population norms for the SF-36 of Australia (Australian Bureau of Statistics, 1995); 
and the female population norms for the SF-36 of the United States of America 
(Ware et al., 2002). 
It is of interest to note that the findings for the current Australian study on 
FM and bladder irritability reveal a poorer state of health as shown by the SF-36 
descriptors than in the other three studies. The item means for all eight SF-36 
domains were lowest in the Australian FM population. The specific impact of the 
urinary symptomatology measured in this current study may be greater because of 
the verification of urological symptoms in this population. The small FM sample 
used in the FM USA study and their less rigorous approach to the confirmation of 
bladder symptomatology may also account for the lower level of quality-of-life 
distress in the Australian population. 
Table 17: Current FM Study Descriptors for the SF-36, Australian Female Population SF-36 
Norms, United States of America Female Population SF-36 Norms, Descriptors for the 
SF-36 FM Participants in Chronic Disorder Population Study (USA). Descriptive 
Statistics: Sample Size, Item Mean, Standard Deviation and Possible Score Ranges 
Domains 
Physical F unctioning 
(Q 3 a-j) 
Role: Physical (Q 4 a-d) 
Population n 
88 Current FM Study 
FM Study (USA) 18 
97Australian Norms 
USA Norms 1412 
88 Current FM Study 
FM Study (USA) 18 
9736 Australian Norms 
USA Norms 1412 
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Item 
Mean 
s.d.
45.40 24.05 
61.67 24.01 
81.1 24.3 
81.47 24.60 
12.22 25.42 
38.89 37.60 
78.8 36 
77.77 36.2 
Possible 
Score 
Ranges 
0- 100
0 -100 
0- 100
0- 100
1-100
1 - 100 
1-100
1 - 100 

The Vulval Symptom Assessment Scale 
The Vulval Symptom Assessment Scale (VSAS) (Appendix K) was 
developed specifically for this study following the findings from the Phase I focus 
groups. Four of the ten women in the focus groups experienced moderate to severe 
vulvodynia-like symptoms of dyspareunia, vulval pain, irritation, burning and 
rawness. As there is no validated data-collecting tool for these symptoms within the 
FM population, the VSAS was developed as an initial screening tool to gauge if 
vulval symptoms were a significant problem in this population of women. The VSAS 
consists of five questions on vulval symptoms and four questions on the impact of 
these symptoms on quality of life. Possible score ranges are from O to 3 with the 
higher score indicating a greater symptomatology and impact. The findings are 
detailed in the following Table 18 
Table 18: The Vulval Symptom Assessment Scale. Descriptive Statistics: Sample Size, Item 
Mean, Standard Deviation and Possible Score Ranges 
Domain 
SYMPTOM 
• Burning
• Stinging
• Irritation
• Rawness
• Pain
IMPACT 
• Daily activities
• Physical
activities
• Social activities
• Sexual activities
n 
90 
90 
90 
89 
89 
89 
87 
87 
73 
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Item 
Mean 
.72 
.63 
.92 
.67 
.82 
.49 
.46 
.31 
.71 
s.d.
.87 
.87 
.88 
.89 
.90 
.71 
.73 
.62 
.92 
Possible 
Score Ranges 
0-3
0-3
0-3
0-3
0-3
0-3
0-3
0-3
0-3
40 
30 
20 
� 10 
C " 
" u: 0 
Vulval burning in the last month 
f\bt at all 
40 
30 
20 
(i' 10 
C "
g u: 0 
50 
40 
30 
20 
ii' 
c: 10 " 
:, 
g 
u:: 0 
C "
:, 
g 
30 
20 
10 
u: 0 
A little Qu�e ab� Aloi 
Vulval irritation in the last month 
f\bl at all A little Quite a lot Aloi 
Vulval rawness in the last month 
f\bt at all A little Quite a lot Aloi 
Vulval pain in the last month 
f\bt at all A little Quite a lot Aloi 
50 
40 
30 
20 
g 10 
" u: 0 
Vulval stinging in the last month 
Notatall A little Quite a lot Aloi 
Figure 19: Visual Summary of the Distribution of Vulval Symptoms 
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Figure 20: Visual Summary of the Distribution ofVulval Symptom Impact 
The relative sizes of the means and the standard deviations reflect the skewed 
distribution followed by the VSAS items, with most subjects taking relatively low 
values (0 or 1) on individual items and a smaller number taking appreciably higher 
values (2, 3 or 4). Figure 19 and Figure 20 display the participants' scores on 
vulvodynia-like symptoms and symptom impact respectively. 
Factor analysis was undertaken to assess the internal structure of the scale. 
The structure of the Vulval Symptom Assessment Scale (VSAS) was examined using 
Principal Component Factor Analysis with V arimax Rotation. Results of the 
Principal Component Analysis (Table 19) revealed two components with eigenvalues 
greater than 1.00 (5.937 and 1.089). These two components explained a total of 
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Figure 21: Plot of Participants' Scores on Both VSAS Factors 
A plot of the subject scores on the two VSAS factors presents an integrated 
picture of the distribution of the subjects in the context of the levels of their vulva! 
symptoms and vulva! problems, and confirms the skewed patterns noted at the 
individual VSAS item levels. For both vulva! symptoms and vulva! problems, the 
majority of subjects clusters at relatively low levels with a smaller number exhibiting 
dramatically higher symptom and vulva! problem experiences. Factor scores are 
scored so that the mean level takes the value zero. The higher the score, the higher 
the levels of symptoms or symptom impact/problem the patient experiences. A score 
of+ 3 on the problem factor is someone who is experiencing a lot of problems while 
a score of -1 on the problem factor is someone who is experiencing very few 
problems. 
To confirm that the items measured by the VSAS constituted a separate 
construct and were not included in the FBI, correlations amongst the Fibromyalgia 
Bladder Index subscales and the Vulval Symptom and Vulval Impact Scales were 
analysed. Only one of the correlations was significant. The correlation between the 
Fibromyalgia Bladder Index Subscale of Urgency and Pain and the Vulval Impact 
score was significant, although relatively modest in magnitude (r = 0.331, p = 0 
.005). None of the other correlations was significant. This suggests that the separate 
assessment of vulval symptoms and their impact is important and distinct, and 
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therefore it cannot be assumed that these vulval symptoms are encapsulated within 
the Fibromyalgia Bladder Index. 
Predictive Ability of Urinary Symptoms and Problems on the Fibromyalgia 
Bladder Index 
Hassard (1991) explains regression analysis as an elegant and informative 
way of testing the possible existence of, and describing a relationship between, a 
dependent variable and one or more explanatory or independent variables. For this 
study, it provides a technique for examining the possibility of the women's 
demographic and health profile characteristics having an influence on their 
Fibromyalgia Bladder Index scores and providing some insight into the possible 
predictive values of these independent variables. The aim of the multiple regression 
here is to determine which of the independent variables have a genuine relationship 
with either of the subscales of the Fibromyalgia Bladder Index and to determine the 
strength and nature of the relationship (Hassard, 1991). 
Is it possible that some of the independent variables can predict the women in 
this study who scored highly on the Urgency and Pain Subscale and the Frequency 
and Nocturia Subscale? How well can these variables predict a particular outcome 
and which variables in the set of variables is the best predictor of the outcome 
(Pallant, 2001)? What variables are the predictors of pain/urgency and 
frequency/nocturia in this FM population? 
Variables from the Fibromyalgia Impact Questionnaire, the Kings Health 
Questionnaire, The SF-36 Health Survey, the Vulval Symptom Assessment Scale, 
the participants' age and the number of years since self-diagnosis of FM from the 
demographic questionnaire were all entered into a forward stepwise multiple 
regression as independent variables. Tables 20 and 21 show the results of this 
analysis for the Pain and Urgency Subscale while Tables 22 and 23 show the results 
from the analysis for the Frequency and Nocturia Subscale. 
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Table 20: Regression Analysis: Pain and Urgency Subscale. Variables Entered 
Step Variables Entered 
1. Kings Health Questionnaire. Total Score for Emotions:
2. SF-36 Questionnaire. Total Score for General Health Questions:
Table 21: Regression Analysis: Pain and Urgency Subscale. Model Summary 
Step 
1. 
2. 
R 
.466a 
.525b 
R Square 
.217 
.276 
F 
24.384 
16.570 
a. Predictors: Kings Health Questionnaire. Total Score of Emotions
df. 
1,88 
2,87 
p 
p = 0.000 
p= 0.000 
b. Predictors: Kings Health Questionnaire Total Score of Emotions, SF-36 Questionnaire general
health questions 1 + 1 l a+ I lb+ 1 lc+ 1 l d
The Kings Health Questionnaire score from the emotions domain enters on 
the first step and explains 21 % of the variance in the Urgency and Pain Subscale. 
The Total Score for this emotions domain is a composite of the three individual 
questions: 'Does your bladder problem make you feel depressed?'; 'Does your 
bladder problem make you feel anxious or nervous?'; and 'Does your bladder 
problem make you feel bad about yourself?' 
The MOS SF-36 Health Survey general health questions enters on the second 
step in a negative relationship with the outcome and explains an additional 5.9% of 
the variance, for a total of 27.6% of the variance in the Urgency and Pain Subscale 
explained. The total score for the MOS SF-36 general health questions is a composite 
of the individual questions: 'In general, would you say your health is excellent, very 
good, good, fair, or poor?'; 'I seem to get sick a little easier than other people: 
definitely true, mostly true, don't know, mostly false, definitely false?'; 'I am as 
healthy as anyone I know: definitely true, mostly true, don't know, mostly false, 
definitely false?'; 'I expect my health to get worse: definitely true, mostly true, don't 
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know, mostly false, definitely false?'; 'My health is excellent: definitely true, mostly 
true, don't know, mostly false, definitely false?' 
Both predictors in this model achieved statistical significance (p = 0.000). 
Once these predictors had been entered into the model, no other explanatory 
variables achieved statistical significance. 
In summary, the Kings Health Questionnaire emotional domain (Do bladder 
problems make one feel depressed, nervous, anxious or bad about oneself?) is highly 
predictive of a woman's score on the Pain and Urgency Subscale. The greater the 
feelings of depression, anxiety and lack of self worth, the higher the subscale score. 
The MOS SF-36 Health Survey general health questions score is also highly 
predictive of the score on the Pain and Urgency Subscale, with a low MOS SF-36 
general health questions score being predictive of a high Pain and Urgency score. 
The poorer the subjects' perceptions of their current health status, and the more 
negative their perceptions of their future health prospects, the higher their Pain and 
Urgency score is likely to be. 
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problem affect your physical activities (eg going for a walk, run, sport, gym etc)?' 
and 'Does your bladder problem affect your ability to travel?' All three predictors in 
this model achieved statistical significance (p = 0.000). No other explanatory 
variables achieved statistical significance. 
In summary, the Kings Health Questionnaire question (How much do you 
think your bladder problem affects your life?) is highly predictive of a woman's 
score on the Frequency and Nocturia Subscale, with the larger the effect on one's 
life, the higher one's score on the Frequency and Nocturia Subscale. The impact of 
the bladder on sleep and tiredness, as measured by the Kings Health Questionnaire 
sleep/energy score, is also highly predictive of a woman's score on this second 
subscale, with the greater the sleep effects and fatigue, the greater the score on 
frequency and nocturia. In addition, the more extensive the physical limitations from 
her bladder problems, the higher a woman's score on the Frequency and Nocturia 
Subscale is likely to be. 
In order to clarify the relationship between the predictors ( and, more 
specifically, the individual questions on which these composite predictor scores were 
based) and the Bladder Pain and Urgency Subscale, the 25% of the sample reporting 
the highest subscale scores and the 25% of the sample reporting the lowest subscale 
scores were identified. The top quartile reported Pain and Urgency scores of 52 or 
greater ( out of a possible range of 0-80), while the bottom quartile reported Pain and 
Urgency scores of 23 or less. 
Table 24 shows the predictor variable characteristics of the 25 subjects 
reporting Pain and Urgency scores> 51. Note that a high score on the Kings Health 
Questionnaire (KHQ): Emotions (Items 1-3) indicates a greater impact on emotional 
health while, for the MOS SF-36 General Health Survey Questions (Items 4-8), a 
high score indicates better health perceptions. 
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Table 24: Impact of the Highest 25% of Scores (score> 51) on the Predictors of the Bladder 
Urgency and Pain Subscale. Item Mean, Median, Standard Deviation and Possible 
Score Ranges 
Item 
Possible 
Item 
n n 
Median s.d. Score Valid Missing Mean 
Ranges 
25 0 2.36 2.00 .95 1-4
25 0 2.56 2.00 .87 1-4
25 0 2.20 2.00 1.12 1 - 4 
25 0 2.12 2.00 .87 1 - 5 
25 0 2.40 2.00 1.35 1 - 5 
25 0 2.24 2.00 1.20 1 - 5 
25 0 2.56 3.00 .92 1 -5 
25 0 1.88 2.00 .97 1 - 5 
Does your bladder problem 
make you feel depressed? 
(KHQ) 
Does your bladder problem 
make you feel anxious or 
nervous? (KHQ) 
Does your bladder problem 
make you feel bad about 
yourself? (KHQ) 
In general would you say 
your health is excellent, 
very good, good, fair, or 
poor? (SF-36) 
How true or false is this 
statement for you? I seem 
to get sick a little easier 
than other people. (SF-36) 
How true or false is this 
statement for you? I am as 
healthy as anyone I know. 
(SF-36) 
How true or false is this 
statement for you? I expect 
my health to get worse. 
(SF-36) 
How true or false is this 
statement for you? My 
health is excellent. (SF-
36) 
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In summary, the Kings Health Questionnaire emotional domain questions on 
the bladder problem making one feel depressed, nervous, anxious or bad about 
oneself predicts a high score on the Pain and Urgency Subscale. The differences of 
the item means of the three emotional domain questions indicate the different levels 
of impact for the highest 25% (Table 24) and the lowest 25% (Table 25) of the scores 
of the women: the higher the score, the greater the impact. For the MOS SF-36 
Health Survey general health questions, a higher score indicates a better health state. 
This is reflected in the item means of these five items. A low score on the SF-36 
general health questions predicts a high score on the Pain and Urgency Subscale. The 
differences of the item means of the five general health questions of the SF-36 
indicate the different levels of impact for the highest 25% (Table 24) and the lowest 
25% (Table 25). 
In order to also clarify the relationship between the predictors (and, more 
specifically, the individual questions on which these composite predictor scores were 
based) and the Frequency and Nocturia subscale, the 25% of the sample reporting the 
highest subscale scores and the 25% of the sample reporting the lowest subscale 
scores were also identified. The top quartile reported Frequency and Nocturia scores 
of >57 ( out of a possible range of 0-80) while the bottom quartile reported Frequency 
and Nocturia scores of< 36. 
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CHAPTER 7 
DISCUSSION: PHASE II 
Introduction 
Within the area of instrument development, Waltz, Strickland and Lenz 
(1991) suggest that it is possible to identify an already existing instrument that is 
acceptable. They state that such an existing instrument may need to be modified and 
imply that modifying an existing instrument is usually more efficient than developing 
a new instrument. Such modifications do result in a new instrument and therefore the 
psychometric properties of the new instrument must be re-evaluated. This was the 
situation for this current study. 
Phase II of this study involved the testing of the ICSI/ICPI instrument for 
reliability and validation within the female FM population. Prior to this current 
study, there was no valid and reliable measure for gauging sensory urinary symptoms 
within the female FM population. This is the first study to modify and validate such 
an instrument for women with FM. The aim of Phase II of this study was to validate 
an existing instrument for FM patients that had been developed and validated for 
urinary symptoms and impact within the interstitial cystitis population. This 
ICSI/ICPI was identified as appropriate for the FM population for a number of 
reasons, firstly, because of the genitourinary symptoms of women with FM and 
secondly because of the similarity of these symptoms to those experienced by 
women with interstitial cystitis. Rationale for the development of this instrument was 
also based on Clauw and colleagues' (1997a) work that suggests the possible 
involvement of the central nervous system mechanisms that contribute to the 
pathogenesis of FM may be operative in IC. 
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This current research has revealed two separate components of urinary 
symptom and urinary problem combinations within the FM population that are 
distinct from the original ICSI/ICPI developed for the interstitial cystitis population. 
These two separate components form the two subscales of the newly developed 
Fibromyalgia Bladder Index. 
The Fibromyalgia Bladder Index 
Munro, Visintainer and Page (1986) describe factor analysis as a tool that 
enables the study of variables in groupings that are not obvious, a method of 
reducing data so it can be easily described and used as an aid in instrument 
development. They describe factor analysis as the most important statistical tool for 
validating the structure of new instruments 
Factor analysis was undertaken to assess the internal structure of the 
ICSI/ICPI using Principal Component Factor Analysis with Varimax Rotation. The 
factor analysis resulted in two components that formed the two subscales of the 
newly developed Fibromyalgia Bladder Index. The difference between the symptom 
and impact combinations of the ICSI/ICPI index and the Fibromyalgia Bladder Index 
are very relevant to the Fibromyalgia population. 
Whereas the ICSI/ICPI consisted of two subscales, one of the symptom index 
and one of the problem index, results from this study suggest that the items are better 
grouped for the Fibromyalgia Bladder Index subscales as a combination of both 
symptoms and problems. This instrument therefore more appropriately measures a 
different grouping of bladder symptoms and symptom impact from the ICSI/ICPI for 
the FM population. Psychometric testing of this structure confirms that this is the 
most valid and reliable measurement framework for the FM population. 
Bladder Urgency and Pain Subscale 
The first subscale of the Fibromyalgia Bladder Index is the Bladder Urgency 
and Pain Subscale that consists of the symptoms of bladder urgency and bladder pain 
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or burning, and the problems that bladder urgency and bladder pam, burning, 
discomfort or pressure present. Urgency is the complaint of a sudden compelling 
desire to pass urine that is difficult to defer and the increased bladder sensation is like 
an early and persistent desire to void (Abrams et al. , 2002a). For women with urinary 
urgency, the urge to void is often compounded by the discomfort and pain resulting 
from these inappropriate and urgent detrusor contractions. Bladder pain is felt 
suprapubically or retropubically, usually increasing with bladder filling, and may 
persist after voiding (Abrams et al. , 2002a). The anxiety and fear of urge 
incontinence further compounds the impact of urinary urgency and pain. 
Bladder Frequency and Nocturia Subscale 
The second subscale of the Fibromyalgia Bladder Index is the Bladder 
Frequency and Nocturia Subscale. Bladder frequency during the day is the complaint 
by the patient who considers that she voids too often (Abrams et al. , 2002a). It can be 
aggravated by urinary urgency and can result in a decrease in bladder capacity. This 
can exacerbate nocturia, when the woman wakes at night one or more times to void 
(Abrams et al. , 2002a) .  For women with FM and nocturia, it is difficult to 
differentiate between the impact of FM on their bladder and the impact of their 
bladder on FM. One study of nocturia in community-dwelling women in the United 
Kingdom (Middlelkoop et al. , 1996) has shown the overall prevalence of nocturia in 
women over 19 years to be 18% and that 63% of these women experienced the 
nocturia as bothersome. Of the women with FM in this current study, nocturia (2 or 
>2 micturitions per night) was experienced by 77% of the participants. Of the women 
who experienced nocturia, 55% reported that this symptom was a medium or big 
problem for them. 
Insomnia, often described as the deprivation of restorative sleep, is a major 
problem for FM sufferers. How much of an impact does the insomnia have on the 
urinary frequency? Is it a behavioural response of 'if I go to the toilet again I may be 
able to go to sleep?' or is it the effect of FM irritability of the bladder that results in 
the increased voiding? As one participant mentioned, 'My frequency does not stop 
just because the sun sets!' Whatever the answer, frequency and nocturia are 
intrinsically linked. 
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The Fibromyalgia Bladder Index therefore measures the two most relevant 
groupings of variables that impact on women with FM who experience bladder 
irritability. This condition-specific instrument is more specific and precise than the 
ICSI/ICPI for the FM population. As indicated above, it specifically reflects the 
reality of symptoms and symptom impact of bladder irritability for women with FM. 
Reliability and Validity of the Fibromyalgia Bladder Index 
Following the development of the Fibromyalgia Bladder Index, the 
psychometric properties of this new instrument were evaluated. Central to all 
measurement is a determination of the reliability of the measurement method. 
Portney and Watkins (1993) describe reliability as the extent that a measurement is 
consistent and free from error and describe a reliable instrument as one that performs 
with predictable consistency under set conditions. These authors also state that 
reliability is fundamental to clinical research because without it therapists cannot 
have confidence in collected data or draw rational conclusions from it. 
The two indicators used to ensure reliability for the Fibromyalgia Bladder 
Index were internal consistency reliability measured by Cronbach's alpha coefficient, 
and test-retest reliability. The interpretation of reliability coefficients depends on 
their proximity to the value of 1. Portney and Watkins (1993) state that a coefficient 
below 0.50 represents poor reliability, coefficients from 0.50 to 0.75 a moderate 
reliability and values above 0. 75 are indicative of good reliability. On this 
interpretation, the Fibromyalgia Bladder Index Bladder Urgency and Pain Subscale 
achieved good reliability with an internal consistency estimate as measured by 
Cronbach's alpha coefficient of 0. 76. The second subscale, the Bladder Frequency 
and Nocturia Subscale also achieved good reliability with an internal consistency 
estimate as measured by Cronbach's coefficient of 0. 76. 
Test-retest reliability assessment establishes that an instrument is capable of 
measuring a variable with consistency (L. Portney & Watkins, 2000). The intraclass 
correlation coefficient was used in this study to analyse test-retest reliability. 
Administering the index to the same study sample at two intervals, two weeks apart, 
and then correlating the scores from both administrations of the same test completed 
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this assessment. Although it was the ICSI/ICPI that was administered, the items of 
both subscales are exactly the same as those of the Fibromyalgia Bladder Index. The 
test-retest of the combined subscales of the Fibromyalgia Bladder Index showed a 
high correlation of 0.85, indicating a reliable scale. The test-retest correlations for the 
subscales of 0.84 for the Urgency and Pain Subscale and 0. 79 for the Frequency and 
Nocturia subscales confirmed that the individual subscales are also highly reliable. 
Following the reliability testing of the Fibromyalgia Bladder Index, it was 
important to test its validity by examining the simple correlations between it and 
other similar instruments. Criterion-related validity was tested as concurrent validity 
by measuring the correlation of the Fibromyalgia Bladder Index with established 
validated measures. The Fibromyalgia Bladder Index was compared with the 'gold 
standard' urinary Kings Health Questionnaire and the Fibromyalgia Impact 
Questionnaire. Eighty-three women completed all three questionnaires. The 
concurrent validity of the Fibromyalgia Bladder Index was confirmed against both of 
these validated questionnaires with significant positive correlations. 
Participants' Characteristics 
The descriptive statistics of this study were used to summarise the stories of 
bladder irritability of these women diagnosed with FM. Approximately 80% of the 
women were between the ages of 30 and 60 years. Littlejohn (1996) states that FM 
can occur at any age, being frequent in adolescent females, reaching its main 
prevalence in the 30- to 40-year age group, but also common in the elderly. At the 
age extremes of this study population, approximately 5% of the participants were 
aged between 24 and 30 years, while approximately 14% of the women were aged 
between 61 and 65 years. 
The majority of participants (62.2%) were either married or in a relationship 
and all but 15% of the participants had children. The demographic information 
revealed that approximately 50% of participants were well educated, with tertiary 
qualifications. Many referred to themselves as 'high achievers' in their chosen 
careers. However, only 21.1 % were currently working in their professional capacity. 
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The main health concerns of the participants reflected the known impact of 
FM on other organ systems of the body. Participants' main health concerns involved 
symptoms from the musculoskeletal system (47.8%) ,  the neurological system 
(33.3%), and the digestive system (33.3%). Many of these symptoms were managed 
pharmacologically, with 65% of participants taking medication for central nervous 
system impact (mainly tricyclics and selective serotonin reuptake inhibitors for pain 
and sleep enhancement), 40% for musculoskeletal dysfunction, 22% for other pain 
medication and 17.8% for gastrointestinal dysfunction. 
Approximately 35% of the participants were using some form of hormone 
replacement therapy. This may have been an artefact of the age range of the 
participants because approximately 90% of the participants were over the age of 40. 
Further studies could consider the possible implications and symptom differences 
between women who were and those who were not taking hormone replacement. 
Surgical histories showed a significant number of the participants had 
undergone a hysterectomy (47.8%), other gynaecological surgery (41. 1%) and 
gastrointestinal surgery (32.2%). In relation to urological symptomatology, it is 
interesting to note that the high hysterectomy and other reproductive organ surgery 
rate may be suggestive of gynaecological surgery increasing sensitisation within the 
pelvic region. Does the increased rate of pelvic surgery indicate a predisposition or 
vulnerability by these women to increased visceral nociception and/or pelvic 
symptomatology, or is the surgical intervention itself part of the etiology and an 
aggravating factor of continuing symptomatology? Further studies considering the 
pre-surgical histories of the women could give some indication. 
The high hysterectomy and other reproductive organ surgery rate and the high 
education level within this sample may possibly represent a selection bias. However, 
a comparison of this study's data with published results with similar populations 
using the FIQ, KHQ and SF-36 indicate that, for these well-validated indicators, the 
results are similar. 
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Impact of Bladder Irritability and Fibromyalgia on Participants 
Responses from the Kings Health Questionnaire indicated that many of the 
women in this FM population reported that their health was fair, and that their 
bladder problem affected their life in a small to moderate way. The higher score on 
the Kings Health Questionnaire indicated a greater impairment of quality of life. The 
six domains of the questionnaire referred to the effects of their bladder on aspects of 
their lives. Responses to questions about their role and physical limitations resulting 
from bladder concerns ranged mainly from not at all to slightly. It is important to 
note that the majority of people diagnosed with FM have many and varied symptoms 
that impact on their activities of daily living, bladder symptoms being only one of 
these (Littlejohn, 1996). Few women experienced social or personal relationship 
limitations because of their bladder. The majority of women responded that their 
bladder problem affected their sleep and they were worn out and tired. Sleep 
disturbance affects 75% of people with FM (Merskey & Bogduk, 1994), resulting in 
unrefreshed sleep and tiredness on waking. This again raises the question as to 
whether it is this FM sleep dysfunction, the nocturia or a combination of both that is 
having the greatest impact on the energy and fatigue levels of women with FM and 
bladder symptomatology. 
The Fibromyalgia Impact Questionnaire data also elucidated the experience 
of the women with FM and bladder irritability. For many women with bladder 
irritability who do not have FM, the impact on their quality of life has been well 
documented. Pinnock and Marshall (1997) have shown that the impact of lower 
urinary tract symptoms on quality of life in an Australian community is a major 
reason for people seeking medical help. Data from this current study on FM and the 
irritable bladder reveals the added burden and subsequent stress placed on these 
women who cope with the other multi-factorial symptomatology of FM as well as 
bladder symptoms. A high score on the FIQ reflected a greater impact on the health 
status of the woman. 
Physical impairment on the FIQ was minimal for this population. This was 
because the FIQ assesses more the activities of daily living rather than activities such 
as running or lifting heavy objects as assessed in the SF-36 Questionnaire. 
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Depression and anxiety were the next lowest scores in this population. Although the 
FIQ is not a validated measure for depression, the questions of how tense or nervous 
they felt or how depressed or blue they were did indicate the participants' personal 
sense of mental well-being at the time. These findings are of interest against the 
backdrop of recent findings by Giesecke and colleagues (2003) whose data supported 
the clinical notion that there are distinct subgroups of patients with FM. Three FM 
groups were described by the authors as patients who experience extreme tenderness 
with no associated psychological or cognitive aspect, an intermediate group who 
exhibit moderate tenderness and experience normal mood, and the third group in 
whom mood and cognitive aspects can be instrumental and influential in symptom 
reporting. In this current study, pain, stiffness and fatigue combined with 'waking 
very tired and non-rested in the mornings' placed an almost suffocating burden on 
the women. The mean total FIQ score for this study was similar to other studies 
revealing the impact of FM (Table 14). 
The MOS SF-36 Health Survey data measured the participants' personal 
perceptions of eight health domains that impacted on their quality of life. Higher 
scores on the SF-36 reflect a minimal impact on health status while low scores 
signify a greater level of impact. Results on the mental health indicators of the SF-36 
were consistent with results from the FIQ. Mental health status of the participants 
was in the moderate range with a mean score of 57.38 within a possible score range 
of 1-100. These findings are in contrast to previous reports of depression and 
inability to cope with life stressors in FM suffers. Although the SF-36 is not a 
validated measure for depression, it describes whether the people were nervous, 
whether they were so down in the dumps that nothing could cheer them up, whether 
they felt calm or peaceful and whether they felt down, or if they were happy people. 
The FIQ and the SF-36 are not diagnostic tools for depression, but rather screening 
tools that indicate potential levels of psychological distress. Low scoring for role 
limitations due to emotional problems impacted on the amount of time the women 
spent at work and other regular daily activities, on the amount they accomplished 
during work or daily activities, and on how carefully they did these activities. Low 
scoring on the bodily pain and vitality domains reflected the levels of pain and the 
chronicity of symptoms typical of FM. 
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Responses to the SF-36 indicated that the greatest negative impact from FM 
was in the physical role domain where the participants had to cut down on time at 
work, accomplished less, and were limited in their work and activities because of 
their physical health. These effects of physical health on role performance together 
with vitality and bodily pain were rated as having the most negative impact. 
This was confirmed in the comparisons with Australian and United States of 
America population norms for the SF-36. The comparisons of the means of the SF-
36 domains from this study with that of the Australian population female norms and 
the United States of America female norms (Table 17) truly reflects the enormous 
impact on the quality of life for the Australian women with FM. The scores of the 
women in this study were significantly lower in all SF-36 domains than those of the 
Australian and United States SF-36 normative data for females. 
The Vulval Symptom Assessment Scale 
The Vulval Symptoms Assessment Scale (VSAS) developed specifically for 
this study has shown that vulvodynia-type symptoms of vulval irritation, vulva! pain, 
vulval burning, vulval rawness and vulval stinging are a reality for many women 
with FM who experience bladder irritability. The symptoms and symptom impact 
experienced ranged from a little to a lot, with 50% ( 45) of the women experiencing 
some vulval burning, 43% (39) with some vulval stinging, 65% (59) with some 
vulval irritation, 46% (41) with some vulval rawness and 57% (51) with some vulval 
pain. These vulval symptoms affected 37% (34) of the women in their daily 
activities, 33% (29) in their physical activities, 24% (21) in their social life and 46% 
(34) in their sexual activities. The inclusion of the VSAS in this study has revealed 
some significant vulval symptoms. 
The VSAS was developed in response to the significant impact that vulval 
symptoms had on four of the ten women in the Phase I focus groups of this study. 
The focus groups were held to ensure all relevant information would be considered in 
the development of, or validation of, an existing instrument for bladder sensitivity 
issues within the FM population. The qualitative approach of the focus group has 
contributed to the quantitative findings of this Phase II of the study by identifying the 
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need for data collection on vulva} symptoms and their impact within this population. 
The findings from the VSAS in Phase II of the study confirmed the presence of 
vulva} symptoms and their associated impact within this FM population. 
Factor analysis was undertaken to assess the structure of the VSAS scale. The 
analysis displayed two factors, the vulva} symptom factor and the vulva} impact 
factor. These were correlated with the two subscales of the Fibromyalgia Bladder 
Index (FBI). The findings displayed the VSAS as a separate construct, not included 
in the FBI. Only one significant and relatively modest correlation was found. This 
suggests that the separate assessment of vulva} symptoms and their impact on women 
with FM is important in urogenital appraisals for these women. The VSAS data 
collection results have also highlighted that the impact of vulva} symptoms 
contributes to the distress of women already coping with FM and bladder irritability. 
The vulva} factor scores illustrate that distinctive subgroups of vulva} 
symptom experiences and vulva} impact/problem experiences are present in this 
study group. Further examination of the nature of these distinct experiences could 
form the basis for further research, perhaps through analysis by cluster and 
discriminant analysis techniques. In particular, the apparent presence of a subgroup 
of women who experience high levels of vulval problems while experiencing 
relatively low levels of vulval symptoms raises questions about the nature of the 
differences between these women and the subgroup of women who, while 
experiencing similar levels of vulva} symptoms, experience much lower levels of 
vulval problems. 
Perhaps the difference between vulvodynia and dyspareunia as described 
below by Graziottin (2004) accounts for this as the VSAS data collection instrument 
for vulva} symptoms and problems did not distinguish between vulvodynia and 
dyspareunia. A recent presentation by Graziottin (2004) describes the results of a 
critical review of the literature on sexual pain disorders and vulvodynia. He describes 
vulvodynia as a pain disorder which may be a predisposing factor to dyspareunia 
while dyspareunia is described as a sexual pain disorder. Graziottin describes the two 
conditions as etiologically different and suggests that, although they do interact and 
- 226 -
overlap, the conditions should be kept separate from the diagnostic and treatment 
perspectives. 
Mcinnes (2003) reminds us that sex is an important contributor to the quality 
of life for many patients with chronic illness and their partners. She emphasises that 
the effects of chronic illness on sexuality are multi-factorial and that they impact on 
all phases of the sexual response. She describes sex for someone whose life is 
restricted by chronic disease as a powerful source of comfort, pleasure and intimacy 
where a satisfying sex life can allow one to feel normal when so much else in life has 
changed. 
Graziottin and colleagues (2004) have also shown that the overactive bladder 
symptoms of urgency, frequency and nocturia have a significant impact on quality of 
life and sexual activity and can affect sexual identity, sexual function and sexual 
relationships. The authors acknowledge that the combination of silence where the 
patient is too embarrassed to disclose symptoms and the physician is sometimes too 
busy to ask often results in the under diagnosis and under treatment of these urinary 
symptoms. According to the epidemiologic survey by Laumann and colleagues 
( 1999), the presence of urinary tract symptoms appears to impact on sexual function. 
The analysis of sexual dysfunctions by risk factors in women shows that urinary tract 
symptoms have a risk ratio of 4.02 (2.75-5.89) of being associated with arousal 
disorders and a risk ratio of 7 .61 ( 4.06-14.26) of being associated with sexual pain 
disorders. Because of the strong association between sexual dysfunction and quality 
of life, Laumann and colleagues (1999) recommend that sexual dysfunction be 
recognised as a significant public health concern. 
Wesselmann (2004) confirms that vulvodynia has detrimental effects on the 
sexual life of women and their sexual partners. She notes that some patients with 
vulvodynia also describe additional pain syndromes, including gastrointestinal, 
pelvic and chronic somatic pain, have been confirmed by epidemiological studies, 
suggesting generalised alterations in pain modulation mechanisms in women with 
vulvodynia. A study by Foster (2004) on the effects of capsaicin injections in normal 
and vulvodynia-afflicted women has shown the pain response of the vulvodynia 
group of women extended far beyond the anatomic location of the primary injection 
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site and they experienced greater spontaneous pam and allodynia. The author 
suggests this as possibly indicative of a central sensitisation state, as cutaneous 
response to capsaicin has been proposed as an assessment tool for central 
sensitisation. 
Further research in this area could focus on the development and validation of 
a vulval symptom and impact instrument, measuring the impact that these vulval 
symptoms have on sexual response, sexual satisfaction, sexual health and sexual 
activities for women in this population. Glazer ( 1999) comments on the lack of an 
interdisciplinary approach to the management of vulvovaginal pain disorders. He 
lists the overlapping specialities treating these conditions as pain management, 
gynaecology, dermatology, urology, gastroenterology, rheumatology, pathology, 
neurophysiology and sex therapy. The development of a validated vulval symptom 
assessment scale as an outcome measure specific to the FM population may promote 
a more focused treatment regime. 
The data from this study combined with many individual vocal stories from 
the ninety women participants. Together they revealed a constellation of feelings of 
helplessness in understanding and managing their varied pelvic symptoms, distress at 
the impact of their symptoms and frustration at not finding 'bladder and/or pelvic 
pain and discomfort solutions'. 
Is there a Clinical Definition for Bladder Irritability in Women with 
Fibromyalgia? 
The development of the Fibromyalgia Bladder Index as a validated 
instrument for measuring sensory symptom and impact within the FM population is a 
start to the understanding and the documentation of the urinary issues experienced by 
these women. Although this research commenced with the intention of validating the 
ICSI/ICPI within the FM population, a more condition-specific instrument for the 
FM population has been developed. This research specifies two distinct areas of 
symptom/impact in the two subscales, one of urinary urgency and pain, the Urgency 
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and Pain Subscale, and the other of urinary frequency and nocturia, the Frequency 
and Nocturia Subscale. 
These two subscales identifying these distinct components have clinical 
implications. The question arises as to whether the Bladder Urgency and Pain 
Subscale reflects the disorder of pain amplification due to the increased sensitivity of 
the pain system for women with FM. Is this a chain phenomenon of sensory pain 
and/or increased bladder sensation resulting in increased urgency, resulting in 
increased frequency? Does the Bladder Frequency and Nocturia Subscale indicate 
increased bladder irritability resulting in increased frequency and smaller bladder 
capacity? Or are we looking at sleep deprivation where night becomes day in 
urological terms, resulting in night time frequency rather than nocturia? These 
questions are difficult to answer because of the multiple symptomatology, the 
enigmatic nature of the function and innervation of the bladder wall, and the severe 
implications of a lack of sleep within this FM population. Jackson ( 1999) confirms 
that nocturia is a highly bothersome symptom with a multi-factorial aetiology and 
recommends further research into the understanding of the aetiology of nocturia. 
Within this area of bladder irritability, research is continuing in identifying 
and validating classification criteria for the diagnosis of certain 
urological/neurological conditions. This was demonstrated at the International 
Consultation on Interstitial Cystitis where clinicians and researchers are combining 
knowledge and experience to specify a definition and diagnostic protocol for 
interstitial cystitis (Bade, Ishizuka, & Yoshida, 2003). Bade and colleagues comment 
on the strict definition of IC that has developed into a universal diagnostic instrument 
for IC research. They feel that, for clinical practice, the criteria are too strict, which 
can result in the under-diagnosis of IC. They refer to the clinical definition of IC as 
the combination of urgency, frequency and bladder or pelvic pain in the absence of 
other pathology. The urological term, overactive bladder (OAB), also refers to the 
symptom complex of frequency, urgency and nocturia with or without urge urinary 
incontinence (Bade et al. , 2003). Currently there are no classification criteria 
available to differentiate between OAB and IC. However patients with OAB by 
definition do not have pain, whereas this is an integral and problematic part of the IC 
syndrome (p 221 lines 6-7). To add to this uncertainty, what is the clinical definition 
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of bladder irritability in FM? Are women with FM presenting with urinary urgency, 
bladder pain, frequency and nocturia being diagnosed and treated for recurrent 
urinary tract infections, overactive bladder or IC? 
The circumstances facing professionals working in the area of interstitial 
cystitis either as clinicians or researchers is similar to that of those working in the 
area of FM. There is confusion regarding the clinical diagnostic criteria because of 
the historically strict criteria for the research diagnosis of the conditions. Perhaps 
FM, like IC, is under-diagnosed? Sensory symptoms of IC and those of women with 
FM and irritable bladders are very similar. Although nocturia seems to be more 
prevalent within the FM population, the effect of insomnia on night time frequency 
must be taken into account. 
Bade and colleagues (2003) postulate that there is a relationship between IC 
and OAB and that this overlap may extend to chronic prostatitis. Clauw and 
colleagues (1997a) in their research on FM and IC also postulate that some of the 
pain of IC may be caused by centrally mediated nociceptive abnormalities rather than 
the peripheral mechanisms involving the bladder. Sant and Theoharides ( 1999a) 
report that, although the pathophysiology of IC is not completely understood, altered 
epithelial permeability, mast cell activation and sensory nerve upregulation play 
pivotal roles. Van De Merwe, Yamada and Sakamoto (2003) at the International 
Conference on Interstitial Cystitis in Kyoto 2003 recognised that IC was often 
associated with other diseases such as FM. 
Kahn, Tatro, Parsons, and Willems (2004) in their study on the incidence of 
IC in patients with vulvodynia have shown a significant majority of patients with 
vulvodynia have a positive potassium sensitivity test which indicates that their pain 
may have a bladder component such as interstitial cystitis. The authors recommend 
that IC be considered in the differential diagnosis of patients with vulvodynia and 
encourage further research into the relationship between these two diseases. 
At the 3rd International Consensus on Incontinence in Monaco in 2004, a 
committee was formed to provide a consensus on painful bladder syndrome. This is 
the first time since the International Consensus on Incontinence was formed under 
the auspices of the World Health Organization in 1998 that painful bladder syndrome 
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has been specifically addressed. Following an extensive literature review, a 
diagnostic and treatment algorithm (Appendix B) was formulated and presented. The 
algorithm provides a more liberal definition of painful bladder syndrome/interstitial 
cystitis compared with the previous NIDDK criteria (Rosamilia, 2004). The initial 
history and symptom assessment includes bladder pain with or without the sensation 
of urinary urgency, urinary frequency and nocturia. 
The development of the Fibromyalgia Bladder Index will be beneficial in 
monitoring the clinical status of FM patients who experience bladder irritability 
symptoms. The index is not a diagnostic instrument developed to help formulate a 
diagnosis, but rather it has been developed as an adjunct to clinical assessment and 
possibly as an outcome measure for intervention therapies for the patient with FM. 
Strengths of the Study 
Recently the National Institute of Arthritis and Musculoskeletal and Skin 
Diseases (NIAMS) of the National Institutes of Health (NIH) in the United States of 
America conducted a 'Fibromyalgia Program Assessment' to provide expert 
recommendations for FM research portfolios (NIAMS, 2003). Approximately forty 
currently funded researchers, scientists, representatives of patient advocacy groups 
and NIH staff attended. One of the listed main challenges in conducting FM research 
was identified as confusion or inconsistency regarding appropriate outcome 
measures. The development of the condition-specific questionnaire, the Fibromyalgia 
Bladder Index, is a beginning in meeting this need for validated and reliable outcome 
measurements. 
This research is the first of its kind in Australia. The relationship between FM 
and IC was first researched in the United States of America when Clauw and 
colleagues (1997a) found many current symptoms were similar for the FM and IC 
populations. This Australian research has added to this knowledge by developing a 
urinary outcome measure validated for the FM female population who experience 
bladder sensitivity. The methodology of the research is sound and confirms the 
theoretical framework that guided this investigation. 
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For the patient with FM and bladder irritability symptoms, this research will 
increase the medical and public awareness of the urogenital implications associated 
with FM. The significant consultation in the FM area as seen in the Canadian 
consensus document on FM (Jain et al., 2004) and the development of a painful 
bladder syndrome committee at the recent International Consensus on Incontinence 
(Rosamilia, 2004) gives a strong indication of the direction of future research and 
continuing consultation in these two areas. 
Limitations of the Study 
The sample was not randomly selected because of the difficulty of recruiting 
sufficient women for the study. It would have been preferable to also have a control 
group of FM women who did not experience sensory bladder symptoms. This would 
have enabled a greater focus on the impact of sensory urinary symptoms on the 
quality of life for women already impacted on by the non-urinary symptoms of FM. 
This study did not compare the differences in urological symptoms between 
the groups of women who were of different educational levels, women of different 
menopausal status, women on different hormone replacement therapy protocols or 
between women who had and who had not had gynaecological/pelvic surgery. These 
group variables should be included in further analysis. 
Subsequent studies with other populations and samples are required to further 
explicate the predictive capabilities of the Fibromyalgia Bladder Index and calculate 
appropriate cut off scores that may be useful in making interpretations. 
However, given the scope of this two-phased study and the time limits 
associated with this doctoral research, the findings emerging from this work make a 
substantive contribution. Further testing in the context of post-doctoral studies should 
involve testing of a larger sample, including a control group, now that a tool has been 
developed and tested and the merits of pursuing this line of inquiry have been 
demonstrated. 
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CHAPTERS 
RECOMMENDATIONS AND CONCLUSIONS 
Introduction 
The Fibromyalgia Bladder Index assesses the important domains of urinary 
urgency, urinary frequency, nocturia and bladder pain and discomfort in the female 
FM population. This new instrument, the Fibromyalgia Bladder Index, has 
demonstrated respectable psychometric properties that indicate that it is a specific 
and potentially helpful additional outcome measure for research and clinical use in 
the Fibromyalgia population. The use of the Fibromyalgia Bladder Index by 
clinicians when assessing women with FM and bladder irritability may help to 
identify women who suffer significantly from these bladder symptoms and/or 
problems and assist in quantifying these symptoms. This index may therefore have a 
place in rheumatology and urology clinics to assess the urinary symptoms and their 
impact on women with FM and expedite treatment regimes. 
Radley and Jones (2004) comment that within the area of urogynaecology 
and pelvic floor medicine, clinician-administered instruments have been shown to 
lack sufficient reliability and objectivity and more accurate measures of health­
related quality of life are achieved through the use of self-completed questionnaires. 
These self-administered health status measures/instruments provide information 
about patients' observations of their own health and can be used for both clinical and 
research purposes. In the development of such instruments, Radley and Jones (2004) 
describe questionnaire validation as an extended process that includes not only the 
psychometric testing of the instrument, but also an evaluation of its performance in 
practice. 
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To date, there has been little in the medical literature to increase practitioners' 
awareness of the severity and impact of FM irritable bladder symptoms on women. 
Therefore, the Fibromyalgia Bladder Index may add to the assessment tools available 
for such a thorough assessment of FM symptomatology. Yunus (2002a) emphasises 
the necessity of a thorough medical and psychological evaluation in helping to 
achieve a proper diagnosis, assess severity, recognise both aggravating and relieving 
features of FM symptoms and recognise associated conditions. 
Recommendations 
This research was initiated because of my association with and clinical 
knowledge of symptomatology of patients who had disabling urological symptoms in 
conjunction with their FM. The purpose of this study was to investigate the impact 
and measurement of these bladder irritability symptoms in Australian women who 
had been diagnosed with FM and to quantify these symptoms through the 
development of an appropriate outcome measure/instrument. This has been achieved 
with the validation of the Fibromyalgia Bladder Index within the FM population of 
women who experience sensory bladder symptoms. The theoretical framework 
formulated at the commencement of this study has provided direction for this study 
by providing a guide for examining variables and their relationships. The theory was 
based on the relevant literature, previous research findings and current research. 
This study has contributed to the knowledge of bladder irritability symptoms 
and the impact of these symptoms on the quality of life of these women. Together, 
these outcomes form a sound foundation for the following six areas of 
recommendation: further refining of the Fibromyalgia Bladder Index; utilisation of 
the index in FM assessments; development of FM educational, support and self help 
programs; pelvic health and pelvic fitness awareness; intervention studies, and the 
development of a vulvodynia index. 
Further Refining of the Fibromyalgia Bladder Index 
The development and validation of the Fibromyalgia Bladder Index may act 
as a catalyst for further research into this area of FM and bladder irritability. A 
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continuation of this research is recommended to develop a scored index with specific 
cut-offs to help interpret severity of symptoms on the Fibromyalgia Bladder Index. 
The use of valid and reliable assessment measures ensures consistency in 
measuring the progress of a patient from pre- and post-intervention assessments and 
encourages the development of evidence-based practice (O'Connell et al., 2002). 
Therefore, a third phase to this study on FM and bladder irritability is recommended. 
This phase would be of a pre-test/post-test study design to assess any changes 
resulting from intervention to assess the sensitivity of the Fibromyalgia Bladder 
Index to detect any resultant changes and responses. Such an intervention could 
include bladder health educational programs that cover bladder education, good 
bladder habits, bladder training and pelvic floor muscle education and training. These 
programs could be conducted by physiotherapy and nurse continence advisors. 
Use of the Fibromyalgia Bladder Index in FM Assessments 
The primary aim of treatment in chronic, incurable conditions is to enable the 
patient to live an occupied and productive life and, therefore, palliation of symptoms 
should be the primary goal of care (Bennett, 2002e ). As quality of life is severely 
impaired with FM patients, Bennett recommends the use of questionnaires that 
provide details on quality of life as providing the best assessment of change in a 
patient's overall state of health. 
Radley and Jones (2004) extend this notion further by suggesting the routine 
implementation of these types of instruments in urogynaecology clinical practice. 
However, these authors recognise that the application of individual condition­
specific instruments in clinical practice is limited by the narrow specification of each 
questionnaire. Therefore, this would necessitate the use of many individual 
questionnaires to adequately address most areas of pelvic floor symptomatology. 
Radley and Jones are aware of the increased time burden that paper-based 
instruments would create for study participants, health care providers and practice 
managers. They suggest that this is the reason that condition-specific questionnaires 
are not used in mainstream clinical practice. 
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With these limits in mind, they recommend the implementation of computer 
interviewing as one option for managing challenges of busy clinics. Radley and 
Jones (2004) cite studies by Velikova, Wright and Smith on automated collection of 
quality-of-life data, comparing paper and computer touch screen questionnaires. 
Studies by Kleinman, Leidy, Crawley, Bonomi and Schoenfeld (2001) have shown 
that the reliability and validity of electronic questionnaires are compatible with paper 
questionnaires. Buxton, White and Osoba (1998) have shown the quality of 
electronic questionnaire-acquired data to be high, with good test-retest reliability. 
This computerised technology may offer a realistic method for the collection and 
monitoring of clinical data. An electronic pelvic floor symptoms assessment (e-PAQ) 
has already been developed and enables participants to provide comprehensive 
assessment of symptoms, data entry and immediate data analysis (Radley & Jones, 
2004) . The e-PAQ is currently being evaluated within the continence area. Radley 
and Jones state that this electronic assessment, the e-PAQ, was developed within the 
area of urogynaecology because of the need to comprehensively evaluate symptoms 
in the related areas of bowel, bladder, vaginal and sexual function. 
The development of a single electronic instrument such as the e-PAQ that 
combines paper-based questionnaires into a single instrument that is acceptable to 
patients, while maintaining data integrity and minimising respondent burden, is an 
attractive proposition for the assessment of patients with FM. Following a diagnosis 
of FM, a combination of valid and reliable indexes relevant to the patient' s specific 
symptoms could be completed and kept on record, following the initial consultation, 
to provide baseline data for continuing assessment and management. With the future 
introduction of computerised questionnaires with immediate data entry and analysis, 
the use of multiple condition- specific questionnaires for conditions such as FM is 
feasible. 
For women with urological symptoms of FM, the Fibromyalgia Bladder 
Index could be included as one of these specific measures as part of an FM primary 
assessment and/or pre-intervention questionnaire. The Fibromyalgia Bladder Index 
will monitor the symptoms and impact of sensory bladder symptoms via the Urgency 
and Pain Subscale and the Frequency and Nocturia Subscale, presenting clear 
indications of bladder symptoms and impact at different time intervals. 
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An Australian study assessed the use of quantitative clinical measurements 
being used by rheumatologists in the longitudinal follow up in outpatient practice of 
patients with rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and FM 
(Bellamy et al., 1999). Rheumatologists agreed that outcome measures for use in 
clinical practice should include simplicity, brevity, ease of scoring, reliability and 
validity, and sensitivity to change. Following the completion of studies on the 
sensitivity of the index to monitor change, the Fibromyalgia Bladder Index, a simple 
eight-item validated reliable outcome measurement tool for women with FM and 
bladder irritability will meet the above criteria. 
Education 
This study has identified a need for increased education of health care 
professionals with respect to urinary symptomatology within this population. 
Professional education for health professionals would include information for 
primary care medical general practitioners, rheumatologists, urologists, 
physiotherapists and continence advisors on the sensory urinary symptoms and 
impact experienced by women with FM. Education on the multifaceted 
symptomatology of FM would include information on the urogenital symptoms. 
Goh, Samanta, Cavendish and Heney (2004) emphasise the need to recognise 
and prioritise the teaching of rheumatology in the undergraduate curriculum and to 
develop a core curriculum that is acceptable worldwide. One of their 
recommendations is the assessment of rheumatological conditions by the use of 
reliable and validated tests. The authors also recommend the acquisition of skills for 
appropriate attitude development in managing patients with chronic conditions (Goh 
et al., 2004). 
The study has also identified a need within the female FM population for 
increased awareness of urogenital symptomatology. The development of self­
help/support groups within local communities for patients with FM with a focus on 
patient education and support is also recommended. The development of an 
Australian FM information pamphlet for patients is an essential part of this patient 
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education and could be distributed via health professionals at times of clinical 
consultation. 
The literature also documents the positive effects of exercise on pain, self­
efficacy, sleep, fatigue and quality of life in the FM population. There is a need for 
further research in this area, with an emphasis on the pelvic health and pelvic fitness 
of women with FM. Education on good bladder habits, bladder training and exercises 
and awareness of the pelvic floor and abdominal musculature specific to pelvic 
awareness and stability should form part of exercise programs for FM. The 
Fibromyalgia Bladder Index will increase the awareness of the specific symptoms 
and impact of sensory bladder symptoms within the female FM population and 
perhaps open the doors to a more inclusive treatment protocol for the re-education 
and maintenance of pelvic fitness in these women. 
Intervention Studies Specifically for Urological Symptoms/Impact of FM 
This study has identified women with FM who experience sensory bladder 
symptoms that have a significant impact on their quality of life, adding to their 
existing FM burden. Further research may quantify with objective testing more 
specifics regarding bladder function in these women with FM. Urodynamic cross­
sectional profiles encompassing measurement of bladder capacity, sensory urgency 
and bladder instability, together with cystoscopy and histology of bladder biopsies in 
patients with FM who also have bladder symptomatology would provide more 
information on these irritable bladders prior to intervention therapy. 
Evidence-based guidelines for the optimal treatment of FM have recently 
been developed (Goldenberg, Burckhardt, & Crofford, 2004). These guidelines 
resulted from a search of all human trials of FM (randomised controlled trials and 
meta-analyses of randomised trials) using the Cochrane Collaboration Reviews and 
extensive medical data bases. The final guidelines suggest that, notwithstanding the 
chronicity and complexity of FM, there are non-pharmacological and 
pharmacological interventions that do have clinical benefit. Based on current 
evidence, these authors recommend a program that emphasises education, some 
medications, exercise, and cognitive therapy (Goldenberg et al. , 2004) . To date, there 
- 238 
have been no specific treatment programs encompassing the evidence-based 
guidelines for optimal treatment as suggested by Goldenberg and colleagues (2004) 
for this area of urogenital symptoms in women with FM. 
The theoretical framework for this study described the central nervous system 
hyperexcitability being responsible for the resultant spectrum of conditions in FM 
(Clauw, 1 995a). As mentioned by Clauw, the clinical spectrum of FM, encompassing 
neurogenic inflammation, increased peripheral and visceral nociception, 
neuroendocrine disturbances and autonomic nervous system dysfunction, can result 
with symptoms being evident in any of the effector arms of the central nervous 
system. This study has focused on the urogenital symptomatology. A randomised 
controlled intervention study on specific assessments and treatment protocols for 
urogenital symptoms for women in this population is indicated. 
Further research in the area of FM and bladder irritability should be 
undertaken. The lower levels of quality of life in the Australian FM sample reported 
in this study, compared with those of the USA chronic disorder population study as 
illustrated by the SF-36 measurement of general health status raises questions about 
the rationale for these differences. One interpretation for these differences may be 
that this current Australian study captures the urinary distress more completely 
because all participants met the study inclusion criteria of having at least two sensory 
urinary symptoms. The data reported in the United States study did not involve 
recruitment of women specifically with bladder symptoms. Therefore the 
combination of FM and urinary symptoms may account for the poorer quality of life 
scores obtained in this Australian study. A larger randomised, controlled study of the 
FM population in Australia would provide more evidence of the specific impact of 
urinary and non-urinary symptomatology in this population. 
Development and Psychometric Testing of a Vulva/ Symptom/Impact Index 
This current research within the FM population of women with urinary 
symptoms has shown the presence and impact of vulvodynia-like symptoms. 
Vulvodynia is described as an under-diagnosed, and difficult to treat gynaecological 
disorder (Masheb, Lozano, Richman, Minkin, & Kerns, 2004). Their recent research 
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on subtypes of vulvodynia showing the absence of differences between subtypes on 
standardised measures of pain, sexual function, psychological function and quality of 
life suggests little clinical significance of these subtypes and buttresses the theory 
that vulvodynia represents a continuum of chronic vulvar pain. 
There is a need to reach a consensus for the diagnostic criteria for vulvodynia 
(Masheb et al., 2004). Gibbons (2004) speculates that the lack of an accurate 
diagnosis or access to contemporary therapy for chronic vulvar pain is partly caused 
by the current confusion in classification and the multitude of treatments advocated. 
Although further research and consultations into the area of vulvodynia and 
dyspareunia and the accurate classification of these conditions should be prioritised, 
the development and testing of a specific instrument for vulval symptoms and impact 
within this FM population and within the non-FM population who experience vulval 
symptoms could provide further insight into this chronic pain condition. 
Conclusion 
The boundaries of evidence-based medicine on FM and other central 
sensitivity syndromes are expanded by Yunus (2004) to include the 
phenomenological aspects of mind, perceptions, feelings and suffering. Yunus refers 
to Cassel's definition of suffering as that which can be defined as the state of severe 
distress associated with events that threaten the intactness of a person. For patients 
with a chronic disease, this intactness can be threatened or lost as a result of the 
anguish, misery, loss of control and sense of hopelessness and helplessness resulting 
from the chronicity (Yunus, 2004). He describes suffering as a phenomenological 
condition, as an entity that goes beyond structural pathology. 
One of the difficulties for women with a diagnosis of FM is the lack of 
objective pathology and diagnostic markers. As a result, it is possible for the health 
professional to underestimate the impact of the disease and therefore the suffering 
that these patients experience. For the FM patient, the added impact of urological 
symptoms may increase morbidity and, therefore, suffering may be intensified. Masi, 
White and Pilcher (2002) suggest that a person-centred approach can assist in the 
subgroupings of patients for greater specificity in care programs and in improved 
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clinical investigations. The authors define a person-centred approach as an attention 
to major biopsychosocial issues of individuals. They suggest that this person­
centered approach can enhance the patient/doctor relationship and assist in 
prioritising the patient's goals in treatment plans (Masi et al., 2002). 
For the health professional, specific FM indexes could elucidate some of the 
very specific symptoms pertinent to this population that impact on quality of life for 
FM patients. Use of such specific indexes is recommended as a clinical tool to 
possibly enhance this person-centred approach. This possibility could be 
demonstrated in the clinical setting where specificity of information from the 
Fibromyalgia Bladder Index could encourage collaborative management of the 
patient between rheumatology and urology disciplines, with increased positive 
outcomes for the patient. 
With this person-centred approach in mind, it is worthwhile to conclude by 
placing the results of this study in the context of the personal burdens experienced by 
women living with a chronic illness such as FM who manage both non-bladder and 
bladder FM symptoms. The concluding quotation reminds us of the relevance of this 
work. 
"Having a chronic illness or living with chronic pain changes not only how 
you do things but who you are. In the face of extraordinary physical challenges, 
some have an easier time than others honing in on the strength and hearty wisdom 
necessary to reinvent a different life and new vision for the future. Inevitably, a 
former self, as well as a previous way of being in the world, fall away and give rise 
to a new way of functioning and embracing life "  (Sveilich, 2005) . 
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Appendix B: Draft algorithm for the treatment of painful bladder syndrome (including IC) 
Painful Bladder Syndrome (including IC) 
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Appendix C: Interview guide - Phase 1 
I am interested to know what bladder symptoms you are experiencing and how these 
symptoms affect your daily life. We will be discussing your experience of 
these symptoms in relation to a specific questionnaire that has been 
developed to measure the severity of the symptoms and how much of a 
problem they are for you. 
1. During the past month how often have you felt the strong need to urinate with little,
or no warning?
2. How would you specifically describe how often you get this strong urge?
3. During the past month, have you had to urinate less than 2 hours after you finished
urinating?
4. How would you specifically describe how often you had to urinate less than 2 hours
after you finished urinating?
5. During the last month, how often did you most typically get up at night to urinate?
6. During the past month, have you experienced pain or burning in your bladder?
7. How would you specifically describe how often you have experienced this?
8. Do you experience pain or burning in any other part of your pelvis other than your
bladder?
9. During the past month, has frequent urination during the day been a problem for
you?
10. Describe how much of a problem this has been.
11. During the past month, has getting up at night to urinate been a problem for you?
12. Describe how much of a problem this has been.
13. During the past month has the need to urinate with little warning been a problem?
14. Describe how much of a problem this has been.
15. During the past month, has burning, pain, discomfort or pressure in your bladder
been a problem?
16. Describe how much of a problem this has been.
17. Are there any other bladder problems or issues that affect you that we have not
discussed?
- 272 -

If you wish to be involved in the second phase of this research, please advise 
me at the end of the focus group discussion. 
If you have any queries you can contact me by telephone on Tel 
during office hours or by email at ......... . My supervisor at Edith Cowan 
University Professor Linda Kristjanson can also be contacted on . . . . . . . . . . if you 
require any further information. 
Thank you so much for participating in this study. 
Kaye Brand 
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Appendix M: Recruiting Notices for Rheumatology Consulting 
Rooms 
FIBROMYALGIA 
IS IT AFFECTING YOUR BLADDER? 
Currently there is research being conducted at Edith Cowan 
University in Perth on Fibromyalgia and its effect on the bladder. 
The researcher, Kaye Brand is a Physiotherapist who has a particular 
interest in Fibromyalgia and has for many years worked as a 
Physiotherapist continence adviser treating women with bladder problems. 
Fibromyalgia is a syndrome that can affect many different areas of the body.
For some women with Fibromyalgia, their bladders can become more sensitive than 
normal and this can create discomfort and sometimes cause a change in their bladder 
patterns. 
Kaye is interested in hearing from women who have been diagnosed with 
Fibromyalgia, who have bladder irritability problems and who may be interested in 
taking part in this research. 
You can help! If you do have bladder symptoms associated with your 
Fibromyalgia, please consider participating in this research. Each piece of 
information contributes to our understanding about this condition. 
To find out further details about the research, please contact (before July 30t11)
Kaye Brand, Edith Cowan University 
Telephone 
Email: 
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Appendix N: Media Release for Study Recruitment 
PRESS / MEDIA RELEASE 
August 2002 
RESEARCH ON FIBROMYALGIA AND THE BLADDER 
Researchers at Edith Cowan University (ECU) are seeking women aged 18-
65 years who have been diagnosed with the condition Fibromyalgia to volunteer as 
participants for a research project. 
This research project will be exploring issues of bladder symptoms in women 
with the condition of Fibromyalgia and the impact that these symptoms have on the 
quality of life of these women. 
Kaye Brand, a Edith Cowan researcher, says that Fibromyalgia is estimated to 
affect between 2 to 4% of the population, and is the most commonly diagnosed 
rheumatological disorder after osteoarthritis. The symptoms of Fibromyalgia can be 
severely debilitating and are characterised by chronic and widespread pain and 
stiffness throughout the body, sometimes accompanied by fatigue, poor sleep, and 
other associated symptoms. 
One of the associated symptoms of Fibromyalgia is bladder irritability. These 
bladder symptoms include urinary frequency (going to the toilet very often), urinary 
urgency (an urgent need to 'go'), bladder pain or pressure or a feeling of bladder 
fullness. 
The symptoms of a chronic illness like Fibromyalgia can radically disrupt a 
woman's life activities and identity. This research will determine the increased 
impact these urinary symptoms have on the quality of life of a woman already coping 
with other symptoms of Fibromyalgia. 
One outcome of the research is to produce an assessment format to be used 
by health professionals that will enable accurate assessment of the symptoms and 
impact of these urinary symptoms within the female Fibromyalgia population. 
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